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Lung cancer is deadly.  
It is estimated that annually 1.6 million deaths are due to lung cancer worldwide, 
making it the leading cause of cancer-related death.1–3 The time of diagnosis directly 
translates to survival, with 5-year survival rates ranging between 12-90% depending 
on the lung cancer stage.4 An important factor is that lung cancer often remains 
symptomless until far progressed and most clinical patients are beyond stage I.4  
Several studies, including randomized controlled trials, have examined or are 
examining the possibility of lung cancer screening with low-dose computed 
tomography (LDCT) to reduce mortality.5,6 After the American National Lung 
Screening Trial (NLST) showed a 20% reduced lung cancer mortality when comparing 
LDCT to conventional chest radiography,7 most US guidelines now recommend LDCT 
lung cancer screening for high-risk individuals.8–10 European stakeholders, however, 
are awaiting the final results of the Dutch–Belgian lung cancer screening (NELSON) 
trial.9,11  
LDCT lung cancer screening consists of a single baseline screening (the first 
screening round) and multiple annual incidence screening rounds. In lung cancer 
screening trials, around 22-51% of participants have non-calcified pulmonary nodules 
at baseline screening.12–21 However, before the results of this thesis were published, 
it became apparent that there only was limited evidence concerning new nodules 
developed after baseline screening, because data were often clustered together with 
baseline nodules.8,22  
As will be argued in this thesis, the distinction between baseline nodules and new 
nodules is crucial and directly affects optimal management. While baseline nodules 
might have been present for years before detection, new nodules after baseline 
developed within a short and pre-specified timeframe. Consequently, compared to 
baseline nodules, new nodules had less time to grow and size cutoffs derived from 
baseline nodules might be too conservative.  
 
Therefore, the aim of this thesis is to provide evidence for the risk-stratification of new 
nodules in incidence screening rounds of LDCT lung cancer screening. The 
development of a new nodule stratification strategy depends on the clarification of 
several open questions. Next to the knowledge concerning the occurrence and lung 
cancer probability of new nodules, size cutoffs for initial detection are of key interest. 
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Similarly, the appropriate risk-stratification strategy of new solid nodules at first follow-
up after initial detection should be investigated. 
 
This research is based on the largest European randomized lung cancer screening 
study – the NELSON trial. The Dutch–Belgian NELSON trial was launched in 
September 2003 as a multicenter randomized controlled trial to investigate whether 
LDCT screening would decrease lung cancer mortality by 25% when compared to no 
screening. Eligible participants were high-risk (ex-)smokers between 50 and 75 years 
of age. Participants received LDCT screening at baseline, 1 year after baseline, 3 
years after baseline, and 5.5 years after baseline. The NELSON trial is the first to 
employ a volume-based instead of a diameter-based nodule management protocol. 
Importantly, while any nodule can be characterized by an unlimited number of 
diameters, it only has one volume.  
The results of this research could affect currently ongoing and future lung cancer 
screening programs as well as clinical practice nodule management guidelines.  
 
The thesis is structured in five sections.  
The first section contains Chapters 1-4 and forms the introduction of this thesis. 
While Chapter 1 provides the outline of the presented thesis, Chapter 2 and Chapter 
3 review the evidence from large lung cancer screening trials to create a basis for the 
assessment of pulmonary nodules detected during lung cancer screening in a more 
clinical relevant manner, instead of clustering baseline nodules and new nodules 
together.  
The second section contains Chapters 4-7 and focusses on the risk-stratification of 
new nodules as well as the impact of new nodules on a screening program. Chapter 
4 assesses the occurrence and lung cancer probability of new solid nodules as well 
as size cutoffs for risk-stratification at initial new nodule detection. Chapter 5 
investigates the optimal new nodule growth-speed and size cutoffs at first follow-up 
after detection. Chapter 6 examines whether new nodule characteristics can improve 
the size-based risk-stratification approach developed in Chapter 4. Chapter 7 
focusses on the appropriate risk-stratification of new subsolid nodules in LDCT lung 
cancer screening. 
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The third section contains Chapters 8 and Chapter 9. Both Chapters investigate the 
relationship between the number of (new) nodules detected in a participant at baseline 
(Chapter 8) or incidence screening rounds (Chapter 9) and lung cancer probability. 
The fourth section contains Chapter 10, Chapter 11 and Chapter 12. Chapter 10 
discusses the results of this thesis and presents the conclusions, while Chapter 11 
and Chapter 12 provide the summary.  
The fifth section contains Chapters 13-14 and forms the Appendix of this thesis. 
 
Research questions addressed in this thesis 
I. What is the occurrence of new nodules in lung cancer screening? 
II. What is the lung cancer probability of new nodules in lung cancer 
screening? 
III. What are optimal size cutoffs for new solid nodules at initial detection? 
IV. What is the appropriate risk-stratification strategy of new solid nodules at 
first follow-up after initial detection? 
V. What is the proportion of resolving new nodules and how does this affect 
risk-stratification? 
VI. Can new nodule characteristics improve size-based new nodule risk-
stratification? 
VII. Does the number of nodules detected in a lung cancer screening participant 
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Currently, lung cancer screening by low-dose computed tomography (LDCT) is widely 
recommended for high-risk individuals by US guidelines, but there still is an ongoing 
debate concerning respective recommendations for European countries. 
Nevertheless, the available data regarding pulmonary nodules released by lung 
cancer screening studies could improve future screening guidelines, as well as the 
clinical practice of incidentally detected pulmonary nodules on routine CT scans. Most 
lung cancer screening trials present results for baseline and incidence screening 
rounds separately, clustering pulmonary nodules initially found at baseline screening 
and newly detected pulmonary nodules after baseline screening together. This 
approach does not appreciate possible differences among pulmonary nodules 
detected at baseline and firstly detected at incidence screening rounds and is heavily 
influenced by methodological differences of the respective screening trials. This review 
intends to create a basis for assessing non-calcified pulmonary nodules detected 
during LDCT lung cancer screening in a more clinically relevant manner. The aim is to 
present data of non-calcified pulmonary baseline nodules and new non-calcified 
pulmonary incident nodules without clustering them together, thereby also simplifying 
translation to the clinical practice of incidentally detected pulmonary nodules. Small 
pulmonary nodules newly detected at incidence screening rounds of LDCT lung 
cancer screening may possess a greater lung cancer probability than pulmonary 
















Lung cancer remains a leading cause of cancer-related death worldwide.1 Various 
efforts have been made to contain the extent of the disease and an early detection of 
lung cancer is crucial for successful treatment and prolonged survival.2,3 Lung cancer 
screening studies using low-dose computed tomography (LDCT) were set up all over 
the world, to assess the feasibility of detecting lung cancer in high-risk individuals as 
early as possible.4–6 The National Lung Screening Trial, which is the largest 
randomized-controlled LDCT lung cancer screening trial, reported a relative reduction 
in lung cancer-specific mortality of 15-20% when comparing chest X-ray and LDCT 
screening.7 Currently, lung cancer screening by LDCT is widely recommended for 
high-risk individuals by US guidelines.8–15 However, there still is an ongoing debate if 
screening should be recommended for high-risk individuals in Europe, and further 
evidence is needed.16 Nevertheless, the vast data on (small) pulmonary nodules 
provided by the lung cancer screening trials enable further insights in the clinical 
management of pulmonary nodules and the development of future screening 
guidelines. 
 
Most LDCT lung cancer screening trials present results for baseline and incidence 
screening rounds separately and elaborate reviews of this data were published 
before.4,5,17,18 Although comparing screening rounds provides valuable information 
about a trial’s lung cancer screening performance in general, this approach does not 
appreciate the possible differences among nodules firstly detected during baseline and 
incidence screening rounds and is heavily influenced by the differences in 
methodology of the respective LDCT lung cancer screening trials. For instance, a lung 
cancer screening trial with an aggressive baseline screening follow-up strategy may 
report lower cancer rates during incidence screening rounds, than a trial with a less 
aggressive strategy at baseline screening, even though the overall lung cancer rate is 
similar. However, only limited evidence concerning the different groups of pulmonary 
nodules identified is provided. Non-calcified pulmonary nodules detected at baseline 
screening consist of a combination of nodules that may have been present for years 
and a fewer number of more recently developed nodules. Non-calcified pulmonary 
nodules firstly detected during incidence screening may be entirely new (not present 
on a previous screen), not new (missed on a previous screen), or below the detection 
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threshold of the respective LDCT lung cancer screening trial on the previous screen 
(hence, these are growing nodules). Unfortunately, lung cancer screening trials 
present their data concerning lung cancer rates in the various groups of non-calcified 
pulmonary nodules differently and the definitions of incidence nodules vary 
widely.4,5,10,16 The recently released British Thoracic Society Guidelines for the 
Investigation and Management of Pulmonary Nodules addresses this issue by stating 
that there is little evidence for the management of new incident nodules that appear 
on follow-up CTs.19  
 
This review intends to create a basis for assessing non-calcified pulmonary nodules 
detected during lung cancer screening in a more clinically relevant manner. The aim 
is to present detection rates of non-calcified pulmonary baseline nodules and non-
calcified pulmonary incident nodules not present on a previous scan (thus new) without 
clustering them together. Furthermore, lung cancer probabilities of non-calcified 
baseline and new non-calcified incident pulmonary nodules will be assessed, as well 
as the lung cancer risk for participants with such nodules. As the majority of trials do 
not explicitly state rates concerning new non-calcified pulmonary incident nodules, 
only limited evidence is available for this nodule group. This review focusses mainly 
on the following European lung cancer screening trials: United Kingdom lung 
screening (UKLS) trial, Italian detection and screening of early lung cancer by novel 
imaging technology and molecular assays (DANTE) trial, Danish lung cancer 
screening trial (DLCST), Dutch–Belgian lung cancer screening trial (NELSON), Italian 
lung study (ITALUNG), German lung cancer screening intervention study (LUSI); 
American lung cancer screening trials: National lung screening study (NLST), early 
lung cancer action project (ELCAP), Mayo CT Screening study (Mayo trial), Pittsburg 
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Pulmonary nodules in baseline screening rounds of LDCT lung 
cancer screening 
 
Prevalence of non-calcified pulmonary nodules at baseline rounds of LDCT lung 
cancer screening 
The prevalence of pulmonary nodules at baseline rounds of LDCT lung cancer 
screening depends on the methodology of the respective screening approach, such 
as the CT protocol or the use of an artificial detection limit. Additionally, a higher 
prevalence of certain diseases, such as histoplasmosis, may influence the number of 
detected solitary lung nodules.20 Most European and American trials with no detection 
limit (PLuSS and Mayo trial) or detection limit of 3mm or 15mm3 (NELSON and UKLS) 
reported a non-calcified pulmonary nodule prevalence in between 41-51% of baseline 
participants (Table 1 and Table 2).21–24 However, the ELCAP and DLCST trial, which 
both did not employ a detection limited, reported lower non-calcified pulmonary nodule 
rates in participants at baseline (23% [233/1,000] and 22% [447/2,052] 
respectively).25,26 These differences could be explained by a plethora of factors, such 
as differences in methodology, patient population, infectious disease prevalence, etc.. 
For instance, the difference between the Mayo trial (51% [780/1,520] non-calcified 
pulmonary nodule baseline prevalence) and ELCAP trial (23% [233/1,000] non-
calcified pulmonary nodule baseline prevalence) has been attributed to differences in 
slice thickness during CT detection.5,25,27 Furthermore, the ELCAP trial only reported 
nodules of participants with less than six nodules, possibly reducing the non-calcified 
pulmonary nodule baseline rate.25
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 UKLS 24 DANTE 4,34 DLCST 4,26 NELSON 4,23,33 ITALUNG 4,29 LUSI 4,30 
Participants 
Received CT screening 
Age, mean (SD) 

























Nodule detection limit ≥15mm3 or ≥3mm None reported None reported ≥15mm3 ≥5mm ≥5mm 
Participants with lung 
cancer 
42/1994 (2.1%) 28/1276 (2.2%) 17/2052 (0.8%) 70/7557 (0.9%) 20/1406 (1.4%) 22/2029 (1.1%)  
Participants with NCNs  













% of NCNs being lung 
cancer 


















































Table 1: Baseline results of selected European low-dose computed tomography lung cancer screening trials. 
UKLS=United Kingdom lung screening trial, DANTE=detection and screening of early lung cancer by novel imaging technology and molecular assays, DLCST=Danish lung cancer 
screening trial, NELSON=Dutch–Belgian lung cancer screening trial, ITALUNG=Italian lung study, LUSI=German lung cancer screening intervention study, SD=standard deviation, 
NCNs=non-calcified pulmonary nodules, NA=not available. 










 NLST 28,35 ELCAP25 IELCAP 6 Mayo† 22 PLuSS† 5,21 
Participants 
Received CT screening 
Age, mean (SD)‡ or median (IQR)§ 






















Nodule detection limit ≥4mm None reported¶ ≥5mm None reported None reported 
Participants with lung cancer 270/26309 
(1.0%)†† 
27/1000 (2.7%) 405/31567 (1.3%) 31/1520 (2.0%) 53/3642(1.5%) 
Participants with NCNs 






















































Table 2: Baseline results of selected American low-dose computed tomography lung cancer screening trials and 
the IELCAP trial. 
NLST=National lung screening study, ELCAP=early lung cancer action project, IELCAP=international early lung cancer action project, Mayo=Mayo CT 
Screening study, PLuSS=Pittsburg 
Lung Screening Study, SD=standard deviation, IQR=interquartile range, NCNs=non-calcified pulmonary nodules, NA=not available. 
† The Mayo and PLuSS trials reported their baseline findings including lung cancers found in baseline nodules during incidence screening rounds.  
¶ Participants with more than 6 NCNs were not reported as having lung nodules. 
†† Low-dose CT detected lung cancer cases. 
‡‡ Bronchioloalveolar carcinomas are considered adenocarcinomas. 
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Strengthening the case for a higher non-calcified pulmonary nodule rate at baseline, 
at least in the European smoker or former smoker population, are the recently released 
results of the UKLS trial’s baseline round. This trial shared an analogous methodology 
with the NELSON trial and confirmed a non-calcified pulmonary nodule baseline 
prevalence in 51% of the participants for the respective screening setting.23,24 Trials 
with a detection limit of 4mm or greater (IELCAP, NLST, ITALUNG, LUSI) reported a 
lower non-calcified pulmonary nodule rate of between 13-30% at baseline.6,28–30 This 
suggests that a great number of non-calcified pulmonary nodules at baseline are small 
pulmonary nodules. Of the trials with no or a low detection limit, the Mayo trial reported 
that 39% (307/780) of participants only had non-calcified pulmonary nodules smaller 
than 4mm and the NELSON trial found that 56% (4,861/8,623) of the non-calcified 
pulmonary nodules detected at baseline were smaller than 50mm3 (roughly 
4.7mm).22,23,27 Within the baseline round of the DLCST trial, 66% (371/560) of the non-
calcified pulmonary nodules were below 5mm and in baseline participants of the 
ELCAP trial, the largest non-calcified pulmonary nodule was smaller than 5mm in 58% 
(136/233).25,26,31 
Concluding, evidence from trials with no or a low detection limit indicates that 22-51% 
of heavy smokers and former heavy smokers have non-calcified pulmonary nodules 
at baseline screening. Of the non-calcified pulmonary nodules detected at baseline, 
possibly up to 56% are small pulmonary nodules below 50mm3 or 5mm.  
 
Lung cancer risk of participants with non-calcified pulmonary nodules at 
baseline and lung cancer probability of non-calcified pulmonary baseline 
nodules 
Unfortunately, data regarding the overall lung cancer risk of participants with baseline 
nodules is not frequently described. Trials rather report how many participants are 
diagnosed with lung cancer per round, irrespective in which round the nodule was 
found initially. However, information about the overall lung cancer risk is crucial, since 
it could directly influence the clinical practice approach of incidentally found lung 
nodules in smokers and provide essential information for the development of new 
guidelines. 
The Mayo trial (5-year results) and PluSS trial (3-year result) report that 4% ([31/780] 
and [53/1,477] respectively) of participants with a non-calcified pulmonary nodule at 
baseline developed cancer in such a nodule within their screening program.21,22 Both 
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trials did not employ a detection limit. The NELSON trial, which used a 15mm3 (roughly 
3mm) detection limit, reported a 2-year lung cancer risk of 3% (94/3,189) for Dutch 
participants with baseline nodules.32 
Regarding the probability of a non-calcified pulmonary baseline nodule being 
diagnosed as lung cancer eventually, the Mayo trial (5-year results) and PLuSS trial 
(3-year results) reported that 2% ([31/1,646] and [53/2,497] respectively) of the non-
calcified baseline nodules turned out to be lung cancer.21,22 
The other trials included here, only reported the baseline detection rate, thus the 
number of lung cancers found in participants at baseline, ranging between 1-3% for 
all participants,6,23–25,29–31,33,34 and 2-11% for participants with non-calcified pulmonary 
baseline nodules.6,23–25,29–31,33,35 During baseline screening, the probability of a non-
calcified pulmonary baseline nodule being detected as lung cancer ranged between 
1-7.4%.23,26,29,32 In particular, the ELCAP and IELCAP trial reported very high lung 
cancer rates (12% [27/233] and 10% [405/4,186] respectively) for participants with 
non-calcified pulmonary nodules during baseline screening.6,25 However, as 
demonstrated previously, these trials also reported a very low non-calcified pulmonary 
nodule overall detection rate.6,25 Apparently, the screening methodology of these 
studies enabled an efficient manner of recognizing individuals with high-risk pulmonary 
nodules, while potentially not detecting or registering unsuspicious nodules. 
As mentioned before, the UKLS and NELSON trial shared a similar screening 
methodology; however, the participant recruiting strategy differed significantly. While 
inclusion in the NELSON trial was mainly based on age and smoked pack-years,23,36 
the UKLS trial used a multivariate conditional logistic regression model (including: 
smoking duration, selected prior respiratory diseases, occupational exposure to 
asbestos, prior diagnosis of malignant tumors and early onset family history of lung 
cancer) based on the Liverpool Lung Project.24,37,38 The UKLS trial included 
participants only if their calculated 5-year lung cancer risk was more or equal to 5%.24 
This difference in selection methodology resulted in an older screening population in 
the UKLS if compared to the NELSON trial (mean age: 67 vs. 59 years) and an 
increased lung cancer baseline detection rate in participants with non-calcified 
pulmonary baseline nodules (4.1% [42/1,015] vs. 1.8% [70/3,816]).23,24,33 This unique 
comparison, which is made possible due to the similar screening methodology, 
demonstrates the impact of pre-test probability and the limited comparability even of 
methodologically similar lung cancer screening trials. 
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Concluding, the sparse existing evidence from the Mayo, PLuSS and NELSON trial 
indicates that 3-4% of heavy smokers or former heavy smokers with non-calcified 
pulmonary nodules at baseline screening will be diagnosed with lung cancer in such 
a nodule within 2-5 years (assuming similar epidemiology as in these trials). However, 
as demonstrated by baseline lung cancer detection rates of the other mentioned trials, 
depending on screening protocol and disease prevalence within the screened 
population, the number may be significantly higher. The translation from lung cancer 
screening trials to clinical practice of incidentally detected nodules relies on careful 
assessment of the study population from which the data was generated. 
 
Stage and histology of lung cancers found in non-calcified pulmonary baseline 
nodules 
Only the Mayo and PLuSS trial reported data in a way that enabled assessment of 
lung cancers found in non-calcified pulmonary baseline nodules across all screening 
rounds. Most lung cancers detected in a non-calcified pulmonary baseline nodule were 
stage I (Mayo: 71% [22/31]), PLuSS: 59% [31/53]).21,22 Only the Mayo trial provided 
information concerning the histology of lung cancer found in non-calcified pulmonary 
baseline nodules during all screening rounds. The majority (74% [23/31]) of lung 
cancers were adenocarcinomas, followed by squamous-cell carcinomas (13% [4/31]) 
and small-cell lung cancer (7% [2/31]). 
The results concerning stage and histology at baseline screening are equivocal. The 
ELCAP trial, IELCAP trial, and LUISI trial reported a very high proportion of stage I 
lung cancer at baseline (82%-86%).6,25,30 The other trials, including the two largest, 
randomized controlled trials (NLST and NELSON), reported lower numbers regarding 
stage I lung cancers (48-67%).7,23,24,29,30,34 There is no data available about differences 
in stage or histology distribution between non-calcified pulmonary baseline nodules 
identified as lung cancers at baseline compared to non-calcified pulmonary baseline 
nodules identified as lung cancers in later rounds. Differences between lung cancers 
found at baseline and incidence rounds, as published for instance by the ELCAP trial,39 
cannot be used for the here performed assessment, since observed variances may be 
due to lung cancers found in newly detected nodules. 
Concluding, lung cancers detected in non-calcified pulmonary baseline nodules are 
mostly adenocarcinomas. Current evidence suggests that only a small fraction is 
small-cell lung cancer. At baseline, lung cancers are stage I in 48-86% of the cases. 
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Data concerning stage distribution of lung cancers detected in baseline nodules at 
subsequent rounds is sparse. 
 
New non-calcified pulmonary nodules in incidence screening 
rounds of LDCT lung cancer screening 
 
Prevalence of new non-calcified pulmonary nodules in incidence rounds of 
LDCT lung cancer screening 
As pointed out by several studies and the recently released British Thoracic Society 
guidelines for the Investigation and Management of Pulmonary Nodules, little evidence 
exists concerning pulmonary incident nodules that appear after baseline screening 
and are not visible in retrospect.10,19,40 In 2005, the Fleischner society reported, citing 
the Mayo trial, that 10% of screening participants develop a new nodule not present in 
retrospect within a 1-year interval, and the PLuSS trial described that 7% [256/3,423] 
of their participants developed a new nodule in the same interval.21,27,41 Numbers from 
the ELCAP and IELCAP publications suggest annual new nodule rates of 3% 
(40/1,184) and 5% (1,460/27,456) respectively in LDCT lung cancer screening.6,42 In 
the annual screening round of the NELSON trial, 5% (344/7,295) of the participants 
developed a new non-calcified solid nodule, while a total of 11% (787/7,295) of 
participants developed a new non-calcified solid nodule within the first two incidence 
screening rounds (3 years after baseline).40  
The NELSON trial reported that 57% (697/1,222) of the newly detected nodules were 
small pulmonary nodules with a volume less than 50mm3 (roughly 4.7mm).40 The 
ELCAP trial reported that in the 30 participants with high-resolution CT confirmed new 
non-calcified pulmonary incident nodules, the largest nodule had had a diameter less 
than 5mm in 53% (16/30) of participants,42 and in 37% (70/191) of participants with 
new non-calcified pulmonary incident nodules in the Mayo trial, the nodules were 
smaller than 4mm.27 
Concluding, current evidence suggests that 3-10% of LDCT lung cancer screening 
participants may develop a new non-calcified pulmonary incident nodule annually and 
up to 57% of these nodules are pulmonary nodules smaller than 50mm3 or 5mm. 
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Lung cancer risk of participants with new non-calcified pulmonary incident 
nodules and lung cancer probability of new non-calcified pulmonary incident 
nodules 
The evidence regarding lung cancer probability of new non-calcified pulmonary 
incident nodules is scarce. Furthermore, differing methodologies of trials make the 
numbers hardly comparable.  
The NELSON trial recently reported that 6% (49/787) of participants with a new non-
calcified solid nodule developed lung cancer in such a nodule, with 4% (50/1,222) of 
the new non-calcified solid incident nodules proving to be lung cancer.40 The ELCAP 
trial reported that 10% (4/40) of participants with new non-calcified pulmonary incident 
nodules on LDCT had lung cancer in a new nodule, and the IELCAP reported this was 
the case for 5% (74/1,460) of its participants.6,21,42 The Mayo trial found a lower rate 
of 1.6% (3/191).27 However, the Mayo trial reported a substantially higher new nodule 
rate than the other trials (see above) and the clinic where the trial was performed is 
located in an area with a high prevalence of histoplasmosis.20 This may explain why 
the Mayo trial found the highest new nodule rate, but the lowest cancer rate in new 
non-calcified pulmonary incident nodules. Without providing numbers, the NLST 
reported that detection of new non-calcified pulmonary incident nodules in the second 
incidence screening round was predictive for cancer if compared to stable nodules.43 
Concluding, there is only little evidence concerning the lung cancer risk of participants 
with new non-calcified pulmonary incident nodules. The two large studies that provide 
data (IELCAP and NELSON trial) show that in 5-6% of participants with new non-
calcified pulmonary incident nodules, such a nodule proves to be lung cancer. The 
only available numbers concerning lung cancer probability of new (solid) incident 
nodules come from the NELSON trial, where 4% of the new solid non-calcified 
pulmonary incident nodules proved to be lung cancer. 
 
Stage and histology of lung cancers found in new non-calcified pulmonary incident 
nodules 
The only trial to provide explicit data concerning lung cancer stage, as well as histology 
for new incident nodule lung cancer, is the NELSON trial. It was found that 68% (34/50) 
of the new incident nodule lung cancers were detected at stage I.40 Of the detected 
lung cancers 38% (19/50) were adenocarcinomas, 22% (11/50) were squamous-cell 
carcinoma, and 10% (5/50) were small-cell lung cancer. The IELCAP trial reported 
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that 86% (64/74) of lung cancers in patients with new non-calcified pulmonary incident 
nodules was detected at stage I.6 
Concluding, it appears that thorough LDCT lung cancer screening can detect most 
new nodule lung cancer at an early and still treatable stage. There is insufficient data 
to make definite statements about cancer histology of new nodule lung cancer 
detected in incidence screening rounds of LDCT lung cancer screening. 
 
Comparing lung cancer probability of small pulmonary nodules 
detected at baseline and newly detected during LDCT incidence 
screening 
 
Due to the differences in screening methodology, baseline nodules and new incident 
nodules should not be compared across lung cancer screening trials. Valid 
conclusions can only be reached through analysis within one screening trial. 
Furthermore, because only a subgroup of participants develops new incident nodules, 
trials have to be large enough to provide a significant sample size of new nodule lung 
cancers. 
The IELCAP trial reported a cancer rate of 10% (405/4,186) in participants with 
baseline nodules and a cancer rate of 5% (74/1,460) for participants with new non-
calcified pulmonary incident nodules.6 However, it is crucial to note that the screening 
method for baseline and incidence screening deviated significantly. While during the 
baseline screening round only nodules greater or equal to 5mm were registered, there 
was no detection limit for new non-calcified pulmonary incident nodules at incidence 
screening rounds.6 The cancer rate at baseline excluded participants who only had 
nodules smaller than 5mm, which as seen in other trials comprise the largest group of 
nodules, but the cancer rate for new incident nodules included them, rendering the 
numbers incomparable.  
The ongoing NELSON trial did not yet provide the cancer rate of nodules detected at 
baseline for the overall screening. A comparison of cancer probability of new non-
calcified pulmonary incident nodules and non-calcified pulmonary baseline nodules 
has to be made indirectly. In the baseline screening round of the NELSON trial, 1% 
(70/7,557) of participants were detected with lung cancer,23 and within the first three 
screening rounds, 3% (200/7,582) participants had screen-detected lung cancer 
Part I - Introduction 
24 
 
(including 44 cancers detected in new solid non-calcified pulmonary incident 
nodules).33,40 As mentioned before, the 2-year cancer risk of participants detected with 
baseline nodules in the NELSON trial has been reported to be 3% (94/3,189). The 
cancer risk of participants detected with new solid non-calcified pulmonary incident 
nodules was 6% (49/749). Comparing these numbers, new solid non-calcified 
pulmonary incident nodules appear to have a higher lung cancer probability than do 
non-calcified baseline nodules. This is underlined by the fact, that the overall cancer 
risk of participants with a new solid non-calcified pulmonary incident nodule was 
similar to the risk of participants with a suspicious nodule at baseline that required 
received further follow-up.40 
New incident nodules are considered fast-growing and some lung cancer screening 
trials and screening guidelines anticipated this by using different cut-off values for 
baseline nodules and new incident nodules.6,44,45 The NELSON trial showed that there 
is a significant difference in the lung cancer probability of small pulmonary non-
calcified nodules already present at baseline and new non-calcified pulmonary incident 
nodules. Within the NELSON trial, baseline nodules that were smaller than 100mm3 
(roughly 5.8mm) had a lung cancer probability of about 0.5-0.7%, which statistically 
did not differ from participants without baseline nodules.32 It was concluded that these 
nodules do not necessitate follow-up. However, this does not apply in case of new 
solid non-calcified pulmonary incident nodules, where 3% of participants whose 
largest new nodule was smaller than 100mm3 (roughly 5.8mm) were eventually 
diagnosed with lung cancer, with 2% (15/819) of new solid non-calcified incident 
nodules smaller than 100mm3 (roughly 5.8mm) found to be lung cancer.40 These 
findings caused the NELSON investigators to propose different cut-off values for the 
follow-up of baseline nodules and new solid non-calcified pulmonary incident nodules. 
Based on the results of the NELSON trial, non-calcified baseline nodules smaller than 
100mm3 (0.6% lung cancer probability) or 5mm (0.4% lung cancer probability) may 
continue in regular screening, non-calcified baseline nodules 100-300mm3 (2.4% lung 
cancer probability) or 5-10mm (1.3% lung cancer probability) represent an 
indeterminate subgroup requiring follow-up with volume doubling time measurement 
(<600 days necessitates further follow-up), and, non-calcified baseline nodules greater 
than 300mm3 (16.9% lung cancer probability) or 10mm (15.2% lung cancer probability) 
should be referred for immediate diagnostic evaluation.32 New non-calcified pulmonary 
incident nodules require a more aggressive follow-up strategy and only a new non-
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calcified solid incident nodule smaller than 27mm3 (0.5% lung cancer probability) or 
3.7mm (0.6% lung cancer probability) should continue regular screening, new non-
calcified solid incident nodules between 27-<206mm3 (3.1% lung cancer probability) 
or 3.7-<8.2mm (3.0% lung cancer probability) represent an indeterminate subgroup 
requiring follow-up and volume doubling time measurement, and new non-calcified 
pulmonary incident nodules greater or equal 206mm3 (16.9% lung cancer probability) 
or 8.2mm (14.2% lung cancer probability) should be referred for immediate diagnostic 
evaluation.40 This verifies part of the LungRads guidelines as provided by the 
American College of Radiologists.44 It has been suggested that the findings regarding 
new nodules may be translated directly into routine clinical practice for the respective 
risk group (i.e. smokers or former heavy smokers) outside a screening program, if the 
nodule can be proven to be newly developed within 1-2 years.40,46 
The explanation for the different lung cancer probabilities at smaller sizes of non-
calcified baseline and new non-calcified pulmonary incident nodules could be the fact 
that compared to new incident nodules, baseline nodules had more time to grow 
before their first detection. Therefore, growing baseline nodules which possess a 
higher lung cancer probability are larger, while even fast-growing new nodules may 
still be relatively small at initial detection. Furthermore, new non-calcified pulmonary 
incident nodules may be inherently more likely to be cancer than non-calcified baseline 
nodules. Nevertheless, more evidence is necessary to expand existing conclusions. 
 
Conclusion 
Reporting lung cancer screening results per round, without providing overall cancer 
risks of participants detected with non-calcified pulmonary nodules at baseline or with 
new non-calcified pulmonary incident nodules at subsequent screening rounds, only 
provides limited information on lung cancer probabilities of the respective nodule 
groups. Much evidence is to gain from a more standardized manner of reporting, 
including subgrouping of the detected nodules according to the moment of the first 
detection, such as baseline nodule or new incident nodule. This would also simplify 
the translation to the current clinical practice of incidentally detected nodules. 
Around half of heavy smokers or former heavy smokers may present with non-calcified 
pulmonary nodules at baseline screening. Though there only is limited evidence, it can 
be expected that at least 3-4% of these individuals will be diagnosed with lung cancer 
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in a non-calcified pulmonary baseline nodule within the next 2-5 years. A majority of 
non-calcified pulmonary nodules detected at baseline are small pulmonary nodules 
smaller than 50mm3 or 5mm and possess a low lung cancer probability.  
Furthermore, 3-10% of heavy smokers or former heavy smokers develop a new non-
calcified pulmonary incident nodule annually, and these nodules prove to be lung 
cancer in 5-6% of participants. Internal comparison of the NELSON trial provided 
evidence that new non-calcified pulmonary incident nodules possess a greater lung 
cancer probability than baseline nodules at a smaller size. This may be due to the 
reduced time they had to grow before first nodule detection, or due to an inherently 
increased cancer probability. Therefore, small pulmonary non-calcified nodules 
detected newly at lung cancer incidence screening rounds should be followed up more 
aggressively than small pulmonary non-calcified pulmonary nodules detected at 
baseline screening. Additionally, for the respective risk population, the findings may 
be extrapolated for the management of incidentally detected nodules in routine clinical 
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While reading thoracic CT examinations, three different sub-types of pulmonary 
nodules are differentiated based on the nodule’s density. Until now, most existing 
evidence concentrated on solid lung nodules. However, in recent years gradually more 
studies are published focusing on subsolid nodules including pure ground-glass 
(nonsolid) nodules (GGNs) and part-solid nodules. A GGN is defined as a 
circumscribed area of increased pulmonary attenuation with preservation of the 
bronchial and vascular margins. When part of the ground-glass opacity completely 
obscures the parenchyma, the nodule is defined as part solid. 
In baseline rounds of CT lung cancer screening, part-solid nodules comprise a higher 
risk of malignancy than do solid nodules.1 Management of subsolid nodules in lung 
cancer screening trials and incidentally detected subsolid nodules in clinical practice 
is based on nodule size and growth.2 In most guidelines, no differentiation is made 
between subsolid nodules already present at a previous CT examination and new 
subsolid nodules. Recently, it was shown that new solid nodules detected in CT lung 
cancer screening have a significantly higher lung cancer probability at smaller nodule 
size compared to baseline solid nodules and need lower size cut-offs.3 Some 
guidelines, such as the British Thoracic Society (BTS) guideline and Lung-RADS, have 
incorporated the higher malignancy risk in solid new nodules.4,5 However, the question 
remains whether new subsolid nodules should be followed more aggressively as well. 
 
Subsolid nodules detected at baseline and incident lung cancer 
screening 
Several lung cancer screening trials have reported the prevalence of subsolid nodules. 
In a large prospective cohort, the International Early Lung Cancer Action Program (I-
ELCAP), it was found that at least one nonsolid nodule was detected in 4.2% of 
participants at baseline, and 5.0% had at least one part-solid nodule at baseline.6 As 
far as we know, only I-ELCAP published separate reports on the prevalence of new 
GGNs and part-solid nodules. 
  
A new GGN was detected in 0.7% (485/64,677) annual repeat screenings. Eleven new 
GGNs nodules were diagnosed as adeno-carcinoma, all stage IA. In both baseline 
and new GGNs, lung cancer was diagnosed only in growing GGNs, and always was 
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stage I, regardless of nodule size. Seventy-eight months (median) after lung cancer 
diagnosis, none of the patients had died from lung cancer. It was concluded that 
screen-detected GGNs either present at baseline or new at incidence screening can 
be followed safely with annual low-dose computed tomography (LDCT).6 
In 0.8% (541/64,667) annual repeat screenings a new part-solid nodule was identified 
in the I-ELCAP.7 Of these new part-solid nodules, 69.7% resolved or decreased in size 
at follow-up. Twenty-eight (5.2%) of the 541 new part-solid nodules were proven to be 
lung cancer, all stage IA adeno-carcinoma. All lung cancers were retrospectively 
visible as GGNs in earlier screening rounds. The lung cancer survival rate of 
participants with a baseline or new part-solid nodule was 100% (median follow-up after 
baseline 89 months). 
In the largest randomized-controlled lung cancer screening trial worldwide, the 
National Lung Screening Trial (NLST), at least one subsolid nodule (GGN and part 
solid not further specified) at baseline or follow-up screening (1 and 2 years after 
baseline) was detected in 9.4% of participants.8 In that study, no distinction was made 
between baseline subsolid nodules and newly detected in incident screening rounds. 
A retrospective analysis on lung cancers detected in NLST participants with a positive 
baseline screen result showed an odds-ratio of 0.24 for lung cancer death for cancers 
arising from GGNs as compared to solid nodules.9 
The percentage subsolid nodules as reported by the NLST is much higher than the 
subsolid nodule prevalence reported in the largest European lung cancer screening 
study, the Dutch-Belgian randomized controlled lung cancer screening (acronym: 
NELSON) trial, in which 3.3% of participants were diagnosed with a subsolid nodule 
(234 participants) during either baseline screening or one of the three incidence 
screening rounds (1, 3, and 5.5 years after baseline).10 Lung cancer in all resected 
subsolid nodules has been diagnosed in stage I, apart from one invasive 
adenocarcinoma (stage IV, delayed resection because of a competing malignancy). 
During follow-up, none of the nonresected subsolid nodules progressed into a clinical 
relevant malignancy. Therefore, it was concluded that even bi-annual follow-up instead 
of immediate resection may be a safe option in the management of subsolid nodules. 
Also, in this study, no differentiation was made between baseline and new subsolid 
nodules or between GGNs and part-solid nodules.10 
In the Multicentric Italian Lung Detection (MILD) trial, 56/ 1866 participants (3.0%) had 
76 subsolid nodules at baseline (48 GGNs, 28 part solid).11 A quarter of the subsolid 
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nodules resolved spontaneously and the majority of nodules remained stable. Five 
percent of the subsolid nodules were diagnosed as early stage adenocarcinoma after 
an active surveillance approach. To the best of our knowledge, data on new subsolid 
nodules detected in incidence screening rounds of the MILD trial have not been 
published. 
 
Guidelines on subsolid nodules detected in daily clinical practice and in 
screening 
Subsolid nodules not only are a regular finding in lung cancer screening participants, 
they are often incidentally detected in asymptomatic patients as well. Two commonly 
used guidelines on the management of incidentally detected subsolid nodules come 
from the Fleischner Society and the BTS.4,12 Lung-RADS is used for the management 
of screen-detected subsolid nodules.5 Issues in the classification of subsolid nodules 
comprise accurate differentiation between solid, part solid, and GGNs by the 
radiologist,13 and subsolid nodule size and growth determination. In contrast to 
measurements of solid nodules, software for semi-automated volume determination 
often fails measuring subsolid nodule’s size. Therefore, subsolid nodule’s size and 
growth determination are usually based on diameter measurements. 
 
Fleischner Society 
For clinical practice, the Fleischner Society recommends that solitary GGNs <6 mm 
do not generally require routine follow-up; however, for GGNs close to 6 mm follow-
up at 2 and 4 years may be reasonable when considering nodule morphology or other 
risk-factors.12 GGNs ≥6 mm should receive a follow-up within 6 to 12 months to confirm 
persistence and repeat scans subsequently every 2 years until 5 years follow-up. For 
part-solid nodules, the Fleischner Society recommends that nodules <6 mm do not 
necessitate routine follow-up, while nodules ≥6 mm should receive a follow-up within 
3–6 months and annual LDCTs for 5 years. Persistent part-solid nodules with a solid 
component ≥6 mm are considered highly suspicious for lung cancer. In case of 
multiple subsolid nodules, management is recommended to be based on the most 
suspicious nodule, and in case of multiple nodules <6 mm a follow-up LDCT within 3–
6 months is advised. 
 
 




The current BTS guidelines do not distinguish GGNs and part-solid nodules.4 
Generally, subsolid nodules <5 mm are not recommended to receive routine follow-
up. For subsolid nodules ≥5 mm it is recommended to perform a repeat LDCT within 
3 months if no previous imaging exists. If unchanged, the Brock risk prediction tool is 
recommended to estimate the risk of malignancy.14 Subsolid nodules with a low lung 
cancer risk (<10%) should receive follow-up LDCTs at 1, 2, and 4 years, while higher 
lung cancer risk may require diagnostic work-up. In case of growth or changes in 
morphology an aggressive diagnostic work-up is advised. 
 
Lung-RADS 
In Lung-RADS, management of screen-detected baseline and new GGNs/new part-
solid nodules is distinguished.5 Short-term follow-up LDCTs (3 or 6 months, lung 
cancer probability 1–15%) is advised for all GGNs with diameter >20 mm and part-
solid nodules with diameter >6 mm (part-solid and nonsolid component combined) or 
any new part-solid nodule with solid component <4 mm at incident screening. More 
stringent follow-up using chest CT with or without contrast, PET-CT (when there is a 
≥ 8mm solid component) or tissue sampling is recommended in case of a new or 
growing part-solid nodule with solid component ≥4 mm or a baseline part-solid nodule 
with solid component ≥8 mm. 
 
Conclusion 
Only limited information is available on the prevalence and lung cancer probability of 
subsolid nodules newly detected after baseline lung cancer screening. It remains 
unknown whether these results are comparable to new subsolid nodules in a 
European population, in which prevalence of subsolid nodules seems significantly 
lower. Nevertheless, current available evidence shows that malignant nonsolid 
nodules in baseline and new nodules typically have an indolent course and can be 
generally managed with follow-up by 1 or 2 years to identify nodule growth or increase 
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Background: US guidelines now recommend lung cancer screening with low-dose 
CT for high-risk individuals. Reports of new nodules after baseline screening have 
been scarce and are inconsistent because of differences in definitions used. We aimed 
to identify the occurrence of new solid nodules and their probability of being lung 
cancer at incidence screening rounds in the Dutch-Belgian Randomized Lung Cancer 
Screening Trial (NELSON). 
Methods: In the ongoing, multicentre, randomised controlled NELSON trial, between 
Dec 23, 2003, and July 6, 2006, 15 822 participants who had smoked at least 15 
cigarettes a day for more than 25 years or ten cigarettes a day for more than 30 years 
and were current smokers, or had quit smoking less than 10 years ago, were enrolled 
and randomly assigned to receive either screening with low-dose CT (n=7915) or no 
screening (n=7907). From Jan 28, 2004, to Dec 18, 2006, 7557 individuals underwent 
baseline screening with low-dose CT; 7295 participants underwent second and third 
screening rounds. We included all participants with solid non-calcified nodules, 
registered by the NELSON radiologists as new or smaller than 15 mm³ (study 
detection limit) at previous screens. Nodule volume was generated semiautomatically 
by software. We calculated the maximum volume doubling time for nodules with an 
estimated percentage volume change of 25% or more, representing the minimum 
growth rate for the time since the previous scan. Lung cancer diagnosis was based on 
histology, and benignity was based on histology or stable size for at least 2 years. The 
NELSON trial is registered at trialregister.nl, number ISRCTN63545820. 
Findings: We analysed data for participants with at least one solid non-calcified 
nodule at the second or third screening round. In the two incidence screening rounds, 
the NELSON radiologists registered 1222 new solid nodules in 787 (11%) 
participants. A new solid nodule was lung cancer in 49 (6%) participants 
with new solid nodules and, in total, 50 lung cancers were found, representing 4% of 
all new solid nodules. 34 (68%) lung cancers were diagnosed at stage I. Nodule 
volume had a high discriminatory power (area under the receiver operating curve 
0.795 [95% CI 0.728-0.862]; p<0.0001). Nodules smaller than 27 mm³ had a low 
probability of lung cancer (two [0.5%] of 417 nodules; lung cancer probability 0.5% 
[95% CI 0.0-1.9]), nodules with a volume of 27 mm³ up to 206 mm³ had an 
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intermediate probability (17 [3.1%] of 542 nodules; lung cancer probability 3.1% [1.9-
5.0]), and nodules of 206 mm(3) or greater had a high probability (29 [16.9%] of 
172 nodules; lung cancer probability 16.9% [12.0-23.2]). A volume cutoff value of 27 
mm³ or greater had more than 95% sensitivity for lung cancer. 
Interpretation: Our study shows that new solid nodules are detected at each 
screening round in 5-7% of individuals who undergo screening for lung cancer with 
low-dose CT. These new nodules have a high probability of malignancy even at a 
small size. These findings should be considered in future screening guidelines, 
and new solid nodules should be followed up more aggressively 




























Lung cancer is a leading cause of death worldwide.1 Randomised controlled trials of 
lung cancer screening in Europe and the USA have explored the value of low-dose 
CT in detection of lung cancer at an early stage to improve prognosis.2,3 The National 
Lung Screening Trial showed a relative reduction in lung cancer mortality of 20% with 
low-dose CT compared with chest radiography.4 In view of these results, most US 
guidelines now recommend lung cancer screening with low-dose CT for high-risk 
individuals.5–12 
So far, most research has focused on lung nodules detected during baseline 
screening. However, new nodules can be detected at subsequent screening rounds 
and complicate management.13 Reports of new nodules have been inconsistent 
because of diﬀerences in deﬁnitions of incident nodules, which restricts comparability.7 
New nodule and respective cancer rates are seldom reported explicitly, and are diﬃcult 
to deduce from published results. In 2005, the Fleischner Society, referring to 
Swensen and colleagues’ Mayo Clinic trial, suggested that 10% of screening 
participants will develop a new nodule annually.14,15 On the basis of results from the 
Early Lung Cancer Action Project (ELCAP),16 the International-ELCAP (I-ELCAP),17 
the Pittsburgh Lung Screening Study (PLuSS),13 and the Mayo trial, an estimated 3.4–
13.1% of screening participants develop a new nodule each year.15 Because these 
nodules developed within a short time-interval, they are expected to be fast growing. 
This factor diﬀerentiates new nodules from those detected at baseline, which might 
have been present for years. Lung cancers found in incidence screening rounds tend 
to be more aggressive than those detected at baseline.18–20 Data from the ELCAP, I-
ELCAP, and Mayo trials show that between 1.6% and 7.5% of participants with new 
nodules develop lung cancer in such a nodule.15–17 
These results suggest that new lung nodules, although mostly benign, might have a 
higher probability of being lung cancer than do nodules detected at baseline. 
Nevertheless, little is known about lung cancer probability and new nodule volume at 
initial detection, or about lung cancer characteristics of new nodules, including 
histology and stage distribution. Up to now, no study has focused on new solid nodules 
found during lung cancer screening. 
We did this analysis to assess the occurrence of new solid nodules and their lung 
cancer probability, and to compare the volume of malignant and benign new solid 
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nodules at initial detection in incidence screening rounds of the Dutch-Belgian 
Randomized Lung Cancer Screening Trial (NELSON). 
  
Methods 
Study design and participants 
The recruitment process and study design of the NELSON trial have been previously 
published and are described in the appendix (pp 1, 2).21–23 Brieﬂy, between Dec 23, 
2003, and July 6, 2006, 15 822 participants from four centres in the Netherlands and 
Belgium were enrolled and randomly assigned to receive low-dose CT screening 
(n=7915) or no screening (n=7907). Eligible patients were adults aged 50–75 years, 
who had smoked 15 or more cigarettes per day for more than 25 years or ten or more 
cigarettes per day for more than 30 years, and were still smoking or had stopped 
smoking less than 10 years previously. People with self-reported moderate or bad 
health (with a questionnaire adapted from the SF-36 questionnaire), inability to climb 
two ﬂights of stairs, bodyweight of 140 kg or more, current or past renal cancer, 
melanoma, breast cancer, or lung cancer diagnosed less than 5 years ago, or a chest 
CT examination less than 1 year ago, were excluded. 
From Jan 28, 2004, to Dec 18, 2006, 7557 participants underwent baseline 
screening.23 The second screening round took place 1 year after the baseline scan 
(annual screen) and the third screening round took place 
2 years after the second screening scan (biannual screen). Results of the fourth 
screening round, done 5.5 years after baseline (2.5 year screening interval), have not 
yet been published, and were not included in the present analysis. 
For our study, we included all participants with a solid non-calciﬁed nodule in the 
second or third screening round, registered by the NELSON radiologists as new or 
smaller than 15 mm³ (study detection limit)24 at previous screens. Nodules not 
registered as new, such as previously missed nodules, were excluded. The NELSON 
trial was approved by Ethics Committees of all participating centres in the Netherlands 
and Belgium, and authorised by the Dutch Health Care Committee. All participants 








The CT scan protocol of the NELSON trial has been previously published.21,23 At all 
screening sites, 16-multidetector CT scanners or, in later rounds, 64-multidetector 
scanners were used (Sensation-16 or Sensation-64, Siemens Medical Solutions, 
Forchheim, Germany; or Mx8000 IDT, Brilliance 16P, or Brilliance 64, Philips Medical 
Systems, Best, Netherlands). Reconstructions were made with 1.0-mm slice width and 
0.7-mm interval. Screening conditions and data acquisition were standard across 
screening sites.21,23 
In the ﬁrst two screening rounds, CT scans were read by at least two independent 
radiologists with experience in thoracic CT ranging from 1 year to more than 20 years. 
In the third and fourth screening rounds, single reading was done by radiologists with 
at least 6 years of experience in thoracic imaging. CT data analysis was done on digital 
workstations (Leonardo, Siemens Medical Solutions, Forchheim, Germany) with 
semiautomated volumetric software (LungCARE, version Somaris/5 VA70C-W, 
Siemens Medical Solutions, Forchheim, Germany). On the basis of the three-
dimensional nodule volume, this software also simulated longest and perpendicular 
nodule diameter in the axial plane. Within the NELSON nodule management protocol, 
radiologists could over-rule protocol-based screening results (done for 195 [6%] of 
3318 participants at the baseline screening round).25 High suspicion of malignancy 
(eg, enlarged mediastinal lymph nodes) or benignity (eg, benign calciﬁcation patterns) 
were reasons for manual adjustment.25 
For subsequent CT scans, nodules were individually matched on previous scans by 
the software’s matching algorithm (depending on consistency, size, and location), and 
visually checked by the radiologists. Nodules were classiﬁed as new if they were not 
present or smaller than the detection limit (<15 mm³) at any previous scan.21 Exact 
volumes of nodules smaller than 15 mm³ at initial detection or at retrospective 
assessment were not recorded in the database. Data generated during CT evaluation 
were immediately uploaded to the NELSON management system.21 For our study, we 
used nodule information at ﬁrst nodule detection as reported in the NELSON 
management system. For nodules eventually diagnosed as cancer, we supplemented 
data with cancer-speciﬁc information obtained at diagnosis, such as histology and 
stage. We included only screen-detected lung cancers in this analysis because interval 
cancers of the NELSON trial’s ﬁrst three rounds have been reported previously.26 
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The NELSON nodule management protocol has been described in detail elsewhere 
and is summarised in the appendix (pp 1, 2).21 In brief, the screening outcome could 
be negative (regular screening continued), indeterminate (short-term follow-up low-
dose CT), or positive (immediate referral to pulmonologist). At ﬁrst detection (baseline 
or incidence screening), solid nodules were assessed based on volume. Because new 
nodules were considered fast-growing, their follow-up strategy diﬀered from baseline 
nodules.21 New nodules measuring 15–50 mm³ without benign characteristics were 
considered indeterminate (follow-up low-dose CT after 1 year), new nodules 
measuring 50–500 mm³ were also considered indeterminate (follow-up low-dose CT 
within 6–8 weeks), and new nodules measuring 500 mm³ or more were considered 
positive (immediate referral to pulmonologist). After initial detection, subsequent 
evaluation of a nodule was based on growth and volume doubling time. Growth was 
deﬁned as a percentage volume change of 25% or more, and led to calculation of the 
volume doubling time as described in the nodule management protocol.21 
In case of positive screening results, participants were referred for diagnostic work-up 
according to national and international guidelines.21,27 Malignancy was based on 
histology, and benignity was based on histology or stable size for at least 2 years.21 
The NELSON chief pathologist reassessed obtained lung cancer specimens.27 
 
Statistical analysis 
At initial detection of a new solid nodule after baseline screening, regular calculation 
of the volume doubling time is impossible because no earlier measurement is available 
for comparison. For our analysis, we estimated a maximum volume doubling time, 







where VDTmax is the maximum volume doubling time, V2 is the volume of the new 
nodule at ﬁrst detection, V1 is the study detection limit of 15 mm³ as maximum volume 
at the previous scan, and Δt is the time between new solid nodule detection and 
previous scan in days. We calculated the maximum volume doubling time for nodules 
with an estimated percentage volume change of 25% or more (≥18.75 mm³), 
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considering 15 mm³ as V1. In theory, the actual volume doubling time in the examined 
time interval might have been faster, but not slower, than the calculated maximum 
time. 
Normality testing for continuous variables was done with the Kolmogorov–Smirnov 
test. Continuous variables were analysed with the Mann–Whitney U test and are 
presented as medians and IQRs. We used Fisher’s exact test to analyse nominal 
variables. We calculated 95% CIs with the Agresti–Coull method. We calculated 
probabilities of lung cancer stratiﬁed by diﬀerent nodule variables by dividing the 
number of lung cancers by the total number of nodules. Receiver operating 
characteristic (ROC) analysis was done for nodule volume and simulated mean nodule 
diameter (mean of longest and perpendicular simulated diameter) at ﬁrst new nodule 
detection with eventual lung cancer diagnosis as the outcome to evaluate their 
performance as predictors of lung cancer and to estimate cutoﬀ values. We derived 
cutoﬀ values with a predeﬁned overall sensitivity of 95% and Youden Indices as 
reference points for further adaption,28 optimising intermediate and high-risk groups. 
Appendix p 2 describes the calculations used for ROC analysis for participant-level 
calculations. We calculated sensitivities by dividing true-positive cases by the numbers 
of true-positive and false-negative cases. We calculated speciﬁcities by dividing true-
negative cases by the numbers of true-negative and false-positive cases. We 
developed a risk prediction model to assess whether the established relation between 
volume of a new solid nodule and lung cancer diagnosis remained signiﬁcant 
independent of other risk factors (ie, age, sex, pack-years, smoking status, time since 
previous scan, solid nodule count at baseline, and nodule imaging and volume; 
appendix p 4). All statistical tests were two-sided and p<0.05 was deemed signiﬁcant. 
We did statistical analysis with SPSS (version 22), R (version 3.2.3), and Microsoft 




Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. JEW, MAH, RV, and HJdK had access to 
the raw data. The corresponding author had full access to all the data in the study and 
ﬁnal responsibility for the decision to submit for publication. 





Figure 1 shows a ﬂowchart of new solid nodules detected within the second and third 
screening round.  
 
 
Figure 1: Flowchart of new solid nodules detected during the second and third screening rounds 
Some participants had a new nodule and, for example, previously missed nodules. Whereas the missed nodule was excluded, 
the new nodule (and therefore the participant) was included 
 
Of the 15 822 participants enrolled in the NELSON trial, 7907 (50%) participants were 
assigned to the no screening group; 620 (8%) of 7915 screening participants did not 
participate in the second screening examination for various reasons (eg, lung cancer 
diagnosis at baseline, death, dropout); 5150 (71%) of 7295 participants in the second 
and third screening rounds had no new nodule described and, in 1605 (75%) of 2145 
participants with new nodules described, a nodule was not identiﬁed as new by the 
radiologist (eg, missed at previous screen), excluding 1321 (18%) participants without 
a new nodule; and 37 (<1%) participants with only calciﬁed or subsolid new nodules 
were not included. 1222 new solid nodules were registered in 787 (11%) of the 7295 
participants who underwent second and third screening scans (not accounting for 
participant dropout; ﬁgure 1). 273 (22%) of new solid nodules represented nodules 
3681 nodules detected in 2145 participants 
registered within the second and third screening 
rounds 
2396 nodules excluded from 1605 participants  
2396 nodules were not registered as new in 
the NELSON management system 
1285 new nodules in 824 participants 
63 nodules excluded from 55 participants  
63 nodules were calcified, part-solid, or 
pure ground-glass 
1222 new solid non-calcified nodules in 787 
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retrospectively identiﬁed as smaller than the detection limit (<15 mm³) in a previous 
screen. limit (<15 mm³) in a previous screen. 




A higher number of pack-years smoked and a lower number of solid nodules at 
baseline screening signiﬁcantly increased the probability of a new solid nodule being 
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lung cancer (table 1). Increased age was not signiﬁcantly associated with lung cancer 
(table 1). In 359 (46%) participants, no solid nodule had been found during baseline 
screening (table 1). In 49 (6%) participants with new solid nodules, a new solid nodule 
was lung cancer (table 1). One participant was diagnosed with synchronous double 
tumours in two new nodules. In total, 50 lung cancers were found, representing 4% of 
all new solid nodules (table 2).  
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Median nodule size at ﬁrst detection of new solid nodules was 41 mm³ (IQR 21–116), 
and median volume of lung cancers (296 mm³ [IQR 73–721]) diﬀered signiﬁcantly from 
benign nodules (39 mm³ [21–103]; p<0.0001). ROC analysis showed an area under 
the curve (AUC) for nodule volume of 0.795 (ﬁgure 2). However, the value of nodule 
size as predictor for lung cancer diﬀered with varying screening interval length; in the 
second screening round nodule volume had an AUC of 0.686, whereas the AUC rose 
in the third screening round to 0.837 (ﬁgure 2). 
 
 
Figure 2: Receiver operating characteristic curves of nodule volume at initial detection, discriminating 
malignant from benign new solid nodules 
Exact volume measurement was not available for 89 benign nodules and two cancers, and they were not included in the 
calculations. AUC=area under the curve. 
 
In the NELSON trial, the volume cutoﬀ value for new nodules, leading to follow-up 
within 6–8 weeks, was 50 mm³ or more, which provided a sensitivity of 81.3% (95% 
CI 67∙8–90∙0) and a speciﬁcity of 57.7% (54.7–60.6) for lung cancer. To reach 95% 
sensitivity, a cutoﬀ value of 27 mm³ or more (sensitivity 95.8% [95% CI 85.2–99.6]; 
speciﬁcity 38.3% [35.5–41.3]) would be necessary. Nodules smaller than 27 mm³ had 
a low lung cancer probability, nodules with a volume of 27 mm³ up to 206 mm³ had an 
intermediate probability, and nodules of 206 mm³ and higher had a high probability 











On the basis of the simulated mean diameter, proposed cutoﬀ values are smaller than 
3.7 mm for a negative screen (≥3.7 mm: sensitivity 95.8% [95% CI 85.2–99.6]; 
speciﬁcity, 32.9% [30.2–35.8]), and 8.2 mm or more for a positive screen (appendix p 
3). 
The median maximum volume doubling time of new nodule lung cancers diﬀered 
signiﬁcantly from the median time of benign new nodules (139 days [IQR 104–211] vs 
278 days [140–549]; p<0.0001; 
appendix p 3). The median maximum volume doubling time of adenocarcinomas was 
191 days (IQR 146–348) and of squamous-cell carcinomas was 133 days (105–182; 
table 4).  
 





However, in this analysis maximum volume doubling time did not improve risk 
stratiﬁcation by nodule volume (data not shown). The median maximum volume 
doubling time of new nodule lung cancers did not diﬀer signiﬁcantly between the 
second and the third screening rounds (127 days [IQR 73–206] vs 144 days 
[105–220]; p=0.48). 
Less than half of screen-detected lung cancers in new solid nodules were 500 mm³ or 
more at ﬁrst nodule detection (table 4). Histologically, most lung cancers were 
adenocarcinomas, squamous-cell carcinomas, or small-cell lung carcinomas (table 4). 
Most small-cell lung carcinomas and squamous-cell carcinomas had volumes greater 
than 500 mm³ at ﬁrst nodule detection (table 4). However, few adenocarcinomas 
initially presented with volumes of 500 mm³ and more, whereas roughly two-ﬁfths were 
smaller than 50 mm³ at ﬁrst detection. Most lung cancers were diagnosed at stage I 
(table 4). Of cancers detected in the second screening round, 11 (79%) of 14 were 
stage I, compared with 23 (64%) of 36 in the third screening round (p=0.50; table 2). 
In about half the lung cancer cases, participants were referred immediately after ﬁrst 
new solid nodule detection (table 4). Adenocarcinomas tended to be referred later, 
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with 16 (84%) of 19 nodules not being referred immediately, whereas only ten (32%) 
of the other 31 cancers were not referred immediately (p=0.00045; table 4). 
 
Discussion 
In this study, we determined the occurrence of solid nodules newly detected in the 
second or third screening round of the NELSON trial, assessed their lung cancer 
probability, and provided information about stage and cancer histology. Furthermore, 
we proposed cutoﬀ values for nodule volume as a guide for further management of 
new solid nodules in lung cancer screening. In the ﬁrst two incidence screening rounds 
of the NELSON trial, radiologists registered new solid nodules in 787 (11%) of 7295 
participants. A new solid nodule was diagnosed as lung cancer in 49 (6%) of 787 
participants. Most lung cancers were adenocarcinoma, squamous-cell carcinoma, and 
small-cell lung cancer, and most were diagnosed at stage I. Nodule volume could be 
used for risk stratiﬁcation in new solid nodules, with a sensitivity of more than 95% for 
a volume cutoﬀ of 27 mm³ or more. In this setting, new solid nodules of 206 mm³ or 
more had a high lung cancer probability.  
Few studies of lung cancer screening have published detailed data regarding new 
nodules at incidence screening rounds. As stated in British Thoracic Society 
guidelines29 for the investigation and management of pulmonary nodules, little 
evidence exists for the management of new nodules that appear in follow-up CTs. Our 
study not only oﬀers insight into the cancer probability of such nodules, but also 
provides information about stage and cancer histology. Furthermore, to our 
knowledge, this is the ﬁrst time nodule volume cutoﬀ values have been established as 
a guide for further management of new solid nodules in lung cancer screening. 
In the second screening round, 344 (5%) of 7295 participants had new solid nodules. 
This number is somewhat similar to annual new nodule numbers reported in the I-
ELCAP trial (1460 [5%] of 27 456 participants), the ELCAP trial (40 [3%] of 1184 
participants), and the PluSS trial (256 [7%] of 3423 participants);13,16,17 the Mayo Clinic 
trial reported a higher proportion (191 [13%] of 1464 participants).15 Nevertheless, 
these data are restricted in their comparability, because new nodules were deﬁned 
diﬀerently within trials and rates of new nodule detection have not been reported 
explicitly.7 
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The clinical signiﬁcance of new solid nodules is underlined by the high cancer rate. In 
the NELSON trial, 70 (1%) of 7557 participants were found to have lung cancer during 
baseline screening,23 and 200 (3%) of 7582 participants were found to have lung 
cancer during the ﬁrst three screening rounds.27 Nevertheless, cancers detected in the 
ﬁrst three rounds include those found within 44 participants with new nodule lung 
cancer (excluding ﬁve participants in whom cancer diagnosis occurred in the fourth 
round). In the present study, a new solid nodule was lung cancer in 6% of participants 
with new solid nodules. When these numbers are compared, new solid nodules seem 
to have a higher lung cancer probability than do baseline nodules. Furthermore, at 
baseline, 3816 (50%) of 7557 participants had at least one pulmonary nodule, causing 
further follow-up in 1570 (21%) participants due to suspiciousness of a nodule.23 
Eventually, lung cancer was found in 80 (5%) of 1570 participants with an 
indeterminate or positive test result at baseline.23 In that sense, mere detection of a 
new solid nodule during incidence screening might carry the same lung cancer 
probability as a suspicious test result during baseline screening (6% vs 5%; p=0.25). 
In 2014, the American College of Radiologists released assessment categories for 
nodules detected during lung cancer screening (so-called Lung-RADS) and, as in the 
NELSON nodule management protocol, follow-up for new nodules is recommended 
at smaller sizes than for baseline nodules.21,30 Our results conﬁrm that new solid 
nodules detected during incidence rounds of lung cancer screening need a more 
aggressive follow-up strategy than baseline nodules, with short-term follow-up 
evaluation for growth assessment required for smaller nodules. At these tiny nodule 
sizes, growth detection based on two-dimensional diameter evaluation is unreliable,31 
favouring volumetry. 
In the NELSON trial, baseline nodules smaller than 100 mm³ had a lung cancer 
probability of about 0.6%, were not predictive of lung cancer, and did not necessitate 
additional follow-up scans.32 However, this criterion does not apply in the case of new 
solid nodules. As shown in the present study, 3% of participants whose largest new 
solid nodule was smaller than 100 mm³ were eventually diagnosed with lung cancer, 
with 15 (1.8%) of 819 new solid nodules smaller than 100 mm³ found to be lung cancer. 
Large volume of new solid nodules was the most important predictor of lung cancer, 
and remained so after correction for possible confounding variables such as time from 
previous CT scan, sex, age, number of pack-years, nodule margin, solid nodule count 
at baseline (multinodularity), and nodule location, with a cutoﬀ value of 27 mm³ or more 
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for further follow-up of new solid nodules having more than 95% sensitivity. Age was 
not signiﬁcantly associated with new nodule lung cancer. Possible explanations could 
be that the number of cases was too low to show the correlation, or perhaps fast 
nodule growth is less associated with age, possibly even with a converse relation, with 
older individuals having less fast-growing nodules. We identiﬁed that new solid 
nodules smaller than 27 mm³ have a low lung cancer probability and their detection 
should be followed by regular screening, new solid nodules of 27 mm³ up to 206 mm³ 
have an intermediate lung cancer probability requiring short-term follow-up, and new 
solid nodules of 206 mm³ or greater have a high lung cancer probability necessitating 
immediate diagnostic evaluation. These ﬁndings could be incorporated into radiology 
protocols under development for new trials of lung cancer screening. Nevertheless, 
the proposed cutoﬀ estimates based on the ﬁrst three rounds of the Nelson trial might 
be adjusted when further data become available from this or other ongoing trials, such 
as the UK Lung Cancer Screening Trial (ISRCTN78513845). Combining trial data from 
NELSON and the UK Lung Cancer Screening Trial, which used the same volume 
screen protocols, could provide further insight into if and how lung cancer screening 
protocols should be improved, and might be necessary to obtain a number of cases 
large enough to enable even more accurate assessment. 
We provided cutoﬀ values for simulated mean nodule diameter. Nodules smaller than 
3.7 mm had low lung cancer probability, nodules of 3.7 mm to less than 8.2 mm had 
intermediate lung cancer probability, and nodules of 8.2 mm or greater had high lung 
cancer probability. These probabilities are in concordance with lung cancer 
probabilities for the respective American College of Radiologists Lung-RADS 
categories.30 However, these diameters represent simulated diameter measurements 
of new nodules, extrapolated from computer-generated volume measurements based 
on three-dimensional voxel analysis.33 Manual diameter measurements are far less 
precise and reproducible,31 and would probably yield diﬀerent results. 
The diﬀerence in risk stratiﬁcation of nodule volume between second and third 
screening rounds (AUC 0.686 [95% CI 0.542–0.829] vs 0.837 [0.767–0.908]) suggests 
that new nodules need time to grow in order to be evaluated based on size only, 
making measures such as the volume doubling time crucial for follow-up assessment. 
Whether our results can be used to guide management of incidentally detected 
nodules depends on the setting in which the nodule was detected. First, a previous 
chest CT must be available to conﬁrm that the nodule is actually new. Second, the 
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presented lung cancer probabilities were based on a high-risk population with a 
relatively high prevalence of lung nodules (about 50%),32 and high overall lung cancer 
risk (about 3% in the ﬁrst 5 years).34 Our results and cutoﬀs should only be 
extrapolated in a population with similar nodule prevalence and lung cancer risk. 
Although we highly recommend separate, more stringent, guidelines for new nodules 
on the basis of our results, future studies based on incidentally detected nodules 
should focus on cutoﬀ values for this nodule group. 
Of the 50 new nodule lung cancers, 34 (68%) were stage I, which is similar to numbers 
recorded during baseline screening of the NELSON trial (46 [64%] of 72 cancers; 
p=0.70) and for overall screening in the ﬁrst three rounds (148 [71%] of 209 cancers; 
p=0.73).23,27 Fewer small-to-intermediate sized lung cancers (<500 mm³) were found 
after biannual screening than after annual screening (ten [71%] of 14 vs 20 [56%] of 
36). However, the proportion of stage I cancers did not diﬀer signiﬁcantly between 
annual and biannual screening, although the number of cancers had roughly doubled 
(14 vs 36 cancers). The maximum volume doubling time was signiﬁcantly lower in new 
nodule lung cancers than in benign new solid nodules. Notably, the median maximum 
volume doubling time of adenocarcinomas (191 days [IQR 146–348]) and squamous-
cell carcinomas (133 days [105–182]) was similar to previously published volume 
doubling time of fast-growing baseline cancers in the NELSON trial of the same 
histological type (196 days [IQR 135–250] and 142 days [91–178], respectively).35 
Perhaps fast-growing baseline cancer and new nodule cancer represent a group of 
relatively young cancers. Nevertheless, even though malignant new nodules might be 
fast growing, detection at an early stage is possible with low-dose CT screening and 
use of volume doubling time for evaluation after ﬁrst detection. Compared with the 
overall screening results of the ﬁrst three rounds,27 new solid nodule cancer comprised 
11 (19%) of 58 cancers found in the second screening round (excluding three new 
nodule lung cancers for which diagnosis occurred in the third round) and 34 (44%) of 
77 cancers even in the third screening round (excluding ﬁve new nodule lung cancers 
for which diagnosis occurred in the fourth round). Thus, management of new solid 
nodules has a great impact on the outcome of a lung cancer screening programme. 
Most trials of lung cancer screening have used an annual screening algorithm. The 
NELSON study was designed to also study the eﬀect of prolonged screening intervals, 
enabling us to provide insights into diﬀerences between annual and biannual 
screening. Presented cutoﬀ values were based on new solid nodules detected after 
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annual and biannual screening and their respective follow-ups, which might make 
direct applications to an annual screening routine diﬃcult. 
Our study had some limitations. We excluded nodules smaller than 15 mm³, because 
they were below the detection limit of the NELSON trial and were therefore not 
reported by the radiologists. We cannot exclude the possibility that the actual number 
of new nodules is somewhat higher than we report based on the NELSON 
management system information. Second, we included only solid nodules, with 
exclusion of part-solid and pure ground-glass nodules. Furthermore, calculation of a 
maximum volume doubling time for new nodules is a new and not yet validated 
approach, and so needs further investigation. Rates of new solid nodules and cancer 
diﬀered between the incidence screening rounds. This inconsistency could be 
explained by the varying time intervals between screening rounds and respective 
follow-up examinations, and by the learning eﬀect of radiologists. Radiologists 
potentially gained increased expertise in distinguishing scars or infections from 
suspicious lesions, and might have refrained from classifying them as suspicious 
nodules to avoid false-positive results. Expertise of radiologists is important to 
decrease false-positive screen results.25 
New solid nodules are detected at each screening round in 5–7% of participants who 
undergo screening for lung cancer by low-dose CT, and have a higher probability of 
lung cancer than do baseline nodules. This factor should be considered in future 
screening guidelines. New solid nodules should be followed up more aggressively than 
nodules detected at baseline screening, for example by using lower volume cutoﬀ 
values (<27 mm³, 27 mm³ to <206 mm³, ≥206 mm³). However, meticulous screening 
and follow-up with volume doubling time enables detection of new solid nodule lung 
cancer at an early stage. Nodule volume should be used to stratify the probability of 
lung cancer of new solid nodules, but more research into new nodules is necessary to 
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Occurrence and lung cancer probability of new solid nodules at incidence CT lung cancer 
screening in the randomized NELSON trial  
 
NELSON nodule management protocol 
At first nodule detection, a nodule is classified by size: 
 
NODCAT 1:  
Nodules with benign characteristics (e.g. benign calcifications, fat component) 
NODCAT 2:  
Solid nodules <50mm³ 
Solid pleural based nodules <5mm in minimal diameter 
Part-solid nodules <8mm in mean diameter 
Part-solid nodules, solid component <50mm³ 
Non-solid nodules <8mm in mean diameter 
NODCAT 3: 
Solid nodules 50-500mm³ 
Solid pleural based nodules 5-10mm in minimal diameter 
Part-solid nodules ≥8mm in mean diameter, and solid component <500 mm3 
Part-solid nodules, solid component 50-500mm³ 
Non-solid nodules ≥8mm in mean diameter 
NODCAT 4: 
Solid nodules >500mm³ 
Solid, pleural based nodules >10mm in minimal diameter 
Part-solid nodules, solid component >500mm³ 
 
If a nodule is detected again at a subsequent screen, it is classified according to its growth rate. 
For nodules with a percentage volume change of >25%, volume-doubling time (VDT) is 
calculated. Nodules are then classified by growth rate:  
GROWCAT A 
Percentage volume change <25% 
VDT >600 days 
GROWCAT B 
VDT 400-600 days 
GROWCAT C 
VDT <400 days 
 
The screen result could be negative (invitation for the next screen round), indeterminate 
(invitation for a short-term follow-up CT to determine the VDT), or positive (referral for 
diagnostic work-up).  
 




INDETERMINATE, LEADING TO A NEGATIVE SCREEN AFTER FOLLOW-UP: 
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NODCAT 3 with GROWCATs A or B at follow-up examination 
INDETERMINATE, LEADING TO A POSITIVE SCREEN AFTER FOLLOW-UP 




Referral algorithm for new nodules at time of first detection in round 2 and 3: 
NEGATIVE: 
NODCAT 1 
INDETERMINATE, LEADING TO A NEGATIVE SCREEN AFTER FOLLOW-UP: 
NODCAT 2 with GROWCATs A or B at follow-up examination 
NODCAT 3 with GROWCATs A or B at follow-up examination 
INDETERMINATE, LEADING TO A POSITIVE SCREEN AFTER FOLLOW-UP 
NODCAT 2 with GROWCAT C at follow-up examination 





Figure 1: Design of the NELSON trial 
 
Analyses of this study include data from the second screening round (annual screen) and the third screening 
round (biannual screen). 
 
 
Calculations on participant-level 
Receiver operating characteristic analysis was conducted for largest new nodule volume in a 
participant at first new nodule detection with eventual lung cancer diagnosis as outcome. Cut-
off values were derived using a predefined overall sensitivity of 95% and Youden indexes as 
reference points for further adaption, optimizing intermediate and high-risk group. ROC 
analysis showed an area under the curve for nodule volume of 0.782 (95% confidence interval 
[95% CI]: 0.717, 0.842, P<0.0001). A cut-off value of ≥30mm3 (sensitivity, 95.7% [95% CI: 
85.0, 99.6]; specificity, 40.8% [95% CI: 37.2, 44.6]) for the largest new nodule provided >95% 
sensitivity. Participants with the largest new nodules <30mm3 had a low lung cancer probability 
of 0.7% (2/281), whereas participants with the largest new nodule 30mm3-<206mm3 had an 
intermediate probability of 5.5% (17/308), and participants with the largest new nodule 
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Table 1: Volume of largest new solid nodule and lung cancer risk (n=730; 683 
participants without and 47 with eventual lung cancer diagnosis)* 
* For 55 participants without and two with eventual lung cancer diagnosis exact volume measurement was not 
available and they were not considered in the calculations. 
 Second and third screening round  
(participants with lung cancer/ all 
participants) 
Lung cancer probability based on 
the largest nodule  
(95% CI) 
 
All participants with new nodules 









































Abbreviations: 95% CI - 95% confidence interval. 
 
 
Table 2: Simulated diameter at first detection and lung cancer probability of new solid 
nodules (n=1,117; 1,069 benign nodules and 48 lung cancers)* 
* For 103 benign nodules and two cancers no simulated diameter measurement was available and they were not 
considered in the calculations.  
Abbreviations: 95% CI - 95% confidence interval. 
a Diameters were simulated from computer generated volume measurements, based on three-dimensional 
voxels. Manually measured diameters are less accurate and will overestimate nodule size, which corresponds 
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Figure 2: Estimated maximum volume doubling time (VDTmax) for benign and 
malignant new solid nodules 
 
Risk prediction model 
 
A risk prediction model was developed to assess whether the established relationship between 
the volume of the newly developed nodule and the occurrence of lung cancer diagnosis 
remained significant independent of other risk factors. The analyses were performed using R-
version 3.2.3 and the R packages RMS, DCA, epiR and pROC.1-5 The following risk factors 
were considered in the analysis: Age, gender, pack-years, smoking status, time in days since 
the previous scan, solid nodule count at baseline, nodule margin, nodule location, and nodule 
volume. 
 
First, the univariate effect of the risk factors was assessed, as well as the effect of applying 
(non-) linear transformations of these factors. Backwards stepwise selection was used for 
variable selection, using a 5% significance level as a stopping criterion (based on Likelihood 
Ratio tests).  
Table 3 shows the risk prediction model resulting from the backward stepwise selection. This 
model had an area under the receiver operating characteristic curve (AUC) of 0.825 (95% CI: 
0.768, 0.882). The univariate effect of solely using the volume of the newly developed nodule 
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yielded an AUC of 0.795 (95% CI: 0.728, 0.862), with the difference between the two AUC’s 
being non-significant (P=0.15). Thus, while considering additional risk factors improved the 
AUC-statistic, nodule volume was shown to be the most important risk factors for malignancy 
in a new nodule. 
 
The calibration of the prediction model presented in Table 3 was investigated. A calibration 
plot was constructed, shown in Figure 3, which compares the estimated risks to the observed 
risks.6 The 45-degree line, which can be described by an intercept of 0 and a slope of 1, 
describes perfect predictions. The calibration-in-the-large compares the overall estimated risk 
by the model to the observed risk in the dataset, which can be quantified as the intercept of the 
calibration plot.7 The calibration-in-the-large provides an overview of whether the model over- 
or under-estimates risk and should be equal to 0. The model has a calibration-in-the-large of 
0.0002 suggesting a good overall mean calibration. The calibration slope represents the 
agreement with the 45-degree line in the calibration plot and represents the amount of 
overfitting. The calibration slope should be equal to 1. The calibration slope of the model was 
1.0001, which suggests no overfitting. Overall, these analyses suggest the model has good 
internal calibration. 
 
Decision curve analysis was performed to assess the range of risk thresholds for which there is 
a net benefit of using the risk prediction model. The decision curve analysis in Figure 4 shows 
that there is a net benefit for using the model compared with assuming none of the nodules are 
cancerous and assuming all of the nodules are cancerous across probability thresholds of 0% 
to at least 14%. The specificity of the model was assessed at the lowest and highest risk 
thresholds that give a similar sensitivity as a cut-off value of ≥27mm3 based on volume alone 
(sensitivity, 95.8% [95% CI: 85.2, 99.6]; specificity, 38.3% [95% CI: 35.5, 41.3] ). The 
corresponding cut-offs for the risk model are 1.2 %, which yields a sensitivity of 95.8% (95% 
CI: 85.8, 99.5%) and a specificity of 38.3% (95% CI: 35.4, 41.2) and 1.68% (sensitivity, 95.8% 
[95% CI: 85.8, 99.5]; specificity, 48.8% [95% CI: 45.8, 53.8]), suggesting that considering 
additional risk factors may improve specificity somewhat. However, nodule volume has been 
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Table 3: Risk prediction model resulting from backward stepwise selection 
Parameter Coefficient Standard error P-value 
Model constant -10.8698 1.9213 - 
One solid nodules at the baseline 
scan (compared to none) 
-1.4106 0.6475 0.0294 
Two solid nodules at the baseline 
scan (compared to none) 
-1.1416 1.0562 0.2798 
Three solid nodules at the baseline 
scan (compared to none) 
-1.4110 1.0437 0.1764 
Four solid nodules at the baseline 
scan (compared to none) 
-1.5970 1.1109 0.1506 
Five solid nodules at the baseline 
scan (compared to none) 
-7.8827 31.3761 0.8016 
Six or more solid nodules at the 
baseline scan (compared to none) 
-0.4598 1.0557 0.6631 
Nodule location in upper lobe 
(compared to lower lobe) 
0.6724 0.3259 0.0391 
Logarithmic transformation of 
number of days since the previous 
scan  
0.5637 0.2796 0.0438 
Logarithmic transformation of the 
new nodule volume (in mm3) 
0.9011 0.1150 <0.0001 
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Persisting new nodules in incidence rounds of the NELSON CT lung 
cancer screening study 
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Background: US guidelines recommend low-dose CT (LDCT) lung cancer screening 
for high-risk individuals. New solid nodules after baseline screening are common and 
have a high lung cancer probability. Currently, no evidence exists concerning the risk 
stratification of nonresolving new solid nodules at first LDCT screening after initial 
detection.  
Methods: In the Dutch-Belgian Randomized Lung Cancer Screening (NELSON; 
trialregister.nl, ISRCTN63545820) Trial, 7,295 participants underwent the second and 
6,922 participants the third screening round. We included participants with solid 
nodules, that were registered as new or <15mm³ (study detection limit) at previous 
screens and received additional screening after initial detection; thereby excluding 
high-risk nodules according to the NELSON management protocol (nodules 
≥500mm3). 
Results: Overall, 680 participants with 1,020 low- and intermediate-risk new solid 
nodules were included. A total of 562 (55%) new solid nodules were resolving, leaving 
356 (52%) participants with a nonresolving new solid nodule of whom 25 (7%) were 
diagnosed with lung cancer. At first screening after initial detection, volume doubling 
time (VDT), volume, and VDT combined with a predefined ≥200mm3 volume cutoff 
had high discrimination for lung cancer (VDT, area under the curve [AUC]: 0.913; 
volume, AUC: 0.875; VDT and ≥200mm3 combination, AUC: 0.939). Classifying a new 
solid nodule with either ≤590days VDT or ≥200mm3 volume positive provided 100% 
sensitivity, 84% specificity, and 27% positive predictive value for lung cancer. 
Conclusions: More than half of new low- and intermediate-risk solid nodules in LDCT 
lung cancer screening resolve. At follow-up, growth assessment potentially combined 












Lung cancer remains a leading cause of cancer-related death worldwide and 
numerous trials are exploring lung cancer screening by low-dose computed 
tomography (LDCT) to improve prognosis.1,2 The National Lung Screening Trial 
showed a 20% reduced lung cancer mortality when comparing LDCT to chest 
radiography.3 Accordingly, most US guidelines currently recommend LDCT lung 
cancer screening for high-risk individuals,4–6 while European stakeholders are 
awaiting the final results of the Dutch–Belgian lung cancer screening (NELSON) 
trial.5,7 
Previously, research focused on nodules detected at baseline screening, but with 
increasing duration of a trial its success depends on the management of new 
nodules.7–9 While baseline nodules might have been present for years before 
detection, new nodules found after baseline by definition have developed within a short 
timeframe. However, there is only limited evidence for the management of new 
nodules and published data uses different definitions of incident nodules.4,8,10–12 
Available data of the Early Lung Cancer Action Project (ELCAP),13 the International-
ELCAP (I-ELCAP),14 the Pittsburgh Lung Screening Study (PLuSS),15 the Mayo trial,16 
NLST17 and the NELSON trial8 suggest that anually between 3-13% of participants 
develop a new nodule after baseline screening. Recently, the NELSON trial provided 
a first in-depth analysis of new solid nodules and proposed lower cutoff values for new 
nodules as compared to baseline nodules,8 which were adopted in a European 
position statement on lung cancer screening.7 Nodule risk stratification is based on a 
nodule’s lung cancer probability, with only high-risk nodules (commonly >15% lung 
cancer probability) warranting immediate referral of a participant to a specialist, 
whereas low (commonly <1% lung cancer probability) and intermediate risk nodules 
receive additional screening LDCT scans.7,8,11,18,19 While size-based management 
strategies for initial new nodule detection have been proposed, with nodules ≥200mm3 
being high-risk,7,8,20 there is insufficient evidence concerning the management of low 
and intermediate risk new nodules at subsequent screening. Furthermore, pulmonary 
nodules are known to be dynamic,21,22 but few studies have assessed resolving 
nodules in general and mostly focussed on subsolid nodules.22–25  
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The aim of this study was to investigate the final outcome of new solid nodule nature 
at first follow-up or regular screening after initial new solid nodule detection in 




Recruitment process and study design of the NELSON trial (trialregister.nl, number 
ISRCTN63545820) have been published before.26–28 Summarized, eligible patients 
were adults aged 50–75 years, who had smoked >15 cigarettes per day for >25 years 
or >10 cigarettes per day for >30 years and were still smoking or stopped smoking 
<10 years previously. The NELSON trial was approved by ethics boards of all 
participating centers. All participants provided written informed consent. Between 
December 2003 and July 2006, 15,792 participants from four centers in the 
Netherlands and Belgium were randomized to low-dose chest CT screening (n=7,900) 
or no screening (n=7,892) and between April 2004 and December 2006, 7,557 
participants underwent baseline screening. Within the NELSON trial’s protocol, 
participants were followed up for 10 years after randomization.27 For this analysis, 
participants with a solid non-calcified nodule initially detected in the second (annual 
screening) or third (biannual screening) screening round and registered by the 
NELSON radiologists as new or <15mm3 (study detection limit) at previous screens 
were included if they had one additional screening LDCT within the NELSON trial. New 
nodules initially detected in the fourth round (2.5 year screening interval), which only 
included a subgroup of patients with a higher proportion of current smokers and more 
participants with at least one non-negative screening,29 were not included to avoid 
confounding through this selection. Participants referred immediately for diagnostic 
work-up after initial new nodule detection and participants without any further 
screening LDCT were excluded from this analysis. 
 
Procedures and Nodule management 
The CT scan procedures were published before and are described in the 
Supplementary Appendix.26,28 New solid nodules were classified into four categories 
(NODCAT I-IV): Calcified nodules or nodules with other benign characteristics 
(NODCAT I, regular screening), new solid nodules 15-50mm3 (NODCAT II, follow-up 
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LDCT within 1 year), new solid nodules 50-500mm3 (NODCAT III, follow up LDCT 
within 6-8 weeks), and new solid nodules ≥500mm3 (NODCAT IV, immediate referral 
to pulmonologist).26 After initial detection, a nodule’s subsequent evaluation was 
based on volume doubling time (VDT, Supplementary Appendix). A smaller VDT 
signifies faster nodule growth.  
For this study, the original nodule data as reported by the NELSON radiologists were 
used. A nodule detected after baseline was considered new if registered by the 
radiologists as new or below the study detection limit of 15mm3 on the previous scan. 
A new nodule was considered resolving if the NELSON radiologists did not register it 
on the subsequent LDCT after detection due to disappearance or if only a non-
measurable scar or calcified nodule persisted.  
Malignancy and benignity was determined on the basis of histology and diagnostic 
work-up according to national and international guidelines and, in case of benignity, 
also on a negative final screening result in the NELSON trial and no interval or post-
screening lung cancer according to the national cancer registries of the Netherlands 
and Belgium and medical file review.9,19,26 
  
Statistical Analysis 
Non-normally distributed continuous variables were analyzed using the Mann-Whitney 
U test and described as medians and interquartile ranges (IQR). Fisher’s exact test 
was used to analyze nominal variables. The 95% confidence intervals (CI) were 
calculated with the Agresti-Coull method.  
The VDT was calculated for all nonresolving new solid nodules based on the volume 
at initial detection and first screening after initial detection. For nodules that decreased 
in size, the consequently negative VDT was converted to positive by subtracting it from 
the maximum (thus slowest) observed positive VDT to enable receiver operating 
characteristic (ROC) analysis with all nodules. The European position statement on 
lung cancer adopted a ≥200mm3 cutoff for high-risk new solid nodules from the 
NELSON trial’s results.7,8 This cutoff was combined with VDT using a binary logistic 
regression model. Receiver operating characteristic (ROC) analysis was performed 
for VDT and volume at follow-up, as well as for the model probabilities of the 
combination of VDT and ≥200mm3, with eventual lung cancer diagnosis as outcome. 
ROC curve comparison was performed using the method described by DeLong et al.30 
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Optimized cutoffs for VDT and volume were derived using Youden Indices as 
reference points for further adaption.31 The identified VDT cutoff was also assessed 
with the predefined ≥200mm3 volume cutoff, classifying a nodule positive when at least 
one criterion was fulfilled. Additionally, predefined VDT cutoffs of <400 days, 400-600 
days and VDT >600 days were assessed. Missing data were excluded from the 
respective analyses and are referenced below the respective Tables and Figures.  
Corresponding calculations for simulated mean diameter (mean of longest and 
perpendicular simulated diameter) as well as cutoff analyses on participant level based 
on the largest or fastest-growing nodule are presented in the Appendix.  
All statistical tests were two-sided. Statistical analyses were performed with SPSS 
version 25.0 (IBM) and R (version 3.3.3).  
 
Results 
Overall, 680 participants with 1,020 new solid nodules and a follow-up or regular 
screening LDCT were included (Figure S1). Median age of included participants was 
59 years (IQR 55-63) at baseline, 76% (514/680) were male, and median smoking 
pack-years at baseline were 39 (IQR 30-49) (Table S1). Of the 1,020 included nodules, 
25 (2.5%) were lung cancer and 232 (23%) could be identified in retrospect as 
minuscule opacity smaller than the detection limit (15mm3).  
 
Resolving and nonresolving new solid nodules 
A total of 562 (55%) of the 1,020 new solid nodules were resolving. In 321 (47%) 
participants all detected new solid nodules resolved, leaving 458 (45%) nonresolving 
new nodules and respectively 359 (53%) participants with at least one nonresolving 
new nodule. New solid nodules visible in retrospect as minuscule opacity below the 
trial’s detection limit were less likely to resolve compared to those not visible in 
retrospect (22% [50/232] vs. 65% [512/788], P<0.0001), and tended to be smaller at 
initial detection with a median of 18mm3 (IQR 16-21mm3) versus 52mm3 (IQR 29-
121mm3, P<0.0001). In total, 97% [224/232] of the nodules visible in retrospect as 
minuscule opacity were <50mm3 at initial detection and the lung cancer probability 
(1.3% [3/224], CI 0.3-4.0%) was similar compared to new solid nodules <50mm3 and 
not visible in retrospect (1.5% [6/394], CI 0.6-3.4%, P=0.855, Table S2).  
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Nonresolving new solid nodules 
In 4 (1.1%) of the 359 participants with nonresolving new solid nodules a benign new 
solid nodule changed to part-solid (n=3) or pure ground-glass (n=1) and in 3 (0.8%) 
participants these nodules were the only new nodules detected. Excluding the 3 
participants with only subsolid nonresolving new nodules, characteristics of the 356 
participants with at least one new solid nodule that persisted are presented in Table 
S3.  
In 25 (7.0%) of the 356 participants a nonresolving new solid nodule was lung cancer 
corresponding to 25 (5.5%) of the 454 nonresolving new solid nodules. At time of 
diagnosis, 23 (92%) of the lung cancers were stage I with adenocarcinoma (16/25 
[64%]) being the most common histology (Table S4). At first follow-up or regular 
screening LDCT, VDT, volume, and simulated mean diameter differed significantly 
between benign nodules and lung cancers (Table 1). ROC analysis demonstrated an 
area under the curve (AUC) of 0.913 (95%CI 0.861-0.965) for VDT, 0.875 (95%CI 
0.822-0.928) for nodule volume, and 0.939 (95%CI 0.904-0.974) for VDT combined 
with the predefined ≥200mm3 cutoff (Figure 1). The AUC of VDT and ≥200mm3 was 
superior to volume (P=0.0322) and statistically comparable to VDT alone (P=0.0535). 
Lung cancer probabilities of nodules stratified by the identified cutoff values for VDT 
(≤590 days) and nodule volume (≥65mm3), as well as the optimized VDT cutoff of ≤590 
days together with the predefined ≥200mm3 volume cutoff are shown in Table 2. The 
performance of these cutoff values stratified by time until first LDCT after initial 
detection is displayed in Table 3. Table S5 summarizes the performance of the 
predefined VDT cutoffs of <400 days, 400-600 days and VDT >600 days for 
comparison. In total, 8.3% (1/12) of new solid nodules with a VDT of 400-600 days 
and 34% (22/64) of nodules with VDT <400 days were lung cancer. The respective 
results stratified by the visibility of the new solid nodule in retrospect is presented in 
Table S6. Using the ≤590 days VDT cutoff together with the predefined ≥200mm3 
volume cutoff reached 100% (95%CI 84-100%) sensitivity, 84% (95%CI 80-87%) 
specificity, 27% (95%CI 19-37%) positive predictive value, and 100% (95%CI 99-
100%) negative predictive value for discriminating lung cancer. The respective 
analyses based simulated mean diameter and calculations based on participant level 
can be found in Tables S7-S9 and Figures S2 and S3. The discriminative performance 
(AUC) of volume compared to simulated-mean diameter was superior (P=0.0011) 
(Figure S1).  
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 All new solid nodules that persisted on the 
first LDCT after detection, n=454 (100%) 
Subsequent LDCT within 120 days, n=210 (46%) 
(short-term follow-up) 
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Table 1: Characteristics of nonresolving new solid nodules that persisted as solid nodule on the first follow-up or regular screening 
after initial detection  
N=454; 429 benign nodules and 25 lung cancer nodules 
Abbreviations: ∞ - decreased size, IQR - Interquartile range, LDCT – Low-dose computed tomography, VDT - Volume doubling time. 
*Diameters were simulated from computer-generated volume measurements, based on three-dimensional voxels. Manually measured diameters are less accurate and will 
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Table 2: Lung cancer probability of nonresolving new solid nodules stratified by volume doubling time and volume at first follow-up or regular 
screening after initial detection  
N=437; 412 benign nodules and 25 lung cancer nodules 
Abbreviations: CI - Confidence interval, IQR - Interquartile range, LDCT – Low-dose computed tomography, VDT - Volume doubling time.  
Exact volume measurement was not available or classification based on radiologist’s size categorization was unattainable for 17 benign nodules, and they were not included in the calculations. 





Figure 1: Receiver operating characteristic curves* of volume doubling time, nodule 
volume and the combination of volume doubling time and ≥200mm3 at first follow-up or 
regular screening after initial detection for discrimination of lung cancer.  
Volume doubling time (AUC: 0.913, 95%CI 0.861-0.965, P<0.0001); Volume (AUC: 0.875, 95%CI 0.822-0.928, 
P<0.0001); Volume doubling time and ≥200mm3 criterion (AUC: 0.939, 95%CI 0.904-0.974, P<0.0001). AUC=area 
under the curve. 
* Exact volume measurement was not available for 34 benign nodules and one lung cancer, and they were not included 
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 All new solid nodules that 
persisted on the first 
LDCT after detection 
Subsequent LDCT within 
120 days 
(short-term follow-up) 
Subsequent LDCT after 
120 days 
 
VDT ≤590 days 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
23/25, 92.0% (73.9-98.9) 
360/412, 87.4% (83.8-90.3) 
23/75, 30.7% (21.3-41.9) 
360/362, 99.4% (97.9-100) 
 
15/17, 88.2% (64.4-98.0) 
137/178, 77.0% (70.2-82.6) 
15/56, 26.8% (17.5-41.0) 
137/139, 98.6% (94.6-99.9) 
 
8/8, 100% (62.8-100) 
223/234, 95.3% (91.7-97.4) 
8/19, 42.1% (23.1-63.8) 
223/223, 100% (98.0-100) 
VDT ≤590days or volume 
≥200mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
 
25/25, 100.0% (84.2-100) 
345/412, 83.7% (79.9-
87.0) 





17/17, 100.0% (78.4-100) 
124/178, 69.7% (62.5-76.0) 
17/71, 24.6% (15.9-36.0) 
124/124, 100.0% (96.4-100) 
 
 
8/8, 100% (62.8-100) 
221/234, 94.4% (90.6-96.8) 
8/21, 38.1% (20.7-59.2) 
221/221, 100.0% (97.9-100) 
Volume ≥65mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
24/25, 96.0% (78.9-100) 
313/412, 76.0% (71.6-79.9) 
24/123, 19.5% (13.4-27.5) 
313/314, 99.7% (98.0-100) 
 
16/17, 94.1% (71.1-100) 
94/178, 52.8% (45.5-60.0) 
16/100, 16.0% (10.0-24.5) 
94/95, 98.9% (93.7-100) 
 
8/8, 100% (62.8-100) 
219/234, 93.6% (89.6-96.2) 
8/23, 34.8% (18.7-55.2) 
219/219, 100% (97.9-100) 
Table 3: Performance of the identified cutoffs at first follow-up or regular screening after 
initial detection 
(N=437; 412 benign nodules and 25 lung cancer nodules) 
Abbreviations: IQR - Interquartile range, LDCT – Low-dose computed tomography, NPV - Negative predictive value, PPV - 
Positive predictive value, VDT - Volume doubling time.  
Exact volume measurement was not available or classification based on radiologist’s size categorization was unattainable for 










This study focused on new solid nodules detected in incidence screening rounds 
(annual and biannual screening) of the NELSON trial and at least one additional 
screening LDCT. These nodules are low and intermediate risk according to the 
NELSON management protocol, since participants with high-risk nodules were 
referred immediately to a pulmonologist without additional follow-up.26  
We report three major findings. First, 55% of the new solid nodules included were 
resolving (65% of the nodules not visible in retrospect, 22% of those visible in 
retrospect as a minuscule opacity below detection limit), and in 47% of the included 
participants all detected new solid nodules were resolving. Second, eventually, 7.0% 
of the participants with a nonresolving new solid nodule that persisted as solid nodule 
had lung cancer in such a nodule, with 5.5% of the nonresolving new solid nodules 
that persisted as solid nodule being diagnosed as lung cancer. Third, at first screening 
LDCT after initial detection, VDT (AUC: 0.913) and volume (AUC: 0.875) had high 
discriminatory power. The combination of VDT and the previously established 
≥200mm3 high-risk cutoff (AUC: 0.939) outperformed volume alone but was not 
significantly better than VDT alone (P=0.0535). Employing the identified ≤590 days 
VDT cutoff together with the ≥200mm3 high-risk cutoff, thereby classifying nodules 
positive when at least one criterion was fulfilled, provided 100% sensitivity and 84% 
specificity for discriminating lung cancer. 
 
A previous study of the NELSON trial examined solid baseline nodules sized 50-
500mm3 and reported that 90% (867/964) of the nodules persisted, with 3% (27/867) 
of nonresolving nodules being diagnosed as lung cancer.24 In this study, 44% of new 
solid nodules sized 50-500mm3 at initial nodule detection persisted with 10% being 
lung cancer, underlining the high lung cancer risk of new nodules. In an earlier study, 
we observed that with longer screening interval the number of new nodules did not 
increase proportionally while the percentage of lung cancers rose.8 This phenomenon 
could be explained by the nature of nonresolving new nodules: The longer a screening 
interval, the higher the proportion of nonresolving new nodules and consequently the 
higher the percentage of lung cancers. Therefore, the screening interval length prior 
to detection might carry implications for the significance and potential lung cancer 
probability of a new nodule. Similarly, new nodules visible as a very small opacity in 
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retrospect were less likely to resolve than new nodules not visible at all. This 
corroborates the finding that at equivalent size, visibility as very small nodule in 
retrospect is significantly associated with lung cancer when compared to new nodules 
not visible at all.20 
 
In our previous study concerning risk-stratification of new solid nodules at initial 
detection, it was shown that new solid nodules <30mm3 (adapted from 27mm3; low 
risk, <1% lung cancer probability) should continue regular screening, new solid 
nodules between 30-<200mm3 (intermediate risk, around 3% lung cancer probability) 
represent an indeterminate subgroup requiring short-term follow-up by LDCT, and new 
solid nodules ≥200mm3 (around 17% lung cancer probability) should be referred for 
diagnostic evaluation.7,8 This study investigated the management approach for low 
and intermediate risk new solid nodules at first LDCT after initial detection. Risk 
stratification by VDT and size (volume, simulated diameter) reached comparable 
sensitivities, but VDT displayed a superior specificity, especially at short-term follow-
up. The observed statistically optimal VDT cutoff of ≤590 days is analogous to 
currently employed cutoffs of ≤600 days, such as in the British Thoracic Society 
guideline for the investigation and management of pulmonary nodules and the 
NELSON management protocol,7,11,26 and its appropriateness is confirmed for the first 
time in new solid nodules. Based on previous findings of the NELSON trial, the British 
Thoracic Society guideline considers nodules with a VDT between 400-600 days as 
intermediate risk group and nodules with a VDT <400 days as high-risk group.11,19,26 
While the overall performance of the VDT risk-stratification approach has been 
confirmed for low- and intermediate-risk new solid nodules with 30% (23/76) of new 
solid nodules with a VDT ≤600 days being lung cancer (8.3% [1/12] of nodules with 
VDT 400-600 days and 34% [22/64] of nodules with VDT <400 days), further research 
is required to determine whether immediate referral might be appropriate for all low- 
and intermediate-risk new solid nodules with a VDT ≤600 days. Furthermore, any 
employed follow-up time interval should enable the detection of the target VDT cutoff. 
Given that lung cancer growth was shown to not always be exponential or linear,32,33 
addition of a volume limit compelling referral to a pulmonologist might prevent slow 
growing lung cancers from evading timely referral. While this approach further 
increased the sensitivity of the risk-stratification approach, it decreased its specificity 
and could potentially lead to overdiagnosis. Addition of a ≥200mm3 volume limit to 
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VDT reclassified 17 persisting new nodules as positive with 11% (2/17) being lung 
cancer. Further research is necessary to confirm the utility of such a volume limit. 
Results concerning newly detected nodules in lung cancer screening may also apply 
to incidentally detected nodules found in routine care.8,34 The results and cutoffs 
should only be extrapolated in a population with similar epidemiology characteristics 
to the population investigated here. Importantly, the size of new nodules detected in a 
specified timeframe reflects its growth rate and incidentally detected new nodules in 
clinical practice could benefit from calculation of the maximal VDT (slowest possible 
VDT).8  
 
This study has limitations. Nodules <15mm3 were not registered in the NELSON trial. 
Additionally, with increasing trial length, radiologists potentially gained increased 
expertise in distinguishing scars or infections from suspicious lesions and might have 
refrained from classifying them as suspicious nodules to avoid false-positive results. 
Expertise of radiologists is important to decrease false-positive screen results.35 The 
possibility that the actual number of very small new solid nodules is somewhat higher 
than reported here cannot be excluded. The screening intervals were predefined in 
the trial and do not directly translate to clinical practice, where new nodules might be 
found after even shorter or longer intervals. This was a secondary analysis of patients 
with new solid nodules and at least one screening after initial new nodule detection. 
While 1,020 low or intermediate-risk new nodules of 680 participants were assessed, 
the proportion of lung cancers was, as anticipated, moderate (25 lung cancers) and 
further multivariate analyses were not performed. An extensive analysis of new solid 
nodule characteristics has been conducted previously.20 The analyses performed 
grouped new solid nodules that were visible as a minuscule opacity in retrospect 
together with new solid nodules not visible in retrospect. Nevertheless, the cutoff 
values performed adequately in both nodule groups. Within the NELSON management 
protocol, new nodules with a VDT ≤400 days were referred for further diagnostic work-
up. To minimize bias through the protocol, this analysis incorporated all follow-up data 
within the NELSON trial including cancer diagnosis in later rounds and post-trial 
information from the national cancer registries.  
 
This study completes our previously established size-based management approach 
at initial new solid nodule detection with volume cutoffs of <30mm³, 30mm³ to 
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<200mm³ and ≥200mm³ representing low-, intermediate- and high-risk groups 
respectively.8 After initial detection, in about half of participants all detected low- and 
intermediate-risk new solid nodules resolve until the next LDCT examination. 
Eventually, in 7.0% of participants with nonresolving low- and intermediate-risk new 
solid nodules the final new nodule outcome is lung cancer and an aggressive 
management strategy is warranted. At first screening after initial detection, a new solid 
nodule with a VDT ≤600 days has a high lung cancer probability and potentially 
requires immediate referral to a pulmonologist. Addition of a ≥200mm3 volume limit for 
new solid nodules that compels immediate referral as well, might further increase the 
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Final outcome of new nodule nature at incidence screening with low-dose CT: analysis of 




CT scan procedure 
The four screening sites used 16-MDCT scanners or 64-MDCT scanners (Sensation-16, 
Siemens Medical Solutions, Forchheim, Germany; or Mx8000 IDT or Brilliance 16P, Philips 
Medical Systems, Best, Netherlands). Datasets were derived from images of the thorax with 
1.0mm slice width and a 0.7mm reconstruction interval. In the first two rounds, two 
independent radiologists evaluated each CT scan individually, and a third reader decided 
ultimately in case of discrepancy.1,2 In the third and fourth screening round, single reading was 
performed. It was shown before that double reading consensus has no benefit with the use of 
semiautomated software.3 CT data analysis was performed on digital workstations (Leonardo, 
Siemens Medical Solutions) using software for semiautomated volume measurements 
(LungCare, version Somaris/5 VA70C-W, Siemens Medical Solutions). Based on the three-
dimensional nodule volume, this software also simulated longest and perpendicular nodule 
diameter in the axial plane. Radiologists were allowed to overrule protocol-based screening 
result (done for 195 [6%] of 3,318 participants at the baseline screening round) and manually 
adjust the volume measurement in case of inappropriate segmentation.4 Manual adjustments 
occurred in case of high suspicion of malignancy (eg, enlarged mediastinal lymph nodes) or 
benignity (eg, benign calcification patterns)4. Individual matching of nodules on subsequent 
LDCT scans was based on the software’s matching algorithm (depending on consistency, size 
and location) and the radiologist’s visual confirmation of the matching. Data generated during 
















in which Δt represents the time between scans in days, V1 represents the volume of the new 
solid nodule at initial new nodule detection, and V2 represents the volume of the new solid 
nodule at first-follow up scan. 
 
Calculations on Participant-level 
Based on the fastest growing nodule or largest nodule respectively, receiver operating 
characteristic analysis showed an area under the curve for the volume doubling time (VDT) of 
0.901 (95% confidence interval [95% CI]: 0.846, 0.956, P<0.0001) and for nodule volume of 
0.849 (95% confidence interval [95% CI]: 0.790, 0.908, P<0.0001). The identified cutoffs 
correspond to those found in the nodule-based analysis and the lung cancer probabilities as 
well as the cutoff performance are shown in Supplementary Table 3 and 4. 
 




Figure S1: Flowchart of new solid nodules detected within second and third screening round 
Some participants had a new nodule and, for example, a previously missed nodule. Whereas the missed nodule 
was excluded, the new nodule (and therefore the participant) was included. 
 




Figure S2: Receiver operating characteristic curves* of volume doubling time, nodule volume, simulated 
mean diameter and the combination of volume doubling time and ≥200mm3 at first follow-up or regular 
screening after initial detection for discrimination of lung cancer. Volume doubling time (AUC: 0.915, 
95%CI 0.862-0.967, P<0.0001); Volume (AUC: 0.871, 95%CI 0.818-0.925, P<0.0001); Simulated mean 
diameter (AUC: 0.822, 95%CI 0.748-0.897, P<0.0001); Volume doubling time and ≥200mm3 criterion 
(AUC: 0.939, 95%CI 0.903-0.975, P<0.0001). AUC=area under the curve. 
* Exact volume measurement or simulated mean diameter was not available for 60 benign nodules and one lung cancer, and they were not 
included in the calculations. Diameters were simulated from computer generated volume measurements, based on three-dimensional 
voxels. Manually measured diameters are less accurate and will overestimate nodule size. 
 
 




Figure S3: Participant level: Receiver operating characteristic curves* of fastest volume doubling time, 
largest nodule volume, and the combination of fastest volume doubling time and ≥200mm3 largest nodule 
volume criterion at first follow-up or regular screening after initial detection for discrimination of lung 
cancer. Volume doubling time (AUC: 0.901, 95%CI 0.846-0.956, P<0.0001); Volume (AUC: 0.849, 95%CI 
0.790-0.908, P<0.0001); Volume doubling time and ≥200mm3 (AUC: 0.923, 95%CI 0.881-0.965, P<0.0001). 
AUC=area under the curve. 
























Table S1: Characteristics of included participants with at least one new solid nodule during second or third 
screening round and subsequent follow-up or regular screening (n=680) 
  At least one new nodule persisted at follow-up  






















50 - 54 
55 - 59 
60 - 64 

































20 - 39 
40 - 59 































Abbreviations: IQR - Interquartile range. 
* In four participants a benign new solid nodule changed to part-solid (n=3) or pure ground-glass nodules (n=1) at follow-up. In three 
participants the respective nodule was the only new solid nodule detected. 
‡ Pack-Year information was missing for one participant. 
 
 
Table S2: New solid nodules at initial detection stratified by volume (N=1020; 995 benign nodules and 25 lung 
cancer nodules) 
 All new solid nodules, 
n=1020 (100%) 
New solid not visible in 
retrospect, n=788 (77%) 
New solid nodules below the trial’s 




% Lung cancer 
Nonresolving nodules 
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Nonresolving nodules 
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Table S3: Characteristics of included participants with at least one new solid nodule during second or third 
screening round that persisted as solid nodule after initial detection.* 
  Lung Cancer  






















50 - 54 
55 - 59 
60 - 64 

































20 - 39 
40 - 59 































Abbreviations: IQR - Interquartile range. 
* In three (<1% [3/359]) of the participants the new nodule did not persist as solid nodule and they were excluded from the calculations. 
† Pack-Year information was missing for one participant. 
 
 
Table S4: Histology and staging of the 25 lung cancers 
 Adenocarcinoma, 
16/25 (64%) 






















* Others included one large cell neuro-endocrine carcinoma, one non-small-cell lung carcinoma not otherwise specified, and two lung 
cancers where the histological diagnosis could not be established. 
 
Table S5: Performance of predefined VDT cutoffs at first follow-up or regular screening after initial detection 
(N=437; 412 benign nodules and 25 lung cancer nodules) 
 All new solid nodules that 
persisted on the first LDCT 
after detection 
Subsequent LDCT within 
120 days 
Subsequent LDCT after 120 
days 
Lung cancer probability 
VDT >600 days (95% CI)  
VDT 400-600 days (95% CI) 
VDT <400 days (95% CI) 
 
2/361, 0.6% (0-2.1) 
1/12, 8.3% (0-37.5) 
22/64, 34.4% (23.9-46.6) 
 
2/139, 1.4% (0.1-5.4) 
0/3, 0% (0-61.7) 
15/53, 28.3% (17.9-41.7) 
 
0/222, 0 % (0-2.0) 
1/9, 11.1% (0-45.7) 
7/11, 63.6% (35.2-85.0) 
VDT <400 days 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
22/25, 88.0% (69.2-96.7) 
370/412, 89.8% (86.5-92.4) 
22/64, 34.4% (23.9-46.6) 
370/373, 99.2% (97.5-99.8) 
 
15/17, 88.2% (64.4-98.0) 
140/178, 78.7% (72.0-84.1) 
15/53, 28.3% (17.9-41.7) 
140/142, 98.6% (94.7-99.9) 
 
7/8, 87.5% (50.8-99.9) 
230/234, 98.3% (95.5-99.5) 
7/11, 63.6% (35.2-85.0) 
230/231, 100% (97.3-100) 
VDT <600 days 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
23/25, 92.0% (73.9-98.9) 
359/412, 87.1 % (83.5-
90.0) 
23/76, 30.3% (21.0-41.4) 
359/361, 99.4% (97.9-100) 
 
15/17, 88.2% (64.4-98.0) 
137/178, 77.0% (70.2-82.6) 
15/56, 26.8% (17.5-41.0) 
137/139, 98.6% (94.6-99.9) 
 
8/8, 100% (62.8-100) 
222/234, 94.9% (91.7-97.4) 
8/20, 40.0% (21.8-61.4) 
222/222, 100% (98.0-100) 
VDT ≤590 days or volume 
≥200mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
25/25, 100.0% (84.2-100) 
345/412, 83.7% (79.9-87.0) 




17/17, 100.0% (78.4-100) 
124/178, 69.7% (62.5-76.0) 
17/71, 24.6% (15.9-36.0) 
124/124, 100.0% (96.4-100) 
 
8/8, 100% (62.8-100) 
221/234, 94.4% (90.6-96.8) 
8/21, 38.1% (20.7-59.2) 
221/221, 100.0% (97.9-100) 
Abbreviations: IQR - Interquartile range, LDCT – Low-dose computed tomography, NPV - Negative predictive value, PPV - Positive 
predictive value, VDT - Volume doubling time.  
Exact volume measurement was not available or classification based on radiologist’s size categorization was unattainable for 17 benign 
nodules, and they were not included in the calculations. 
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Table S6: Performance of identified cutoffs for new solid nodules stratified by their visibility in retrospect 
(N=437; 412 benign nodules and 25 lung cancer nodules) 
 New solid nodules at initial detection not 
visible in retrospect 
New solid nodules at initial detection 
visible in retrospect as minuscule nodule 
below the trial’s detection limit 
VDT ≤590 days 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
19/21, 90.5 (69.9-98.6) 
191/236, 80.9% (75.4-85.5) 
19/64, 29.7% (19.8-41.8) 
191/193, 99.0% (96.1-100) 
 
4/4, 100% (44.4-100) 
169/176, 96.0% (91.9-98.2) 
4/11, 36.4% (15.0-64.8) 
169/169, 100% (97.3-100) 
VDT ≤590 days or volume ≥200mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
21/21, 100% (81.8-100) 
174/232, 74.6% (68.6-79.7) 
21/79, 25.9% (17.6-36.5) 
176/176, 100.0% (97.4-100) 
 
4/4, 100% (44.4-100) 
169/176, 96.0% (91.9-98.2) 
4/11, 36.4% (15.0-64.8) 
169/169, 100% (97.3-100) 
Volume ≥65mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
21/21, 100% (81.8-100) 
141/236, 59.7% (53.4-65.8) 
21/116, 18.1% (12.1-26.2) 
141/141, 100% (96.8-100) 
 
3/4, 75% (28.9-96.6) 
172/176, 97.7% (94.1-99.3) 
3/7, 42.9% (15.8-75.0) 
172/173, 99.4% (96.5-100) 
Abbreviations: IQR - Interquartile range, NPV - Negative predictive value, PPV - Positive predictive value, VDT - Volume doubling 
time. 
Exact volume measurement or simulated mean diameter was not available and classification based on the radiologist’s size 
categorization was unattainable for 17 benign nodules, and they were not included in the calculations. 
 
Table S7: Performance of identified cutoffs at first follow-up or regular screening after initial detection for 
nodules with simulated mean diameter classification available (N=432; 407 benign nodules and 25 lung cancer 
nodules) 
 All new solid nodules that 
persisted on the first LDCT 
after detection 
Subsequent LDCT within 
120 days 
Subsequent LDCT after 120 
days 
VDT ≤590 days 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
23/25, 92.0% (73.9-98.9) 
357/407, 87.7% (84.1-90.6) 
23/73, 31.5% (22.0-42.9) 
357/359, 99.4% (97.9-100) 
 
15/17, 88.2% (64.4-98.0) 
135/174, 77.6% (70.8-83.2) 
15/54, 27.8% (17.5-41.0) 
135/137, 98.5% (94.5-99.9) 
 
8/8, 100% (62.8-100) 
222/233, 95.3% (91.7 -97.4) 
8/19, 42.1% (23.1-63.8) 
222/222, 100% (98.0-100) 
VDT ≤590 days or volume 
≥200mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
25/25, 100.0% (84.2-100) 
342/407, 84.0% (80.1-87.3) 




17/17, 100.0% (78.4-100) 
122/174, 70.1% (62.9-76.4) 
17/69, 24.6% (15.9-36.0) 
122/122, 100.0% (96.3-100) 
 
8/8, 100% (62.8-100) 
220/233, 94.4% (90.6-96.8) 
8/21, 38.1% (20.7-59.2) 
220/220, 100.0% (97.9-100) 
Volume ≥65mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
24/25, 96.0% (78.9-100) 
311/407, 76.4% (72.0-80.3) 
24/120, 20.0% (13.8-28.1) 
311/312, 99.7% (98.0-100) 
 
16/17, 94.1% (71.1-100) 
93/174, 53.4% (46.0-60.7) 
16/97, 16.5% (10.3-25.2) 
93/94, 98.9% (93.6-100) 
 
8/8, 100% (62.8-100) 
218/233, 93.6% (89.6-96.1) 
8/23, 34.8% (18.7-55.2) 
218/218, 100% (97.9-100) 
Simulated mean diameter 
≥5mm 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
24/25, 96.0% (78.9-100) 
284/407, 69.8% (65.1-74.0) 
24/147, 16.3% (11.2-23.2) 
284/285, 99.6% (97.8-100) 
 
16/17, 94.1% (71.1-100) 
76/174, 43.7% (36.5-51.1) 
16/114, 14.0% (8.7-21.7) 
76/77, 98.7% (92.3-100) 
 
8/8, 100% (62.8-100) 
208/233, 89.3% (84.6-92.7) 
8/33, 24.2% (12.6-41.3) 
208/208, 100% (97.8-100) 
Abbreviations: IQR - Interquartile range, LDCT – Low-dose computed tomography, NPV - Negative predictive value, PPV - Positive 
predictive value, VDT - Volume doubling time.  
Exact volume measurement or simulated mean diameter was not available and classification based on the radiologist’s size categorization 
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Table S8: Lung cancer probability for participants with at least one persisting new solid nodule stratified by 
volume doubling time and volume at of the largest or fastest-growing new solid nodule at first follow-up of 
regular screening after initial detection 
 Participants with lung 
cancer/participants meeting criterion 


















24/112, 21.4% (14.8-30.0) 
VDT and volume 
>590 days and <200mm3 







Abbreviations: CI - Confidence interval, IQR - Interquartile range, VDT - Volume doubling time.  
In 14 participants without lung cancer insufficient nodule size data led to their exclusion from the analysis. 
 
Table S9: Performance of identified cutoffs in participants based on the largest or fastest-growing new solid 
nodule at first follow-up or regular screening after initial detection 
 All new solid nodules that persisted on the first LDCT after detection 
VDT ≤590 days 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
23/25, 92.0% (73.9-98.9) 
267/315, 84.8% (80.4-88.3) 
23/71, 32.4% (22.6-44.0) 
267/269, 99.3% (97.2-100) 
VDT ≤590 days or volume ≥200mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
25/25, 100.0% (84.2-100) 
253/315, 80.3% (75.6-84.3) 
25/87, 28.7% (20.2-39.0) 
253/253, 100.0% (98.2 -100) 
Volume ≥65mm3 
Sensitivity (95% CI) 
Specificity (95% CI) 
PPV (95% CI) 
NPV (95% CI) 
 
24/25, 96.0% (78.9-100) 
227/315, 72.1% (66.9-76.7) 
24/112, 21.4% (14.8-30.0) 
313/314, 99.6% (97.4-100) 
Abbreviations: IQR - Interquartile range, LDCT – Low-dose computed tomography, NPV - Negative predictive value, PPV - Positive 
predictive value, VDT - Volume doubling time. 
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PURPOSE: New nodules after baseline are regularly found in low-dose CT lung 
cancer screening and have a high lung cancer probability. It is unknown whether 
morphological and location characteristics can improve new nodule risk stratification 
by size. 
METHODS: Solid non-calcified nodules detected during incidence screening rounds 
of the randomised controlled Dutch-Belgian lung cancer screening (NELSON) trial 
and registered as new or previously below detection limit (15 mm3) were included. A 
multivariate logistic regression analysis with lung cancer as outcome was performed, 
including previously established volume cut-offs (<30 mm3, 30-<200 mm3 and 
≥200 mm3) and nodule characteristics (location, distribution, shape, margin and 
visibility <15 mm3 in retrospect). 
RESULTS: Overall, 1280 new nodules were included with 73 (6%) being lung cancer. 
Of nodules ≥30 mm3 at detection and visible <15 mm3 in retrospect, 22% (6/27) were 
lung cancer. Discrimination based on volume cut-offs (area under the receiver 
operating characteristic curve (AUC): 0.80, 95% CI 0.75 to 0.84) and continuous 
volume (AUC: 0.82, 95% CI 0.77 to 0.87) was similar. After adjustment for volume 
cut-offs, only location in the right upper lobe (OR 2.0, P=0.012), central distribution 
(OR 2.4, P=0.001) and visibility <15 mm3 in retrospect (OR 4.7, P=0.003) remained 
significant predictors for lung cancer. The Hosmer-Lemeshow test (P=0.75) and 
assessment of bootstrap calibration curves indicated adequate model fit. 
Discrimination based on the continuous model probability (AUC: 0.85, 95% CI 0.81 to 
0.89) was superior to volume cut-offs alone, but when stratified into three risk groups 
(AUC: 0.82, 95% CI 0.78 to 0.86), discrimination was similar. 
CONCLUSION: Contrary to morphological nodule characteristics, growth-
independent characteristics may further improve volume-based new nodule lung 








Lung cancer remains as a leading cause of cancer-related death worldwide, and US 
guidelines recommend lung cancer screening by low-dose CT (LDCT) for high-risk 
individuals.1–5 Presently, lung cancer screening guidelines and nodule management 
protocols primarily focus on size and nodule growth for risk stratification, but the 
potential incremental value of morphological and location nodule characteristics has 
been underlined.6–11 It has been reported that nodules smaller than 5–6 mm (roughly 
65–113 mm3) have a very low likelihood of being lung cancer.8,10,12,13 However, current 
knowledge concerning nodule management in lung cancer screening is mainly based 
on baseline nodules that may have been present for years before their 
detection.14,15 New nodules after baseline develop within a known timeframe and entail 
a group of young and potentially fast-growing nodules. Recently, the Dutch-Belgian 
lung cancer screening trial (NELSON) published a more detailed analysis on new 
nodules detected in incidence screening rounds.14 It was shown that compared with 
baseline nodules, new solid nodules possess a greater lung cancer probability already 
at smaller size,13,14 and subsequent data from the National Lung Cancer Screening 
Trial indicated similar findings.16 Furthermore, it has been suggested that participants 
with new nodule lung cancer have poorer survival outcomes compared with 
participants who had at least one positive screen prior to cancer diagnosis.17 Based 
on the results in the NELSON trial, it was proposed in an European position statement 
on lung cancer screening that new solid nodules identified at an incidence screen 
and <30 mm3 volume (adapted from 27 mm3, <1% lung cancer probability) or <4 mm 
(simulated mean) diameter (adapted from 3.7 mm, <1% lung cancer probability) 
comprise low risk nodules, new solid nodules 30–<200 mm3 (adapted from 206 mm³, 
around 3% lung cancer probability) or 4–8 mm (simulated mean) diameter (adapted 
from 8.2 mm, around 3% lung cancer probability) represent indeterminate risk nodules 
and new solid nodules ≥200 mm3 (around 17% lung cancer probability) or ≥8 mm 
(simulated mean) diameter (around 14% lung cancer probability) are high-risk 
nodules, which was also adopted in the British Thoracic Society Guidelines for the 
Investigation and Management of Pulmonary Nodules.11,14 
In the clinical setting, physicians evaluate solid pulmonary nodules based on 
their size and based on their morphological and location characteristics, and likewise 
in lung cancer screening, the expertise of a radiologist was shown to decrease false-
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positive screen results.9 18 19 Nodule location in the upper lung and right upper lung in 
particular as well as marginal spiculation have been typically identified as risk factor 
for lung cancer in screening studies.10,16,20–22 Nevertheless, consistent 
characterisation of very small nodules can be challenging and evidence concerning 
the discriminative value of new nodule morphology and location for lung cancer in new 
nodules in incidence screening rounds of LDCT screening is lacking. 
The aim of this study was to assess whether addition of morphological and 
location characteristics to currently proposed volume-based three-category 





The NELSON trial was authorised by the Dutch Health Care Committee. All 
participants provided written informed consent. The recruitment process and study 
design were published before.7,23,24 Summarised, eligible patients were adults aged 
50–75 years, who had smoked >15 cigarettes per day for >25 years or >10 cigarettes 
per day for >30 years and were still smoking or stopped smoking <10 years previously. 
Between April 2004 and December 2006, 7557 participants underwent baseline 
screening in four centres in the Netherlands and Belgium. The incidence screening 
rounds took place 1 year, 3 years and 5.5 years after baseline screening. In this study, 
participants with a solid non-calcified nodule detected during the incidence screening 
rounds and registered by the NELSON radiologists as new or <15 mm3 (study 
detection limit) at previous screens were included. 
 
CT scanning protocol 
The CT protocol was published before.7,24 The four screening sites used 16-MDCT 
scanners or 64-MDCT scanners (Sensation-16, Siemens Medical Solutions, 
Forchheim, Germany, or Mx8000 IDT or Brilliance 16P, Philips Medical Systems, Best, 
The Netherlands). Scans of the entire chest were performed without contrast in spiral 
mode in caudio-cranial direction with 16×0.75 mm collimation and 1.5 pitch. Low dose 
settings (80–90 kVp, 120 kVp and 140 kVp) were adjusted depending on body weight 
(<50 kg, 50–80 kg or >80 kg), matching a CT dose index volume of 0.8 mGy, 1.6 mGy 
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or 3.2 mGy, respectively. Datasets were derived from images of the thorax with 
1.0 mm slice width and a 0.7 mm reconstruction interval. Screening conditions and 
data acquisition were standard across screening sites.7,24 
 
Image reading 
In the first two rounds, two independent radiologists with experience in thoracic CT 
reading ranging between 1 year and 20 years evaluated each CT scan individually, 
and in case of discrepancy, a third reader made the final decision.7,24 In the third and 
fourth screening rounds, single read was performed by radiologists with at least 6 
years of experience in thoracic imaging after it was shown that double reading 
consensus has no benefit when using semiautomated software.25 CT data analysis 
was performed on digital workstations (Leonardo, Siemens Medical Solutions) using 
software for semiautomated volume measurements (LungCare, version Somaris/5 
VA70C-W, Siemens Medical Solutions). Lung windows were assessed at a width of 
1600 HU and a level of −700 HU. All images were interpreted both in lung window and 
mediastinal settings. 
A non-calcified nodule was considered solid if the underlying structures were 
completely obscured by its lung opacity. A nodule’s shape was classified as spherical, 
polygonal or irregular.19 The nodule margin was classified as smooth, lobulated, 
spiculated or irregular.21,26Additional to the nodule location in the lung, the distribution 
(peripheral and central) within the lung parenchyma was characterised based on the 
distance to the costal pleura. If the distance to costal pleura was less than one-third of 
the total distance to hilum-costal pleura, the nodule was defined as peripheral and if it 
was more than one-third, the nodule was defined as central.19,27 After detection, the 
software’s matching algorithm matched nodules individually (depending on 
consistency, size and location) with previous scans and the radiologists visually 
confirmed the matching. In this analysis, a nodule was considered new if it was 
registered by the radiologist as new or below the study detection limit of 15 mm3 on 
the previous scan. Radiologists could overrule protocol-based screening result (done 
for 195 (6%) of 3318 participants at the baseline screening round) in case of high 
suspicion of malignancy (eg, enlarged mediastinal lymph nodes) or benignity (eg, 
benign calcification patterns) and to adjust the volume measurement in case of 
inappropriate segmentation.18 Data obtained during CT evaluation were directly 
uploaded to the NELSON management system.7 For this study, nodule information as 
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reported by the radiologists in the NELSON management system was used, and no 
retrospective measurements was performed. 
 
Nodule management protocol 
The NELSON nodule management protocol has been described in detail 
previously.7 Summarised, solid nodules detected within the NELSON trial were 
classified into four categories (NODCAT I–IV) according to their size and benign 
characteristics. After baseline screening, calcified nodules or nodules with other 
benign characteristics were considered benign (NODCAT I), new solid nodules without 
benign characteristics measuring 15–50 mm3 (NODCAT II, follow-up LDCT within 
1 year) and new solid nodules 50–500 mm3(NODCAT III, follow-up LDCT within 6–
8 weeks) were defined indeterminate, whereas nodules 
measuring ≥500 mm3 (NODCAT IV, immediate referral to pulmonologist) were 
considered positive. After initial detection, a nodule’s subsequent evaluation 
was based on volume doubling time.7 A volume doubling time <400 days led to referral 
to a pulmonologist for further diagnosis. 
 
Outcomes 
For this study, a nodule was classified as lung cancer when it was diagnosed as lung 
cancer during diagnostic workup according to national and international guidelines 
including histological examination.7 Nodules were classified as benign when either: 
(A) the nodule was benign at histological examination; (B) extensive diagnostic 
evaluation had a negative finding; (C) the nodule was ruled negative during the 
participant’s last follow-up screening of the NELSON trial and the participant did not 
present with postscreening lung cancer according to the Dutch and Belgian national 
cancer registries and medical file review.7 13 28 
Previously established volume cut-offs for new nodules at initial detection 
Considering a previous analysis of the first two incidence screening rounds of the 
NELSON trial concerning optimal new nodule volume cut-offs at initial 
detection,14 nodules were classified as <30 mm3 (low risk), 30–
<200 mm3 (intermediate risk) or ≥200 mm3 (high risk) based on their semiautomated 
volume measurements (continuous volume) or the radiologist’s nodule classification 
(<50 mm3, 50–500 mm3, >500 mm3; performed for 4% (50/1280) of the included 
nodules).11 





The normality assumption was tested using the Kolmogorov-Smirnov test as well as 
visual assessment. Continuous variables are presented as median and IQR, and 
categorical variables are presented as frequencies and respective percentages. CIs 
of proportions were calculated using the Agresti-Coull method. The Mann-Whitney U 
test was used to compare the nodule volume of benign nodules and lung cancers at 
initial detection. Nominal variables were analysed with Fisher’s exact test. Logistic 
regression analysis with new nodule lung cancer as outcome was performed to assess 
morphological and location nodule characteristics together with the previously 
established new nodule volume cut-offs (<30 mm³, 30–<200 mm³ and ≥200 mm³)11,14. 
The final parsimonious model included nodule characteristics that were significant 
(P<0.05) for new nodule lung cancer when adjusted for the volume cut-offs. The model 
calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test and 
bootstrap calibration plots of actual probability versus predicted probability, with ideal, 
apparent and bias-corrected curves. The model probability was stratified through 
assessment of Youden Indices to maximise the area under the receiver operating 
characteristic curve (AUC) for three categories (termed low risk, intermediate risk and 
high risk) and provide at least 95% sensitivity, analogous to the previously established 
volume cut-offs.14 The performance for discriminating new nodule lung cancer was 
quantified by the AUC. The model performance was internally validated using 10-fold 
cross-validation. AUC comparison was performed with the method described by 
DeLong et al.29 Decision curve analysis was used to estimate clinical usefulness of 
the model by plotting the net benefit (y-axis) over a continuum of potential decision 
probability thresholds (x-axis).30,31 The net benefit represents the sum of true-positive 
minus false-positive classifications weighted by the respective probability threshold 
(eg, a decision threshold of 10% would imply that for every true-positive classification 
nine false-positive classifications are clinically acceptable). Missing data were 
excluded from the respective analyses. Statistical analyses were performed with 
SPSS V.25.0 (IBM, Armonk, USA), R V.3.3.3 (R Foundation for Statistical Computing, 
Vienna, Austria) and Microsoft Excel 2010 (Microsoft Corporation, Redmond, 
Washington, USA). 





In total, 1280 new solid nodules detected in 809 participants during the three incidence 






























Figure 1: Flowchart of new solid nodules included in this analysis. 
 
 
Median participant age at baseline screening was 59 years (IQR 55–63 years), and 
77% (622/809) were male. Of the included nodules, 20% (255/1280) were visible as 
small nodule <15 mm3 in retrospect. Eventually, 6% (73/1280) of the new solid 
nodules were diagnosed as lung cancer. At initial detection, median nodule volume 
was 50 mm3(IQR 23–156 mm3) with 34% (429/1280) being <30 mm3, 43% (547/1280) 
being 30–<200 mm3 and 24% (304/1280) being ≥200 mm3.  
Table 1 presents the nodule characteristics of benign new solid nodules and lung 
cancers at initial nodule detection and the proportion of lung cancers stratified by the 
volume cut-offs. Overall, new solid nodules visible in retrospect <15 mm3 were smaller 
15 nodules from 8 participants were excluded 
because the participant’s eventual lung cancer 
diagnosis could not be matched to a nodule with 
certainty. 
 
1 nodule excluded from 1 participant because it 
was a prostate cancer metastasis. 
 
117 nodules from 100 participants were excluded 
because no follow-up scan after new nodule 
detection was available for reasons such as death 
or end of screening. 
 
71 nodules (69 benign, 1 lung cancer) from 64 
participants were excluded because exact volume 
measurement was not available and no unequivocal 
size categorization (<30mm3, 30-<200mm3, 
≥200mm3) could be attained based on the 
information in the NELSON Management System. 
 
 
1,280 new solid nodules detected in 809 participants during 
the three incidence screening rounds 
1,484 new solid nodules registered in 949 participants 
during the three incidence screening rounds 
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and less often lung cancer compared with new solid nodules not visible in retrospect 
(3% (8/255) vs 6% (65/1025)). However, of new solid nodules ≥30 mm3 at detection 
and visible <15 mm3 in retrospect, 22% (6/27) were lung cancer compared with 8% 
(65/824) of new solid nodules ≥30 mm3 and not visible in retrospect. Table 2 displays 
the results of the logistic regression analysis. Larger volume, location in the right upper 
lung, central distribution, irregular shape and a lobulated or spiculated margin were 
associated with lung cancer in univariate analysis. After addition of the volume cut-off 
categories to the selected nodule characteristics by multivariate logistic regression, 
only location in the right upper lung and central distribution significantly improved lung 
cancer prediction. Furthermore, after addition of the volume cut-offs, visibility in 
retrospect as small nodule <15 mm3 was significantly associated with lung cancer. In 
other words, at equivalent size a new solid nodule visible in retrospect <15 mm3 was 
more likely lung cancer than a new nodule not visible at all. The full model included 
the nodule volume cut-offs, location in the lung, distribution in the lung and visibility in 
retrospect 
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Table 1: Nodule characteristics of benign nodules and lung cancers 
Abbreviations: IQR - Interquartile range. Missing values were excluded from analyses. 




 Univariate analysis Volume cutoffs added to 
each characteristic 
Full model 
 Odds Ratio  
(95% CI) 
P Value Odds Ratio  
(95% CI) 
P Value Odds Ratio  
(95% CI) 
P Value Beta coefficient 
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Table 2: Logistic regression analysis of nodule characteristics and volume cutoffs with lung cancer as outcome 
Abbreviations: 95% CI - 95% confidence interval. Missing values were excluded from analyses. Full model equation: logit(p)=-5.31 + Volume 30-<200mm3*2.818 + 
Volume >200mm3*4.825 + Location in right upper lung*0.687 + Central distribution*0.885 + Visibility in retrospect as small nodule <15mm3*1.543. 




Figure 2 displays the ROC curves of the volume cut-off values, the full model 
and the model stratified into three risk categories. Discrimination based on volume cut-
offs (AUC: 0.80, 95% CI 0.75–0.84) and continuous volume (AUC: 0.82, 95% CI 0.77 
to 0.87) was similar. The full model (AUC: 0.85, 95% CI 0.81 to 0.89) provided superior 
discriminative performance compared with the volume cut-offs alone. The 10-fold 
cross-validated mean AUC was similar (0.846±0.050). The Hosmer-Lemeshow test 
was non-significant (P=0.75) suggesting a good overall fit (supplementary figure 1).  
 
 
Figure 2: ROC curves of the volume cut-off values, the full model and the full model 
stratified into three categories for discrimination of lung cancer.  
AUC, area under the curve; ROC, receiver operating characteristic curve 
 
The clinical utility of the model in terms of an increased number of true positive 
predictions without increase in the false-positive rate (net benefit) was assessed over 
a continuum of potential risk thresholds using decision curve analysis (figure 3). The 
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model displayed consistent positive and larger net benefit for risk thresholds above 
2% (intermediate and high-risk nodule thresholds) when compared with the volume 
cut-offs alone. Nevertheless, when stratifying nodules into three categories based on 
model cut-off values for a maximal AUC (AUC: 0.82, 95% CI 0.78 to 0.86), thereby 
reflecting a three risk-group stratification (low risk, intermediate risk and high risk), 




Figure 3 Decision curve analysis of the full model and volume cut-offs alone.  
Net benefit: sum of true-positive minus false-positive classifications weighted by the respective risk threshold. For 
a specific threshold probability, a larger net benefit indicates a greater number of true positive predictions without 
increase in the rate of false positives. Not using a model would assume that all nodules have the same risk and is 
illustrated by the two alternatives of either assuming that all nodules are low risk or that all nodules are high risk. 
This figure illustrates that, when compared with the volume cut-offs, clinical utility of the model is pronounced at 
higher risk thresholds. 
Discussion 
This study aimed to evaluate the potential incremental value of morphological and 
location characteristics to volume-based lung cancer risk stratification of new solid 
nodules identified after baseline LDCT lung cancer screening. Overall, 1280 new solid 
nodules detected in 809 participants during the incidence screening rounds of the 
NELSON trial were included, with 6% (73/1280) being diagnosed as lung cancer. 
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Studies on new nodules detected in incidence screening rounds of LDCT screening 
are sparse, and only limited evidence concerning management of these nodules 
exist.8,14,32 To our knowledge, this is the first study to investigate the incremental value 
of morphological and location nodule characteristics to nodule volume cut-offs for lung 
cancer prediction in new nodules after baseline screening. 
We report five central findings. First, at initial detection new solid nodule volume 
and, therefore, its growth speed was the strongest predictor for malignancy. Second, 
nodule features traditionally attributed to lung cancer, such as location in the upper 
lung, central distribution, irregular shape and a lobulated or spiculated margin, were 
associated with lung cancer in new solid nodules in univariate logistic regression 
analysis. This is consistent with previous findings, mainly in baseline nodules.16,19–
21 Third, when added to the previously established new solid nodule volume cut-off 
values (<30 mm3, 30–<200 mm3 and ≥200 mm3),11,14 only location in the right upper 
lung and central distribution provided incremental value, while nodule shape and 
margin did not improve lung cancer discrimination. This contrasts findings in baseline 
nodules, where aside of location, nodule morphology remained significantly 
associated with lung cancer when corrected for nodule size.19–21 This discrepancy may 
be caused by the augmented predictive information of nodule size in new solid 
nodules, which developed in a short and known timeframe, as compared with baseline 
nodules, that could have been present for years before detection. The volume of a 
baseline nodule primarily represents its current size, whereas the volume of a new 
nodule more directly translates to its growth rate. This is supported by the observation 
that only morphological characteristics forfeit their predictive association through 
addition of nodule volume, while growth independent features remain significant 
predictors. Next to that, new solid nodules tend to be smaller than baseline nodules at 
initial detection,14 which could hamper classification of morphology. Fourth, visibility 
as very small nodule in retrospect was significantly associated with lung cancer when 
combined with the volume cut-offs. While this finding could have implications for new 
nodules ≥30 mm3 at detection where 22% (6/27) of those visible in retrospect as small 
nodule were lung cancer as compared with 8% (65/824) of those not visible in 
retrospect (P=0.02), implications for nodules <30 mm3 seem redundant considering 
the respective comparison of <1% (2/228) versus 0% (0/201, p=0.501) being lung 
cancer. Nodules visible in retrospect likely are persisting nodules that could explain 
their higher cancer risk when further growing. Fifth, the identified new solid nodule 
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characteristics did not significantly improve risk stratification by volume when 
considering a three category (low risk, intermediate risk and high risk) stratification 
approach such as advocated in current guidelines.8,11,14 Although some of the selected 
nodule characteristics provided incremental discriminatory information and clinical 
utility in decision curve analysis, it was limited compared with the volume cut-offs. 
This study has limitations. Nodules that remained <15 mm3 could not be 
included as they were below the NELSON trial’s detection limit and were not registered 
by radiologists. Another possible limitation may be observer variation that was not 
considered. However, single read was only performed by radiologists with at least 6 
years of experience in thoracic imaging. Next, only solid nodules were included, with 
exclusion of part-solid and pure ground glass nodules. Furthermore, nodules without 
an additional follow-up scan within the NELSON trial were excluded from the analysis 
to provide the most consistent appreciation of benign and malignant nodules. Because 
these nodules likely were benign, the proportion of lung cancers may be slightly 
overrepresented. The overall occurrence and lung cancer probability of new solid 
nodules within the NELSON trial were reported before.14 
In new solid nodules detected during incidence screening rounds of LDCT lung 
cancer screening, morphological and location characteristics only have limited 
incremental discriminatory value for lung cancer additional to volume cut-offs. Nodule 
characteristics not influenced by nodule growth, such as location in the right upper 
lung and a central distribution, can potentially improve volume-based risk stratification, 
but in a three category (low, intermediate and high risk) stratification approach, this is 
negligible. Newly detected nodules ≥30 mm3 and visible as small nodule (<15 mm3) in 
retrospect have a high lung cancer probability. Overall, new solid nodule volume and, 












1  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 
2017;67:7–30. doi:10.3322/caac.21387 
2  van der Aalst CM, ten Haaf K, de Koning HJ. Lung cancer screening: latest 
developments and unanswered questions. Lancet Respir Med 2016;4:749–61. 
doi:10.1016/S2213-2600(16)30200-4 
3  Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 
2016: A review of current American Cancer Society guidelines and current 
issues in cancer screening. CA Cancer J Clin 2016;66:95–114. 
doi:10.3322/caac.21261 
4  Moyer VA. Screening for lung cancer: U.S. preventive services task force 
recommendation statement. Ann Intern Med 2014;160:330–8. 
doi:10.7326/M13-2771 
5  De Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed 
tomography lung cancer screening strategies: A comparative modeling study for 
the U.S. Preventive services task force. Ann Intern Med 2014;160:311–20. 
doi:10.7326/M13-2316 
6  American College of Radiology. LungRADSTM Version 1.0 Assessment 
Categories Release date: April 28, 2014. 
http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Lu
ngRADS/AssessmentCategories.pdf (accessed 1 Sep 2016). 
7  Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the 
NELSON randomised lung cancer screening trial. Lung Cancer 2006;54:177–
84. doi:10.1016/j.lungcan.2006.08.006 
8  Callister MEJ, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines 
for the investigation and management of pulmonary nodules. Thorax 2015;70:1–
54. doi:10.1136/thoraxjnl-2015-207168 
9  MacMahon H, John M Austin BH, Gamsu G, et al. Guidelines for Management 
of Small Pulmonary Nodules Detected on CT Scans: A Statement from the 
Fleischner Society. Radiology 2005;237:395–400. 
doi:10.1148/radiol.2372041887 
10  MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of 
Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner 
Society 2017. Radiology 2017;0:161659. doi:10.1148/radiol.2017161659 
11  Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on 
lung cancer screening. Lancet Oncol 2017;18:e754–66. doi:10.1016/S1470-
2045(17)30861-6 
12  Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: 
suspiciousness of nodules according to size on baseline scans. Radiology 
2004;231:164–8. doi:10.1148/radiol.2311030634 
13  Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in 
patients with CT-detected pulmonary nodules: A prespecified analysis of data 
from the NELSON trial of low-dose CT screening. Lancet Oncol 2014;15:1332–
41. doi:10.1016/S1470-2045(14)70389-4 
Part II – Risk-stratification of New Nodules 
119 
 
14  Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer 
probability of new solid nodules at incidence screening with low-dose CT: 
Analysis of data from the randomised, controlled NELSON trial. Lancet Oncol 
2016;17:907–16. doi:10.1016/S1470-2045(16)30069-9 
15  Walter JE, Heuvelmans MA, Oudkerk M. Small pulmonary nodules in baseline 
and incidence screening rounds of low-dose CT lung cancer screening. Transl 
lung cancer Res 2017;6:42–51. doi:10.21037/tlcr.2016.11.05 
16  Pinsky PF, Gierada DS, Nath PH, et al. Lung Cancer Risk Associated With New 
Solid Nodules in the National Lung Screening Trial. Am J Roentgenol 2017;:1–
6. doi:10.2214/AJR.17.18252 
17  Schabath MB, Massion PP, Thompson ZJ, et al. Differences in Patient 
Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the 
CT Arm of the National Lung Screening Trial. PLoS One 2016;11:e0159880. 
doi:10.1371/journal.pone.0159880 
18  Heuvelmans MA, Oudkerk M, de Jong PA, et al. The impact of radiologists’ 
expertise on screen results decisions in a CT lung cancer screening trial. Eur 
Radiol 2015;25:792–9. doi:10.1007/s00330-014-3467-4 
19  Xu DM, van Klaveren RJ, de Bock GH, et al. Limited value of shape, margin and 
CT density in the discrimination between benign and malignant screen detected 
solid pulmonary nodules of the NELSON trial. Eur J Radiol 2008;68:347–52. 
doi:10.1016/j.ejrad.2007.08.027 
20  McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in 
pulmonary nodules detected on first screening CT. N Engl J Med 2013;369:910–
9. doi:10.1056/NEJMoa1214726 
21  Xu DM, van der Zaag-Loonen HJ, Oudkerk M, et al. Smooth or attached solid 
indeterminate nodules detected at baseline CT screening in the NELSON study: 
cancer risk during 1 year of follow-up. Radiology 2009;250:264–72. 
doi:10.1148/radiol.2493070847 
22  Horeweg N, Van Der Aalst CM, Thunnissen E, et al. Characteristics of lung 
cancers detected by computer tomography screening in the randomized 
NELSON trial. Am J Respir Crit Care Med 2013;187:848–54. 
doi:10.1164/rccm.201209-1651OC 
23  Van Iersel CA, De Koning HJ, Draisma G, et al. Risk-based selection from the 
general population in a screening trial: Selection criteria, recruitment and power 
for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial 
(NELSON). Int J Cancer 2007;120:868–74. doi:10.1002/ijc.22134 
24  van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of Lung Nodules 
Detected by Volume CT Scanning. N Engl J Med 2009;361:2221–9. 
doi:10.1056/NEJMoa0906085 
25  Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the 
NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. 
Thorax 2016;72:1–9. doi:10.1136/thoraxjnl-2016-208655 
26  Gurney JW. Determining the likelihood of malignancy in solitary pulmonary 
nodules with Bayesian analysis. Part I. Theory. Radiology 1993;186:405–13. 
doi:10.1148/radiology.186.2.8421743 
Part II – Risk-stratification of New Nodules 
120 
 
27  Zhao YR, Heuvelmans MA, Dorrius MD, et al. Features of Resolving and 
Nonresolving Indeterminate Pulmonary Nodules at Follow-up CT: The NELSON 
Study. Radiology 2014;270:872–9. doi:10.1148/radiol.13130332 
28  Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Risk stratification based on 
screening history: the NELSON lung cancer screening study. Thorax 
2017;72:819–24. doi:10.1136/thoraxjnl-2016-209892 
29  DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two 
or more correlated receiver operating characteristic curves: a nonparametetric 
approach. Biometrics 1988;44:837–45. doi:10.2307/2531595 
30  Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a 
novel method for evaluating diagnostic tests, prediction models and molecular 
markers. BMC Med Inform Decis Mak 2008;8:53. doi:10.1186/1472-6947-8-53 
31  Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven 
steps for development and an ABCD for validation. Eur Heart J 2014;35:1925–
31. doi:10.1093/eurheartj/ehu207 
32  Bach PB, Mirkin JN, Oliver TK, et al. Benefits and Harms of CT Screening for 


























Characteristics of new solid nodules detected in incidence screening rounds 





Supplemental Figure 1: Bootstrap calibration plots of actual probability vs. model predicted 








Part II – Risk-stratification of New Nodules 
122 
 




New subsolid pulmonary nodules in lung cancer screening 
Journal of Thoracic Oncology (2018), Sep;13(9):1410-1414. 
 
 
 Walter JE, 
Heuvelmans MA, 
ten Haaf K, 
Vliegenthart R, 
van der Aalst CM, 
Yousaf-Khan U, 
van Ooijen PMA, 
Nackaerts K, 
Groen HJM, 
de Bock GH, 





















Introduction: Low-dose computed tomography (LDCT) lung cancer screening is 
recommended in the United States. While new solid nodules after baseline screening 
have a high lung cancer probability at small size and require lower size cutoff values 
than baseline nodules, there only is limited evidence on management of new subsolid 
nodules. 
Methods: Within the Dutch-Belgian randomized controlled LDCT lung cancer 
screening trial (NELSON), 7557 participants underwent baseline screening between 
April 2004 and December 2006. Participants with new subsolid nodules detected after 
the baseline screening round were included. 
Results: In the three incidence screening rounds, 60 new subsolid nodules (43 [72%] 
part-solid, 17 [28%] nonsolid) not visible in retrospect were detected in 51 participants, 
representing 0.7% (51/7295) of participants with at least one incidence screening. 
Eventually, 6% (3/51) of participants with a new subsolid nodule were diagnosed with 
a (pre-)malignancy in such a nodule. All (pre-)malignancies were adenocarcinoma (in 
situ) and diagnostic work-up (referral 950, 364, and 366 days after first detection 
respectively) showed favorable staging (stage I). Overall, 67% (33/49) of subsolid 
nodules with an additional follow-up screening were resolving. 
Conclusions: Less than 1% of participants in LDCT lung cancer screening presents 
with a new subsolid nodule after baseline. Contrary to new solid nodules, data suggest 
















Lung cancer screening is recommended in the US, while European stakeholders are 
in anticipation of the final results of the randomized-controlled Dutch-Belgian Lung 
Cancer Screening Trial (NELSON).1–3 A central challenge in low-dose computed 
tomography (LDCT) lung cancer screening is the identification of clinically relevant 
lung cancer, while preventing overdiagnosis and overtreatment.4 Subsolid nodules are 
particularly challenging as they carry a relatively high malignancy rate but possess a 
slow growth rate. Current (clinical) guidelines propose a watchful waiting approach 
with CT surveillance.5,6 Nodules found at baseline screening and new nodules 
thereafter need to be differentiated since they develop within different timeframes. 
Recently, it was shown that new solid nodules have a high lung cancer risk at small 
size and require lower size cutoff values than baseline nodules,7 which was adopted 
in a European position statement on lung cancer screening.1 A subsequent analysis 
of new solid nodules in the National Lung Screening Trial provided similar findings.8 
However, currently there only is limited evidence on management of new subsolid 
nodules.9–11 Aim of this study was to assess the occurrence, characteristics and lung 
cancer probability of subsolid nodules detected in incidence screening rounds of the 
NELSON trial. 
 
MATERIAL AND METHODS 
The NELSON trial (trial registration number, ISRCTN63545820) was authorized by the 
Dutch Health Care Committee and approved by Ethics Committees of all participating 
centers in the Netherlands and Belgium. The recruitment process and study design 
were published before.12,13 Summarized, eligible patients were adults aged 50–75 
years, who had smoked >15 cigarettes per day for >25 years or >10 cigarettes per 
day for >30 years, and were still smoking or stopped smoking <10 years previously. 
While the final results of the NELSON trial have not been released yet, most 
participants are likely Caucasian. Written informed consent was obtained from all 
participants. Between April 2004 and December 2006, 7,557 participants underwent 
baseline screening. Three incidence screening rounds took place 1 year, 3 years, and 
5.5 years after baseline screening. Details regarding imaging acquisition/analysis and 
nodule measurements, are provided in the Supplement. Participants with subsolid 
nodules detected in the three incidence screening rounds and registered as new or 
previously below the trial’s detection limit were assessed. 
Part II – Risk-stratification of New Nodules 
126 
 
A nodule was classified as (pre-)malignancy when it was diagnosed as lung cancer 
during diagnostic workup according to national and international guidelines including 
histologic assessment. Nodules were classified as benign when either the nodule was 
benign at histologic examination or diagnostic evaluation had a negative finding. A 
nodule was also considered benign if it was ruled negative during the participant’s last 
follow-up screening of the NELSON trial and the participant did not present with post-
screening lung cancer according to the Dutch and Belgian national cancer registries 
and medical file review.14  
 
Statistical Analysis 
Continuous variables are presented as median and inter quartile range (IQR) and 
categorical variables are presented as frequencies and respective percentages. 
Confidence intervals of proportions were calculated using the Agresti-Coull method. 
Nominal variables were analyzed with Fisher’s exact test. Statistical significance was 
considered for P < 0.05 and all tests were 2 tailed. Statistical analysis was performed 
with SPSS version 25.0 (IBM) and R (version 3.3.3). 
 
RESULTS 
Within the three incidence rounds of the NELSON trial, 79 new subsolid nodules were 
detected in 67 participants (0.9% [67/7295] of participants with at least one incidence 
screening). After exclusion of 16 subsolid nodules that were visible in retrospect 
according to the NELSON radiologists (31% [5/16] (pre-)malignancies: four 
adenocarcinoma in situ and one adenocarcinoma stage IA), two new subsolid nodules 
from one participant with also baseline nodules because the eventual diagnosis 
(adenocarcinoma in situ) could not be matched unequivocally to a nodule, and one 
new subsolid nodule because it was a renal cell carcinoma metastasis, a total of 60 
new subsolid nodules in 51 participants (0.7% [51/7295] of participants with at least 
one incidence screening) were included in the final analysis (Figure 1). 




Figure 1: Flowchart of new subsolid nodules in the NELSON trial 
 
Median baseline age of these participants was 59 years (inter quartile range [IQR] 54-
63 years), 82% (42/51) were men, and median smoking pack-years at baseline was 
39 (IQR 31-49). In total, 25% (15/60) of new subsolid nodules were detected in the 
second screening round (1 year after baseline), 50% (30/60) in the third screening 
round (3 years after baseline) and 25% (15/60) in the fourth screening round (5.5 years 
after baseline). Characteristics of new subsolid nodules and (pre-)malignancy 
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Total n=60 (100%) n=43 (72%) n=17 (28%)  
Size category 
Nonsolid component <8mm 
Nonsolid component ≥8mm 
Solid component >500mm3 
 












































































4/14 (29)  
10/14 (71) 
 
(Pre-)malignancies (%, 95% CI) 
(Pre-)malignancies in 
nonresolving nodules 
3/60 (5, 1-14) 
 
3/16 (19) 
1/43 (2, 0-13) 
 
1/12 (10) 




Table 1. Characteristics of new subsolid nodules in the three incidence screening rounds 
Abbreviations: IQR - Interquartile range.  
*Missing values were excluded from analyses. 
 
Eventually, 6% (3/51) of participants with a new subsolid nodule had a (pre-
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 Nodule 1 Nodule 2 Nodule 3 
Nodule type Part-solid Non-solid Non-solid 
Mean diameter (mm) 11.7 8.2 10.2 
Shape  Non-spherical  Non-spherical  Non-spherical  
Margin Smooth Smooth Lobulated 
Location Left upper lobe Right upper lobe Right upper lobe 
Time until referral (days) 950 366 364 
Cancer stage at diagnosis IA   





in situ  
Table 2. Primary lung cancers detected in new subsolid nodules 
 
After initial detection of a new subsolid nodule, 86% (44/51) of participants received 
an additional screening in the NELSON trial (1 ended screening and 6 were referred 
immediately for diagnostic work-up). On first follow-up after initial detection, 33% 
(16/49) of subsolid nodules had persisted. The median time until first follow-up was 51 
days (IQR: 47-87 days). For both nonresolving and resolving nodules the first follow-
up primarily took place within 90 days after initial detection (81% and 82%). Of the 




This study focused on new subsolid nodules detected in the incidence screening 
rounds of the NELSON trial. Until now, there are limited data concerning new subsolid 
nodules detected in LDCT lung cancer screening trials. We report four major findings. 
First, new subsolid nodules were found in <1% of participants with at least one 
screening after baseline. Second, only 33% of subsolid nodules with an additional 
screening after detection persisted until first follow-up. Third, 6% of participants with a 
new subsolid nodule were diagnosed with a (pre-)malignancy in such a nodule, with 
19% of the persistent new subsolid nodules being identified as (pre-)malignant lesion. 
Fourth, new subsolid (pre-)malignancies were adenocarcinoma (in situ) and diagnostic 
work-up (referral 950, 364, and 366 days after first detection respectively) showed 
favorable staging (stage I). 
Our study shows that the occurrence of new subsolid nodules is low in a lung cancer 
screening program and that the lung cancer stage is favorable even with referral after 
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a year. This is comparable to findings of the I-ELCAP trial, where <1% of participants 
presented with new part-solid or new non-solid nodules respectively and all lung 
cancer cases were stage I.9,10 Similarly, previous prospective studies from Japan 
indicated the conservative nature of subsolid nodules with all pathologically confirmed 
tumors being stage I and ≤1% of subsolid nodules being invasive 
adenocarcinomas.15,16 Additionally, an analysis of lung cancer manifesting as nonsolid 
nodule in the National Lung Screening Trial concluded that annual follow-up is 
appropriate.17 Furthermore, as also shown in this study, a large proportion of new 
subsolid nodules resolve until first follow-up, which is comparable to previous reports 
where 40-70% of subsolid nodules were transient.18,19 New subsolid nodules that 
persist may require additional screening or referral for diagnostic work-up with 19% 
being (pre-)malignant.  
Considering the presented data and results of the I-ELCAP trial,9,10 there is no 
indication that new subsolid nodules detected after baseline require a more aggressive 
follow-up than baseline subsolid nodules. This contrasts findings for new solid nodules 
which have a high lung cancer risk even at small size, necessitating adapted cutoffs.7 
This study has limitations. Although the NELSON study is the second largest lung 
cancer screening trial, the number of new subsolid nodules was limited. The precise 
malignancy rate remains unknown because a part of the nonresolving subsolid 
nodules were not resected. While these nodules were not diagnosed as interval lung  
cancer, the final survival rates of the NELSON trial are not yet available. 
In conclusion, new subsolid nodules after baseline are rare and often resolve during 
follow-up. Lung cancer found in new subsolid nodules presents with favorable stage. 
Considering the existing data, a more aggressive follow-up for new subsolid nodules 
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OBJECTIVES: To explore the relationship between nodule count and lung cancer 
probability in baseline low-dose CT lung cancer screening. 
MATERIALS AND METHODS: Included were participants from the NELSON trial with 
at least one baseline nodule (3392 participants [45% of screen-group], 7258 nodules). 
We determined nodule count per participant. Malignancy was confirmed by histology. 
Nodules not diagnosed as screen-detected or interval cancer until the end of the fourth 
screening round were regarded as benign. We compared lung cancer probability per 
nodule count category. 
RESULTS: 1746 (51.5%) participants had one nodule, 800 (23.6%) had two nodules, 
354 (10.4%) had three nodules, 191 (5.6%) had four nodules, and 301 (8.9%) had>4 
nodules. Lung cancer in a baseline nodule was diagnosed in 134 participants (139 
cancers; 4.0%). Median nodule count in participants with only benign nodules was 1 
(Inter-quartile range [IQR]: 1-2), and 2 (IQR 1-3) in participants with lung cancer 
(p=NS). At baseline, malignancy was detected mostly in the largest nodule (64/66 
cancers). Lung cancer probability was 62/1746 (3.6%) in case a participant had one 
nodule, 33/800 (4.1%) for two nodules, 17/354 (4.8%) for three nodules, 12/191 (6.3%) 
for four nodules and 10/301 (3.3%) for>4 nodules (p=NS). 
CONCLUSION: In baseline lung cancer CT screening, half of participants with lung 
nodules have more than one nodule. Lung cancer probability does not significantly 
change with the number of nodules. Baseline nodule count will not help to differentiate 
between benign and malignant nodules. Each nodule found in lung cancer screening 














In 2011, the National Lung Screening Trial (NLST) reported a 15–20% reduction in 
lung cancer mortality among individuals screened by annual low-dose CT, if compared 
to participants screened by annual chest X-ray [1]. Following the publication of this 
positive result, adapted guidelines were published, all recommending lung cancer 
screening in a high-risk population [2–5]. A remaining problem in lung cancer 
screening, however, is the high rate of false-positive screen results.  
In CT lung cancer screening trials, about half of screened participants have pulmonary 
nodules, the overwhelming majority being benign [1,6,7]. A key issue in lung cancer 
screening is to differentiate benign and malignant nodules at an early stage. Several 
radiological features, such as size, growth rate, morphology, and location are 
associated with an increased lung cancer probability and may help radiologists in 
adequately identifying a high-risk baseline nodule [8,9].  
A commonly overlooked aspect is the number of nodules per screenee (nodule count) 
at the time of nodule detection. Generally, nodule management in lung cancer 
screening is based on the largest or most suspicious nodule, but often more than one 
nodule is present. While only limited data concerning the impact of nodule count on 
lung cancer probability is available, one study indicated a negative linear relationship 
between nodule count and lung cancer probability and incorporated it in a risk 
calculator for nodules detected at baseline screening [10].  
However, in a preliminary, limited analysis on multinodularity and lung cancer 
probability for nodules detected in the first and second screening round of the Dutch-
Belgian Randomized Lung Cancer Screening Trial (acronym NELSON), the 
relationship between nodule count and lung cancer probability in participants was 
found to be ambiguous, with varying lung cancer probabilities as nodule count 
increased [7]. The purpose of this study was to explore in-depth the relationship 
between nodule count and lung cancer probability in the baseline round of the 
NELSON trial. 
 
Materials and methods 
NELSON trial and study participants  
The NELSON trial was designed to investigate whether low-dose spiral CT screening 
will decrease 10-year lung cancer mortality by at least 25% in high-risk (ex-) smokers. 
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The Dutch Minister of Health and the ethics board of each participating center 
approved the NELSON trial. All participants gave written informed consent. The design 
of the NELSON trial, including participant selection and lung nodule management has 
been published [11,12]. In brief, 15,792 current and former smokers [13], aged 50–75 
years, who smoked > 15 cigarettes daily for over 25 years or > 10 cigarettes daily for 
over 30 years were included. Participants were randomized 1:1 to usual care without 
screening or screening. Between April 2004 and December 2006, 7557 participants 
underwent baseline screening. Baseline screening was performed in year 1, and 
incident screening rounds took place in year 2 (second round), year 4 (third round), 
and year 6.5 (fourth round). For this retrospective analysis, we included all participants 
with non-calcified nodules detected at baseline. We included all nonsolid, part-solid 
and solid nodules with volume ≥ 15 mm3 and/or sub-solid diameter ≥ 4 mm (study 
detection limits).  
 
Lung cancer screening  
CT scan protocol, reading and data set Participants were invited to one of four 
screening sites each using a 16-multidetector CT scanner (three Sensation-16 
systems, Siemens Medical Solutions, Forchheim, Germany and one Brilliance 16P 
system, Philips Medical Systems, Cleveland, OH, USA). A non-contrast low-dose CT 
scan of the entire chest was obtained in a cranio-caudal direction in one breath-hold 
(about 12 s in spiral mode with 16 × 0.75 mm collimation and pitch 1.3). Typical 
technical parameters for the low-dose setting depended on body weight (< 50 kg, 50–
80 kg and > 80 kg): 80–90 kVp, 120 kVp and 140 kVp respectively [11]. Image data 
sets with isotropic voxels were available, allowing analyses with software for semi-
automated volume measurements (Syngo LungCARE, Siemens Healthcare, 
Erlangen, Germany). All images were read by two independent radiologists with 
experience in chest CT reading ranging between 1 and 20 years, and in case of 
discrepancy a third, expert reader made the final decision [11,14]. Radiologists could 
overrule a protocol-based screening result (done for 6% of participants at the baseline 
screening round) and manually adjust the volume measurement in case of 
inappropriate segmentation [14]. Nodule management was based on size, density and 
growth rate of the largest nodule. The nodule size criteria were published before [11]. 
In short, NODCAT 2 comprised solid nodules with volume 15–50 mm3 and subsolid 
nodules with diameter 4–8 mm, and led to a negative screen result (invitation for 
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regular next screening round). NODCAT 3 were solid nodules with volume 50–500 
mm3 and subsolid nodules ≥ 8 mm. NODCAT 4 nodules were defined as potentially 
malignant (solid, > 500 mm3 , positive screen result), and required immediate referral 
to the pulmonologist for work-up. NODCAT 3 nodules were assigned an indeterminate 
test result, requiring a repeat scan after 3–4 months to assess nodule growth. Growth 
was defined as change in volume of > 25% and volume doubling-time was calculated 
as described previously [11,15]. Screenees having a nodule with volume doubling time 
< 400 days (fast growing, positive screen result) were referred to a pulmonologist for 
work-up.  
 
Nodule characteristics  
Both readers reported information regarding nodule volume, location, distance to 
costal pleura and margin. Nodule location was defined as upper lobe (middle, left or 
right upper lobe) or lower lobe (left or right lower lobe). In case of distance to costal 
pleura less than one-third of the total distance of hilum-costal pleura, nodules were 
considered to be peripheral, and with more than one-third of the total distance, nodules 
were considered to be non-peripheral. Nodule margin was classified as smooth, 
lobulated, spiculated or irregular [16].  
 
Nodule count 
Nodule count was defined as the number of non-calcified lung nodules present in the 
baseline screening round. We compared nodule count at baseline for participants with 
only benign nodules and participants with lung cancer. Five categories based on 
nodule count were defined: 1 nodule, 2 nodules, 3 nodules, 4 nodules and > 4 nodules. 
Histology was the reference for diagnosis. In case a nodule was not diagnosed as 
screen-detected lung cancer or interval cancer until the end of the fourth screening 
round, the nodule was regarded as benign.  
 
Statistical analysis 
 Descriptive statistics were reported as numbers and percentages. We tested data 
distribution with normality plots. Normally distributed variables were described by 
mean and 95% confidence interval (95%- CI), while non-normally distributed variables 
were described by median and inter-quartile range (IQR). We assessed the 
relationship of participant age and smoked pack-years with nodule count by using 
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Spearman’s rank correlation coefficient. We derived lung cancer probability per 
screenee and per nodule for categories based on number of baseline nodules, by 
dividing the number of lung cancer cases per category by number of screenees and 
number of nodules, respectively. We tested the relationship between the presence of 
lung cancer and the number of baseline nodules by using chi-square. We used SPSS 
Statistics version 22 (IBM, Armonk, NY) for all analyses, and considered a p-value of 
< 0.05 as statistically significant.  
 
Results  
Characteristics of study population  
In this study, we included 3392 participants with 7258 non-calcified baseline nodules 
(45% of all screen-group participants). Median participant age was 58 years (IQR 55–
63 years); 84.4% (2863/3392) were male (Table 1). In total, 1746 participants (51.5%) 
had one nodule, 800 (23.6%) had two nodules, 354 (10.4%) had three nodules, 191 
(5.6%) had four nodules, and 301 (8.9%) had five or more nodules. Fig. 1 shows the 
distribution of nodule count per participant. The percentage of screenees with 
actionable nodules (NODCAT 3 or 4; short-term follow-up or referral) increased 
linearly with the number of baseline nodules, from 36.4% to 90.0% (Table 1). 
Spearman’s correlation coefficient showed slightly more nodules by increasing age 
(correlation coefficient 0.044; p = 0.01). No difference was found in number of nodules 
by smoked pack-years (correlation coefficient 0.026; p = 0.13). 
 















































Gender Male N (%) 2,863 (84.4) 1,455 (83.3) 674 (84.3) 298 (84.2) 169 (88.5) 267 (88.7) 
NODCAT_maxa 2, N (%) 
3, N (%) 



















Table 1: Characteristics of participants with at least one pulmonary nodule at baseline screening 
round 
a Largest nodule at baseline screening. A NODCAT 2 nodule is solid nodules with volume 15-50 mm³ or sub-solid with diameter 4-8 















Description of cancers in study population  
During four screening rounds, 139 baseline nodules in 134 participants were proven 
to be lung cancer. Simultaneous double tumours were found in five participants. Of 
the 139 cancers, 70 were diagnosed to be malignant immediately after the baseline 
round (66 screenees). At baseline, lung cancer was histologically confirmed in the 
largest nodule in 64/66 (97.0%) screenees (double tumours counted once), and in the 
second largest detected nodule in 2/66 (3.0%) cases. In later rounds, 49/56 (87.5%) 
screen-detected lung cancers and 10/12 (83.3%) interval cancers were found in 
baseline nodules that were the largest at the baseline CT. On population basis, median 
nodule count was 1 (IQR 1–2) in participants with only benign nodules, and 2 (IQR 1–
3) in participants with lung cancer. Range of nodule count was equal for participants 
with only benign nodules and participants with lung cancer (1–18 nodules). 
 
Nodule characteristics  
Baseline nodules most often were located in the lower lobes, in the periphery of the 
lung, and had a smooth shape. Compared to benign baseline nodules, malignant 
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nodules were larger and more often subsolid, had more often a non-smooth margin, 
and were more often located in the upper lobes of the lung. Nodule characteristics per 
nodule count are shown in Table 2.  
 
Lung cancer probability: participant-based analysis 
In 62 of 1746 participants with one baseline nodule (3.6%; 95% CI, 2.8-4.6%), the 
solitary nodule was lung cancer. Of 800 participants with two lung nodules, 33 (4.1%; 
95% CI, 2.9-5.8%) were diagnosed with lung cancer in one of these nodules. In 17 of 
354 participants with three nodules (4.8%; 95% CI, 2.9-7.7%), 12 of 191 participants 
with four nodules (6.3%; 95% CI, 3.4-11.0%), and ten of 301 participants with at least 
five nodules (3.3%; 95% CI, 1.7-6.2%), lung cancer was diagnosed (Table 3). Lung 
cancer probability did not differ significantly for the different nodule count categories 
(p = 0.34).  
Of the 12 participants with a baseline nodule diagnosed as interval cancer, three 
participants had a single baseline nodule, five had two nodules at baseline, two had 
three baseline nodules, one had four and one had > 4 nodules at baseline.  
 
Lung cancer probability: nodule-based analysis  
Lung cancer probability per nodule was 3.6% in case of one nodule, 2.1% in case of 
two nodules, 1.8% in case of three nodules, 1.7% in case of four nodules and 0.7% in 
case of screenees with more than four nodules.  
Table 4 shows an increasing lung cancer risk in increasing nodule categories (overall; 
NODCAT 2 0.3%, NODCAT 3 2.5% and NODCAT 4 30.1%). There was no difference 
in lung cancer probability for a NODCAT 2 nodule found in screenees with only one 
nodule or screenees with a higher nodule count. For actionable nodules (> 50 mm3; 
NODCAT 3 or 4), the risk of malignancy in a particular nodule decreased in case a 
nodule was found in screenees with four or more nodules per screenee, compared to 
actionable nodules found in screenees with only one nodule (p < 0.001 for NODCAT 
3 and p < 0.05 for NODCAT 4 nodules). 
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   1 Nodule 2 Nodules 3 Nodules 4 Nodules >4 Nodules Benign Malignant P-
value 
Volume (mm3)a   Median 36.9 38.3 38.3 38.6 38.9 37.7 328.6 <0.001 
 IQR 23.8-69.0 24.1-70.3 25.1-70.1 24.9-71.6 24.6-67.5 24.2-67.3 112.7-1130.5  
          
NodCat 2 959 (64.0) 972 (62.0) 707 (63.5) 476 (62.3) 1,444 (62.4) 4545 (63.8) 13 (9.4) <0.001 
 3 484 (32.3) 537 (34.2) 374 (33.6) 263 (34.4) 834 (36.0) 2,430 (34.1) 64 (46.0)  
 4 55 (3.7) 60 (3.8) 32 (2.9) 25 (3.3) 36 (1.6) 144 (2.0) 62 (44.6)  
Nodule Typeb Solid 1,439 (96.8) 1,504 (96.5) 1,074 (96.7) 744 (97.4)  2,277 (98.6)   6,915 (97.5)   123 (88.5)  <0.001 
  Part-solid 15 (1.0) 27 (1.7) 18 (1.6) 8 (1.0) 11 (0.5) 72 (1.0) 7 (5.0)  
  Nonsolid 33 (2.2) 28 (1.8) 19 (1.7) 11 (1.4) 21 (0.9) 103 (1.5) 9 (6.5)  
           
Locationc,d Upper Lobe 569 (38.6) 620 (40,0) 381 (34.9) 276 (34.9) 760 (34.2) 2,517 (36.2) 89 (64.0) <0.001 
  Lower lobe 906 (61.4) 929 (60,0) 712 (65.1) 472 (63.1) 1,465 (65.8) 4,434 (63.8) 50 (36.0)  
           
  Peripheral 1,204 (81.6) 1,252 (80.7) 923 (83.2) 623 (81.9) 1,983 (86.1) 5,872 (83.1) 113 (81.9) 0.73 
  Non-peripheral 271 (18.4) 300 (19.3) 186 (16.8) 138 (18.1) 321 (13.9) 1,191 (16.9) 25 (18.1)  
           
Shapee Non-smooth 89 (6.9) 108 (7.8) 67 (6.9) 30 (4.8) 65 (3.1) 299 (4.9) 60 (45.5) <0.001 
 Smooth 1,206 (93.1) 1,276 (92.2) 903 (93.1) 594 (95.2) 1,920 (96.7) 5,827 (95.1) 72 (54.5)  
Table 2: Nodule characteristics detected at baseline screening round. 
Unless otherwise indicated, data are numbers of nodules, with percentages in parenthesis. Abbrevations: IQR – Interquartile range.  
a In 193/7258 (2.7%) no volume measurement was possible, for instance in sub-solid nodules. 
b In 29/7258 (0.4%) nodule type was not specified, mostly due to very small nodule size (<50 mm3). 
c,d In 225/7258 (3.1%) location was not specified (168/7258 (2.3%) peripheral versus non peripheral and 57/7258 (0.8%) upper versus lower lobe). 
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1 Nodule 1,746 62 3.6% 2.8-4.6% 30 1.7% 1.2-2.5% 32 1.8% 1.3-2.6% 
2 Nodules 800 33 4.1% 2.9-5.8% 17 2.1% 1.3-3.5% 16 2.0% 1.2-3.3% 
3 Nodules 354 17 4.8 % 2.9-7.7% 6 1.7% 0.7-3.8% 11 3.1% 1.6-5.7% 
4 Nodules 191 12 6.3% 3.4-11.0% 7 4.2% 2.0-8.4% 5 2.6% 1.0-6.3% 
>4 Nodules 301 10 3.3% 1.7-6.2% 6 2.0% 0.8-4.5% 4 1.3% 0.4-3.6% 
Total 3,392 134 4.1% 3.4; 4.8% 66 2.0% 1.5; 2.5% 68 2.0% 1.6; 2.6% 
Table 3: Lung cancer probability with 95% confidence intervals on participant basis: cancer detection at baseline versus at later screening 
rounds 
Note - Data are numbers of participants, with percentages in parenthesis; Abbreviations: 95% CI - 95% confidence interval.* lung cancer diagnosed in a nodule 
already present at baseline  
 






Cancer Yes No Yes No Yes No 
Overall cancer 13 (0.3) 4,545 (99.7) 64 (2.6) 2,431 (97.4) 62 (30.1) 144 (69.9) 
Nodule count 1 6 (0.5) 1,102 (99.5) 29 (5,1) 543 (94,9) 27 (40.9) 39 (59.1) 
Nodule count 2 4 (0.4) 988 (99.6) 16 (2.9) 536 (97.1) 15 (26.8) 41 (73.2) 
Nodule count 3 3 (0.4) 682 (99.6) 9 (2.6) 334 (97.4) 7 (20.6) 27 (79.4) 
Nodule count 4 0 (0) 471 (100) 7 (2.6) 265 (97.4) 6 (28.6) 15 (71.4) 
Nodule count > 4 0 (0) 1,302 (100) 3 (0.4) 753 (99.6) 7 (24.1) 22 (75.9) 
Table 4. Lung cancer probability by nodule count for NODCAT* 2-4 nodules 
*A NODCAT 2 nodule is solid nodules with volume 15-50 mm³ or sub-solid with diameter 4-8 mm, a NODCAT 3 nodule is solid with 
volume 50-500 mm³, or sub-solid ≥8 mm, and a NODCAT 4 nodule is solid >500 mm³ 




With the use of multi-detector low dose CT scanners (very) small lung nodules can be 
detected, the minority being malignant. Whether the number of lung nodules (nodule 
count) plays a role in the determination of lung cancer probability still remains largely 
unknown. This study shows that at baseline CT lung cancer screening, nearly half of 
screening participants with lung nodules have more than one lung nodule (1746/3392 
[51.5%]), representing about one-fourth of all screenees. We found no statistically 
significant relationship between nodule count and lung cancer probability in 
participants with baseline nodules. We observed a non-significant trend whereby lung 
cancer probability increased as a function of nodule count, with a peak in lung cancer 
probability in subjects with four baseline nodules (6.3%). However, this non-significant 
increasing trend did not continue. The implications of these findings partly differ from 
previous observations by McWilliams et al., where nodule count was incorporated in 
a model for the prediction of malignancy in pulmonary nodules [10]. In their risk 
calculator, they found a linear reduction of a baseline nodule’s lung cancer probability 
with an increased number of pulmonary nodules per screenee. 
In our subgroup of the NELSON study containing all participants with non-calcified 
baseline nodules, we found lung cancer in a baseline nodule in 134/3392 (4.0%) 
participants, up to six years after baseline (information regarding new nodules was 
published elsewhere [17]). In the PanCan study, the overall rate of malignancy was 
5.5%. In comparison to the findings of McWilliams et al. [10], we found a much lower 
mean nodule count per screened participant. The subjects with benign nodules in the 
PanCan study had a mean of 6.2 nodules, compared to 2.1 nodules (median 1 nodule) 
in our study. In the PanCan study, subjects with lung cancer had a mean of 4.8 
nodules, in contrast to our findings of 2.3 nodules on average (median 2 nodules). 
Differences may be explained by differences in inclusion criteria for screenees. The 
NELSON study recruited participants aged 50–75 years without a history of lung 
cancer, who smoked > 15 pack-years. The PanCan study used a different approach 
for recruiting participants, namely via a risk-prediction model [18]. Participants with an 
estimated risk of developing lung cancer in the next 3 years of ≥ 2% were included. 
Geographical differences in pulmonary nodule nature (i.e. prevalence of fungus 
infestations [19]) may have influenced the number of nodules in these studies on two 
different continents as well.  
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In 64/66 (97.0%) of participants with lung cancer detected at baseline, malignancy was 
detected in the nodule with the largest volume. This contrasts with the results by 
McWilliams et al. [10], who showed that in one-fifth of the participants, the largest 
nodule was not the one that turned out to be malignant at baseline or follow-up. This 
discrepancy might be explained by the use of semi-automated, volumetric 
measurement in our study, while manual, two-dimensional diameter measurements 
were performed in the PanCan study. Previously, it has been shown that nodule 
measurements are more accurate with volumetric techniques compared to diameter 
techniques [20–22]. Possibly, diameter measurements cannot identify the largest 
nodule as good as volumetry.  
The American College of Radiology’s Lung Imaging Reporting and Data System 
(Lung-RADS) proposed to classify screening CTs by the nodule with highest malignant 
risk (usually the largest nodule) [23]. Our results confirm this policy. Each nodule found 
in lung cancer screening subjects should be assessed separately whereby the largest 
nodule has the highest probability to be malignant. While reporting and measuring all 
lung nodules might be time consuming, it is important to lung cancer screening for two 
reasons. First, new nodules are regularly found after baseline screening and were 
shown to carry a higher lung cancer probability than do baseline nodules even at 
smaller size [24]. To ensure the appropriate detection of new nodules, previously 
present nodules need to be well documented. Secondly, after initial detection a 
nodule’s risk-stratification relies on growth assessment which is based on the size 
difference between two scans and therefore the previous measurements [7,25].  
We found that the more nodules per screenee, the greater the likelihood that the 
largest nodule was classified as indeterminate (NODCAT 3, see Table 1). 
Indeterminate pulmonary nodules led to an extra follow-up CT examination after 3 
months. Therefore, the more nodules per screenee, the more follow-up scans were 
made to assess growth.  
Higher age and number of smoked pack-years are associated with an increased risk 
of developing lung cancer [10]. In our analysis, higher age at baseline was correlated 
with a slightly increased risk of having more pulmonary nodules. In contrast, no 
relationship was found between nodule count at baseline and number of smoked pack-
years.  
We included all non-calcified nodules, and did not differentiate between solid, part- 
solid and pure nonsolid nodules. More detailed research on the influence of multiple 
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nodules from different subtypes (solid, sub-solid) on lung cancer probability is 
recommended. Furthermore, external validation of the nodule count and lung cancer 




At baseline CT lung cancer screening, nearly half of screened participants with lung 
nodules have more than one lung nodule, representing a quarter of all screenees. 
Lung cancer probability did not significantly change with number of nodules, therefore 
baseline nodule count proved to be not useful for prediction of malignancy. Each 
nodule found in lung cancer screening subjects should be assessed separately 
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Background: New nodules are regularly found after the baseline round of low-dose 
computed tomography (LDCT) lung cancer screening. The relationship between a 
participant’s number of new nodules and lung cancer probability is unknown.  
Methods: Participants of the ongoing Dutch-Belgian Randomized Lung Cancer 
Screening (NELSON) Trial with (sub)solid nodules detected after baseline and 
registered as new by the NELSON radiologists were included. The correlation between 
a participant’s new nodule count and the largest new nodule size was assessed using 
Spearman's rank correlation. To evaluate the new nodule count as predictor for new 
nodule lung cancer together with largest new nodule size, a multivariable logistic 
regression analysis was performed. 
Results: In total, 705 participants with 964 new nodules were included. In 48% 
(336/705) of participants no nodule had been found previously during baseline 
screening and in 22% (154/705) of participants >1 new nodule was detected (range 1-
12 new nodules). Eventually, 9% (65/705) of the participants had lung cancer in a new 
nodule. In 100% (65/65) of participants with new nodule lung cancer, the lung cancer 
was the largest or only new nodule at initial detection. The new nodule lung cancer 
probability did not differ significantly between participants with 1 (10% [56/551], 95%CI 
8-13%) or >1 new nodule (6% [9/154], 95%CI 3-11%, P=0.116). An increased number 
of new nodules positively correlated with a participant’s largest nodule size (P<0.001, 
Spearman's rho 0.177). When adjusted for largest new nodule size, the new nodule 
count had a significant negative association with lung cancer (odds ratio 0.59, 0.37-
0.95, P=0.03).  
Conclusion: A participant’s new nodule count alone only has limited association with 
lung cancer. However, a higher new nodule count correlates with an increased largest 
new nodule size, while the lung cancer probability remains equivalent, and may 










Lung cancer screening using low-dose computed tomography (LDCT) is currently 
recommended by US guidelines for high-risk individuals,1–3 after the National Lung 
Screening Trial reported a 20% reduced lung cancer mortality for LDCT compared to 
chest radiography screening.4 Lung nodules are common findings in LDCT lung 
cancer screening. European and American trials with no or very low detection limits 
reported a noncalcified lung nodule prevalence in 41-51% of participants at baseline 
screening.5–9 Since most detected nodules are benign, the effective identification of 
potentially malignant nodules is central to current lung cancer screening programs. 
While nodule management is mainly based on size and growth,10,11 other nodule 
characteristics, such as nodule morphology or nodule location, have traditionally been 
associated with an increased probability for lung cancer. 10–13 Furthermore, patient 
characteristics such as age or smoking pack-years play a crucial role in identifying 
high-risk individuals eligible for screening.8,12,14 
However, within a lung cancer screening program, but also in regular clinical practice, 
individuals may be diagnosed with several nodules at baseline or at follow-up 
screening.5–9,12,13 There are only limited data concerning the relationship of the 
number of nodules detected in a participant (or nodule count) and lung cancer 
probability. For nodules detected at baseline screening, a recent analysis of the largest 
European lung cancer screening trial indicated that the baseline nodule count alone 
does not predict lung cancer.15 On nodule level, one large study indicated a negative 
association between the nodule count and a baseline nodule’s lung cancer probability 
when assessed together with other known risk-factors, also reflecting the low 
incidence of double malignancies.12  
During a lung cancer screening program, annually in 3-13% of participants new 
nodules are detected that were not present at baseline screening.5,16–19 Recently, it 
was shown that new nodules carry a higher lung cancer probability at smaller size than 
do baseline nodules.19 However, an array of non-malignant diseases may be 
associated with the development of new lung nodules and some participants may tend 
to develop multiple benign lung nodules of varying size.9,20 The appropriate risk-
stratification of new nodules is important to a lung cancer screening program, as they 
account for a significant proportion of lung cancers found after the baseline 
round.19,21,22 Till recently most research focused on nodules detected at baseline 
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screening and there is only limited evidence on the management of new nodules.1,11,19 
In a current European position statement on lung cancer screening, it was stressed 
that the management of new nodules should be different from baseline nodules since 
they have a higher pretest probability which was also adopted in the British Thoracic 
Society Guidelines for the Investigation and Management of Pulmonary Nodules.22 At 
present, there is no evidence regarding an association of the new nodule count after 
baseline lung cancer screening and the development of new nodule lung cancer. Aim 
of this study was to assess the relationship of a participant’s number of new nodules 
and the new nodule lung cancer probability, using data from the largest European 
randomized controlled lung cancer screening trial.  
 
Material and methods 
Study Population 
The Dutch-Belgian Randomized Lung Cancer Screening (acronym NELSON, trial 
registration number: ISRCTN63545820) trial’s study design and recruitment process 
have been published previously.7,23,24 Briefly, (ex-) smokers aged 50-75, who had 
smoked at least 15 cigarettes daily for 25 years or 10 cigarettes daily for 30 years and 
were still smoking or stopped smoking less than 10 years ago were eligible. The Ethics 
committees of all participating centers approved the NELSON trial. All participants 
provided their written informed consent. Between April 2004 and December 2006, 
7,557 participants underwent baseline screening. The subsequent incidence 
screening rounds took place 1 year, 3 years, and 5.5 years after baseline screening. 
The current study included participants in whom the NELSON radiologists registered 
a new noncalcified nodule during the three incidence screening rounds. 
 
CT Scanning Protocol and image reading 
Low-dose CT scans were performed at one of four screening sites using 16-MDCT 
scanners or 64-MDCT scanners (Sensation-16, Siemens Medical Solutions, 
Forchheim, Germany; or Mx8000 IDT or Brilliance 16P, Philips Medical Systems, Best, 
Netherlands). Depending on the participant’s body weight (<50kg, 50-80kg, or >80kg), 
low-dose settings (80-90kVp, 120kVp, and 140kVp) were adapted to match a dose 
index volume of 0.8mGy, 1.6mGy, or 3.2mGy respectively. Datasets were derived 
from images of the thorax with 1.0mm slice width and a 0.7mm reconstruction interval. 
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The data acquisition and imagining protocols were standard across screening sites 
7,23. CT-image analysis occurred on digital workstations (Leonardo, Siemens Medical 
Solutions) which enabled semiautomated volume analysis using software (LungCare, 
version Somaris/5 VA70C-W, Siemens Medical Solutions). Image reading was 
performed by two independent radiologists in the first two rounds and by one 
radiologist in the third and fourth round, after it was demonstrated that reading 
consensus provides no benefit with the use of semiautomated software.25 In case of 
high suspicion of malignancy (eg, enlarged mediastinal lymph nodes) or benignity (eg, 
benign calcification patterns), radiologist could overrule protocol-based screening 
results (as done for 195 [6%] of 3,318 participants at the baseline screening round) 
and adjust the nodule volume in case of inappropriate segmentation.26 Detected 
nodules were matched to previous scans by the software’s algorithm and matching 
was visually confirmed by the radiologist. Data generated during CT evaluation were 
immediately uploaded to the NELSON management system. This study included data 
and measurements as uploaded to the NELSON management system and no new or 
repeat measurements were performed. Nodules were considered new if labeled as 
new and not present on previous scans by the NELSON radiologists.  
 
Nodule Management Protocol 
The detailed NELSON nodule management protocol was published previously.23 At 
first detection, new nodules were classified into four categories according to their size 
and characteristics (NODCAT I-IV). Calcified nodules and nodules with other benign 
characteristics were considered benign (NODCAT I). New solid nodules measuring 
15-50mm3 and new subsolid nodules with diameter 4-8mm (NODCAT II, follow-up 
LDCT within one year) as well as new solid nodules 50-500mm3 and new subsolid 
nodules ≥8 mm (NODCAT III, follow up LDCT within six-eight weeks) were considered 
indeterminate, requiring nodule growth assessment. New solid nodules ≥500mm3 
(NODCAT IV, immediate referral to pulmonologist) were considered positive. 
 
Outcomes 
A nodule was classified as lung cancer when it was diagnosed as lung cancer during 
diagnostic workup according to national and international guidelines including 
histologic examination.23 Nodules were classified as benign when either: (a) the 
nodule was benign at histologic examination; (b) extensive workup by a pulmonologist, 
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including contrast material–enhanced CT, PET, and bronchial washing, had a negative 
finding; (c) the nodule was ruled negative during the participant’s last follow-up in the 
NELSON trial. As far as accessible in this ongoing trial, data was linked with the Dutch 
and Belgian national cancer registries and medical files reviewed concerning the 
occurrence of post-screening lung cancer (completed for the second and third 
incidence screening round) .21,23,27 
 
Nodule counts 
For this study two nodule counts were calculated for each participant. First, the number 
of new noncalcified nodules detected simultaneously at a participant’s first new nodule 
detection after baseline and second, the number of noncalcified nodules detected at 
baseline screening. The new nodule count may reflect the presence of non-malignant 




Normality of continuous variables was evaluated through the Kolmogorov–Smirnov 
test and visual assessment. All included continuous variables were non-normally 
distributed and are presented as median and interquartile range (IQR). Categorical 
variables are shown as frequencies and respective percentages. The Agresti-Coull 
method was used to calculate 95% confidence intervals (95%CI) of proportions. The 
correlation of the participant’s new nodule count and the participant’s age at baseline, 
the smoking pack-years at baseline, the volume of the largest nodule and the volume 
of all new nodules was assessed using Spearman's rank correlation. Categorical 
variables stratified by the new nodule count (0, 1, 2, 3, 4, ≥5) were assessed using 
Fisher’s exact test or the χ² test as appropriate. The Mann–Whitney U test was used 
for comparison of nodule volume between two groups. The discriminative performance 
of the nodule count with new nodule lung cancer as outcome was evaluated through 
construction of the area under the receiver-operating-characteristic curve (AUC). To 
evaluate new nodule count as predictor for new nodule lung cancer together with 
largest new nodule size (i.e. one case per participant), multivariable logistic regression 
analysis was performed including new nodule count and size (highest new nodule 
NODCAT classification and largest new solid nodule volume respectively). In 
participants where the largest new nodule could not be established based on the exact 
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volume measurement (1% [10/705]), the nodule with the highest NODCAT 
classification was considered largest. The model calibration was assessed by a 
Hosmer-Lemeshow goodness-of-fit test and through comparison of observed and 
predicted probabilities. Statistical analyses were performed with SPSS version 24.0 
(IBM, Armonk, NY, USA), Medcalc version 17.1 (Medcalc Software, Mariakerke, 
Belgium), and Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). 
 
Results 
In total, 705 participants with 964 new nodules were included (Figure 1). Participant 
characteristics are presented in Table 1. Median participant age at baseline was 59 
years (IQR 55-63 years) and 79% (558/705) of participants were male. Subsolid new 
nodules were detected in 6% (49/705) of participants and 5% (3/65) of the new nodule 
lung cancers were found in subsolid lesions. In 48% (336/705) of participants no 
nodule had been found previously during baseline screening and in 22% (154/705) of 
participants >1 new nodule was detected (range 1-12 new nodules). Eventually, 9% 
(65/705) of the participants were diagnosed with lung cancer in one of the detected 
new nodules. In all participants with new nodule lung cancer, the largest (14% [9/65]) 
or only (86% [56/65]) new nodule was diagnosed as lung cancer. 
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Table 1: Participant characteristics stratified by number of new nodules detected 
Abbreviations: IQR - Interquartile range. 
 
Part III - Number of Nodules and Lung Cancer Probability 
163 
 
On participant level, receiver operating curve analysis demonstrated no significant 
predictive ability of the new nodule count for lung cancer (AUC 0.55, 95%CI 0.48-
0.62). A participant’s overall new nodule lung cancer probability did not significantly 
differ between participants with 1 new nodule (10% [56/551], 95%CI 8-13%) or >1 new 
nodule (6% [9/154], 95%CI 3-11%, P=0.116). Participants with multiple new nodules 
that clustered in one lung lobe had a lower but not statistically different lung cancer 
frequency when compared to participants with multiple new nodules but no clustering 
(2% [1/44] vs. 7% [8/110), P=0.232). On nodule level, a lower number of 
simultaneously detected new nodules showed a moderate predictive ability for lung 
cancer (AUC 0.67, 95%CI 0.61-0.72) with no double cancers being detected. The 
participant’s nodule count at baseline screening demonstrated no significant 
discriminative performance for new nodule lung cancer, neither participant level (AUC 
0.52, 95%CI 0.45-0.59) nor nodule level (AUC 0.53, 95%CI 0.46-0.60).  
The nodule size and lung cancer probability stratified by the participant’s 
number of new nodules are shown in Table 2. While the median volume of the 
participant’s largest nodule increased significantly with more new nodules detected 
(P<0.001, Spearman's rho 0.177), the lung cancer probability remained equivalent 
(P=0.63). The lung cancer probability of participants in whom the only detected new 
nodule was NODCAT III or IV was significantly higher compared to participants with 
NODCAT III or IV nodules but >1 new nodule detected (15% [50/333], 95%CI 12-19% 
vs. 8% [9/119], 95%CI 4-14%, P=0.04). When adjusted for the size of the largest new 
(solid) nodule (Table 3), the new nodule count was a significant predictor, having a 
negative association with new nodule lung cancer.  
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Table 2: Nodule size and new nodule lung cancer probability stratified by number of new nodules detected 
Abbreviations: CI - Confidence interval, IQR - Interquartile range. 
a NODCAT II, Solid nodules measuring 15-50mm3 and subsolid nodules with diameter 4-8mm; NODCAT III, solid nodules 50-500mm3 and subsolid nodules ≥8 mm; 
NODCAT IV, solid nodules ≥500mm3 
bSpearman's rho 0.177 
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Participants with a new (sub)solid nodule  
 Univariate analysis Multivariate analysis 
 Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Number of new nodules 0.67 (0.42-1.07) 0.093 0.59 (0.37-0.95) 0.030 













Participant with a new solid nodule  
 Univariate analysis Multivariate analysis 
 Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Number of new nodules 0.60 (0.34-1.04) 0.07 0.37 (0.17-0.77) 0.008 
Size of largest new solid nodule 
Ln-Volume 




Table 3: Number of new nodules in the prediction of new nodule lung cancer 
Abbreviations: CI - Confidence interval. 
a NODCAT II, Solid nodules measuring 15-50mm3 and subsolid nodules with diameter 4-8mm; NODCAT III, solid nodules 




This analysis focused on participants with new nodules detected during the three 
incidence rounds of the NELSON trial. We assessed the relationship between the 
number of new nodules detected in a participant and the probability of developing lung 
cancer in a new nodule.  
There are five major findings. First, in 22% (154/705) of participants more than 
one new nodule was detected at initial new nodule detection. Second, the lung cancer 
probability, did not differ significantly between participants with one and more than one 
new nodule. Third, an increased number of new nodules was correlated with a greater 
largest new nodule size. Fourth, the new nodule count had a significant negative 
association with new nodule lung cancer when assessed together with nodule size. 
Fifth, the participant’s overall nodule count at baseline screening was not significantly 
associated with new nodule lung cancer.  
 
To our knowledge, this is the first study providing evidence concerning a possible 
impact of a participant’s nodule count and the lung cancer probability in new solid 
nodules. Lung cancer screening participants only have one baseline screen, but 
potentially many incidence screenings and with increasing duration, a program’s 
success depends on the management of new nodules. Contrary to baseline nodules, 
which may have been present for years, new nodules develop in a known timeframe 
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and comprise a group of comparably young nodules.19 A study focusing on the 
development of a lung cancer risk model for baseline nodules reported a reduced lung 
cancer probability with an increasing number of baseline nodules.12 The findings of 
this study show similar results for new nodules on nodule level. Nevertheless, on 
participant level the new nodule count alone showed limited discriminative 
performance for new nodule lung cancer (AUC 0.55, 95%CI 0.48-0.62). This is 
comparable to a recent analysis of the NELSON baseline round, where baseline lung 
cancer probability did not differ significantly per baseline nodule count.15 However, the 
here presented findings indicate that in combination with new nodule size the new 
nodule count has a significant negative association with new nodule lung cancer. This 
may be explained through the observation that an increased new nodule count is 
associated with a greater size of the largest nodule found in a participant, while the 
lung cancer probability remains at least equivalent.  
At initial nodule detection and before growth assessment is feasible, nodule 
size is the most important predictor for lung cancer in both baseline and new nodules 
and is used for risk-stratification in present guidelines.10,11,19,22 Currently, the 
management of detected nodules in lung cancer screening and clinical practice, 
focusses on the most suspicious or typically largest nodule detected.10,11,19,22 This 
reflects a participant-based approach with a theoretical lung cancer probability of 
smaller nodules not taken into account. The findings of this study show that factoring 
in the new nodule count could adapt a participant’s lung cancer risk stratification in a 
multivariate approach that includes the largest nodule size. However, additional data 
is needed to confirm these findings and assess new nodule count together with other 
risk factors. 
 
This study has limitations. The NELSON trial’s detection limit was 15mm3 and smaller 
new nodules could not be considered in this analysis. However, newly detected 
nodules above 15mm3 and visible below the studies detection limit on a previous scan 
were excluded. Further, the expertise of radiologist was shown to decrease false-
positive screening results.26 Radiologists potentially increased their expertise in 
distinguishing scars or infections from suspicious lesions during the trial and could 
have refrained from classifying them as suspicious nodules to avoid false-positive 
results. We cannot exclude the possibility that the actual number of new nodules is 
slightly higher than reported in the NELSON management system. Within the 
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NELSON management protocol, larger nodules potentially received an additional 
follow-up LDCT or were referred for further diagnostic work-up. To minimize bias 
through the protocol, this analysis incorporated all follow-up data of a nodule within 
the NELSON trial including cancer diagnosis in later rounds and information from the 
national cancer registries concerning post-screening lung cancer.  
 
Conclusion 
In around one-fifth of participants with new nodules in incidence lung cancer screening 
rounds, more than one new nodule is present. A participant’s number of new nodules 
alone only provides limited discriminatory information for new nodule lung cancer 
probability. However, with an increasing number of new nodules, the largest new 
nodule tends to be bigger, while the participant’s overall new nodule lung cancer 
probability remains equivalent. Therefore, relating the largest new nodule size with the 
number of new nodules found could adjust a participant’s lung cancer risk based on 
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The general discussion evaluates and summarizes the main findings of this thesis and 
presents a list of conclusions with general recommendations for new nodule risk-
stratification. Finally, the impact of the thesis until now is briefly reviewed and future 
perspectives presented. 
 
Lung cancer screening by LDCT is recommended in the United States and experts 
have recommended to prepare for the potential commencement in Europe.1 
Furthermore, with increasing availability of high-end medical care, incidentally found 
pulmonary lung nodules are increasingly common in clinical practice.2 Lung cancer 
screening with LDCT consists of one baseline screening round and multiple incidence 
screening rounds.3,4 Furthermore, participants with suspicious nodules might receive 
additional follow-up within one round.5,6 Current nodule risk-stratification protocols are 
mainly based on nodule size at first detection and nodule growth in subsequent 
screening rounds.1,7–10 Appropriate risk-stratification and thus the accurate 
identification of high-risk participants that require immediate referral for diagnostic 
work-up as well as the identification of low-risk participants is key to any screening 
program. Underestimating the risk may cause delayed lung cancer diagnosis, thereby 
effectively increasing the mortality of participants.2,11,12 Conversely, a risk 
overestimation may cause unnecessary and potentially harmful procedures.13–15 
 
Nodules detected at baseline potentially have been present for years, whereas 
nodules newly developed after baseline are possibly fast-growing. Although this is a 
very intuitive concept, prior to this thesis, there was only very limited evidence 
concerning the risk-stratification of new nodules detected after baseline.9,16,17 New 
nodule management was mostly based on expert-opinion or data derived from 
baseline nodules.6–9,16 Recognizing this, this thesis investigated the appropriate risk-
stratification of new nodules based on data of the incidence screening rounds of the 
largest European randomized-controlled lung cancer screening trial. The results of this 
thesis might apply to both, participants in lung cancer screening programs as well as 








Occurrence of New Nodules in Lung Cancer Screening 
Considering the results of this thesis and other lung cancer screening trials, it appears 
that new nodules are regular findings in low-dose CT lung cancer screening. In annual 
screening, 5% of the NELSON participants developed a new non-calcified solid 
nodule, while 11% of the NELSON participants developed a new non-calcified solid 
nodule within the first two incidence screening rounds (3 years after baseline).17 The 
annual new solid nodule occurrence was similar to numbers from the ELCAP and 
IELCAP studies (3% and 5% respectively) as well as the PLuSS trial (7%).18–20 
However, the location and screening population compositing can impact the 
occurrence of new nodules significantly. Exemplifying this, the Mayo trial, being 
conducted in an area with a high prevalence of histoplasmosis, reported a high annual 
occurrence of new nodules in >10% of participants annually.21,22 In response to the 
NELSON trial’s results, an analysis of the NLST reported an annual incidence of new 
nodules in around 3% of participants (note: only nodules ≥4mm were registered as 
compared to 15 mm³ [around 3mm] in the NELSON trial).23 Nevertheless, these 
numbers are limited in their direct comparability, as new nodules were defined 
differently within trials and rates have not been reported explicitly.16,24 However, new 
nodules are consistently found in lung cancer screening trials. Importantly, the 
frequency of new nodule detection is not directly linear with screening interval length. 
In the NELSON trial, 5% of participants presented with new solid nodules in the second 
screening round (1 year after baseline) but only 7% of participants had new solid 
nodules in the third screening round (3 years after baseline).17 This will be further 
explored in a subsequent section of this discussion. 
Compared to new solid nodules, non-solid new nodules are less common. New 
subsolid nodules were found in <1% of participants with at least one screening after 
baseline.25 This is comparable to findings of the I-ELCAP trial, where <1% of 
participants presented with new part-solid or new non-solid nodules respectively.26,27 
Thus, new lung nodules should be expected in any lung cancer screening program. 
This particularly underscores the need to register every observable nodule in a 
participant and not only the most prominent. The meticulous identification of new 
nodules is key for any risk-stratification strategy to be implemented. 
 
 




Lung Cancer Probability of New Nodules in Lung Cancer Screening 
As shown in this thesis, new solid nodules have already at smaller size a higher lung 
cancer frequency as compared to nodules present at baseline, but LDCT lung cancer 
screening enables the detection of new nodule lung cancer at an early stage. 
Conversely, new subsolid nodules have a lung cancer frequency and course 
comparable to subsolid baseline nodules. 
In this thesis it was found that 6% of participants with a new non-calcified solid nodule 
developed lung cancer in such a nodule, with 4% of the new solid nodules proving to 
be lung cancer.17 In a previous analysis of the NELSON trial, 1% of participants were 
detected with lung cancer during the baseline screening round,5 and for the first three 
rounds it was reported that approximately 3% of participants were detected with lung 
cancer (including new nodule cancer).28 The ELCAP trial reported that 10% of 
participants with new non-calcified pulmonary incident nodules on LDCT had lung 
cancer in a new nodule, and the IELCAP reported this was the case for 5% of its 
participants.18–20 In response to the NELSON trial’s analysis, data of the NLST 
confirmed the results, with 6% of the new solid nodules being lung cancer as compared 
to only 3% of the baseline solid nodules.23,29 Of the detected new solid lung cancers 
in the NELSON trial, 38% were adenocarcinomas, 22% were squamous-cell 
carcinoma, and 10% were small-cell lung cancer.17 To our knowledge, until its 
publication, the NELSON trial was the first to provide specific data concerning new 
solid nodule lung cancer stage and histology.17,24 The NLST trial reported that 27% of 
new solid nodule lung cancer were adenocarcinoma and 16% were small-cell lung 
cancer.23 In the NELSON trial, it was found that 68% of the new solid nodule lung 
cancers were detected at stage I which was comparable to baseline screening 
(64%).17 The IELCAP trial reported that 86% of lung cancers in patients with a new 
non-calcified pulmonary incident nodule was detected at stage I, whereas the NLST 
trial found 60% of new solid nodule lung cancer at stage I.19,23 Thus, LDCT lung cancer 
screening enables the early detection of new nodule lung cancer. 
Here it was found that 6% of participants with a new subsolid nodule had a lung cancer 
diagnosed in such a nodule, with 5% of the new subsolid nodules being lung cancer.25 
Until now the I-ELCAP is the only other trial that reported new subsolid nodule lung 
cancer frequencies.30,31 Overall, 4% of the new subsolid nodules detected in the I-
ELCAP trial were lung cancer.26,27 All new subsolid nodule lung cancers detected in 




the NELSON trial were stage I or adenocarcinoma in situ.25 This is comparable to 
results of the I-ELCAP trial where all new subsolid lung cancer cases were stage I.26,27 
Additionally, previous prospective Japanese studies reported that all pathologically 
confirmed tumors in subsolid nodules were stage I and ≤1% of subsolid nodules were 
invasive adenocarcinomas.32,33 Furthermore, an analysis of lung cancer manifesting 
as nonsolid nodule (baseline and incident clustered together) in the NLST concluded 
that annual follow-up is appropriate.34 
The high lung cancer probability of new solid nodules as well as their relatively frequent 
occurrence in lung cancer screening underlines the need for an appropriate risk-
stratification strategy. However, the presented results also demonstrate that LDCT 
lung cancer screening enables the detection of new nodule lung cancer at an early 
stage. In the fourth screening round of the NELSON trial, 5.5 years after baseline 
screening, the majority of lung cancers was found in new nodules.35 Moreover, around 
half of lung cancers in the NELSON trial were found in participants with previously 
negative screening results.35 This stresses the significance of new nodules detected 
in lung cancer screening. With ongoing duration, the appropriate management and 
risk-stratification of new nodules will determine the success of a screening program. 
 
Risk-stratification of New Solid Nodules at Initial Detection 
Considering the findings presented in this thesis, new solid nodules have a higher lung 
cancer probability than baseline nodules at smaller size. Size cutoff values derived 
from baseline nodules or mixed-nodule groups potentially underestimate the lung 
cancer risk of new solid nodules. At initial detection, a low-risk cutoff of 30mm3 and a 
high-risk cutoff of 200mm3 can be used to stratify new solid nodules in LDCT lung 
cancer screening. 
There only is little evidence from other lung cancer screening trials concerning the 
stratification of new solid nodules. As presented in this thesis, new nodule size at initial 
detection provided moderate to high discriminative ability for lung cancer.17 Comparing 
the second screening round (1 year screening interval) and the third screening round 
(2 year screening interval), the discriminative ability increased with a longer screening 
interval.17 This suggests that new nodules need time to grow in order to be evaluated 
based on size only, making growth speed measures such as the volume doubling time 
crucial for follow-up assessment. Nodule volume provided superior discriminative 




ability when compared to the computer simulated mean nodule diameter. Moreover, 
as manual diameter measurements are even less precise and reproducible,36,37 they 
might have performed even worse.  
The new solid nodule lung cancer probability is high at a small size, especially in 
comparison with nodules detected at baseline.17 Prior to the presented studies, data 
of the NELSON trial suggested that baseline nodules smaller than 100mm³ had a lung 
cancer probability of about 0.6%, were not predictive of lung cancer, and did not 
necessitate additional follow-up scans.28,38,39 However, this criterion does not apply in 
the case of new solid nodules. As shown in this thesis, 3% of participants whose 
largest new solid nodule was smaller than 100mm³ were eventually diagnosed with 
lung cancer, with 2% of new solid nodules smaller than 100mm³ found to be lung 
cancer.17 These findings were later confirmed by an analysis of the NLST which, at 
smaller size, reported a significantly higher lung cancer risk in new solid nodules as 
compared to baseline nodules.23 The optimized volume cutoffs for new solid nodules 
were <27mm3 (<1% lung cancer probability, low risk), 27-206mm3 (3% lung cancer 
probability, intermediate risk), and ≥206mm3 (17% lung cancer probability, high risk), 
providing 95% sensitivity.17 It has been proposed by a European expert group to adapt 
these cutoffs for clinical implementation to 30mm3 and 200mm3 respectively.1 The 
optimized computer simulated mean diameter cutoffs were <3.7mm (<1% lung cancer 
probability, low risk), 3.7-8.2mm (3% lung cancer probability, intermediate risk), and 
≥8.2mm (14% lung cancer probability, high risk), providing 95% sensitivity.17 These 
probabilities are in concordance with lung cancer probabilities for the respective 
American College of Radiologists Lung-RADS categories.8 However, these diameters 
represent simulated diameter measurements of new nodules, extrapolated from 
computer-generated volume measurements based on three-dimensional voxel 
analysis,1,40 with manual diameter measurements being less precise or reproducible.36 
The results of the NELSON trial were subsequently confirmed by data of the NLST.23 
It was found that especially at very small size, the lung cancer risk between new solid 
nodules and baseline nodules differed markedly: 4-6mm mean diameter (2.3% vs. 
0.4%, 6 times higher) and 6-8mm mean diameter (5.4% vs. 1.3%, 4 times higher).23 
Even more remarkably, while the NLST did not include nodules with a longest diameter 
<4mm (around 34mm3) and therefore cannot represent these nodules accurately, the 
researchers reported a significantly higher lung cancer risk in nodules with a mean 
diameter <4mm (1.1% vs. 0.1%).23 In light of these results, the currently advocated, 




new solid nodule size diameter cutoff in LungRADs of 4mm,8 should be reviewed to 
assess whether it appropriately represents the actual lung cancer risk of new solid 
nodules.  
In the NELSON trial, around 60% of new solid nodules detected were smaller than 
50mm3 (roughly 4.5mm).17,24 The ELCAP and Mayo trial reported similar numbers 
between 40-55% for new nodules smaller than 5mm and 4mm respectively.18,21 At 
these tiny nodule sizes, growth detection based on two-dimensional diameter 
evaluation is unreliable,31 favoring volumetry. It was found that already for intermediate 
sized nodules (50-500mm3, roughly 4.5-10mm), intra-nodular diameter variation, 
varied by 2.8mm which is above the 1.5mm cutoff for nodule growth currently 
employed in the United States.41 Furthermore, even a computer simulated mean 
diameter provided inferior performance for new nodule risk-stratification when 
compared to semi-automated volume measurement.17  
This thesis introduced the concept of a predicted maximum volume doubling time 
(VDTmax) or slowest possible volume doubling time for a new solid nodule at initial 
detection.17 It enables a growth speed estimation at initial new nodule detection by 
accounting for the known time interval in which the new nodule must have developed. 
It does not represent the actual volume doubling time for which two exact volume 
measurements at two distinct time points are necessary. In other words, the VDTmax 
corrects the size of a new nodule at initial detection for the time the nodule had to 
grow. While this might be of limited use in the screening setting, where time intervals 
are generally predefined, it could be of clinical utility when assessing incidentally 
detected nodules in patients that have a prior CT scan available in clinical practice. In 
the presented setting, the estimated VDTmax was signiﬁcantly faster in new nodule lung 
cancers than in benign new solid nodules and the median VDTmax of adenocarcinomas 
and squamous-cell carcinomas was similar to the previously reported true VDT of fast-
growing baseline cancers in the NELSON trial.42  
Nevertheless, most new solid nodules are small and will receive additional follow-up 
to determine the necessity for referral.8,17,23 Consequently, evaluation of growth-speed 
could further improve risk-stratification of low and intermediate-risk new solid nodules. 
 
Risk-stratification of New Solid Nodules at First Follow-up After Initial Detection 
In this thesis, it was found that volume doubling time-based risk-stratification is 
appropriate for new solid nodules after initial detection. The addition of a volume limit 




that confers immediate referral prevents slow growing lung cancers from evading 
timely referral. Classifying a new solid nodule with either <600days volume doubling 
time or ≥200mm³ volume positive provides very high sensitivity and specificity for lung 
cancer with a positive predictive value >25%.  
At follow-up after new solid nodule detection, volume provided high and volume 
doubling time provided very high discrimination for lung cancer.43 The performance 
was higher than at initial detection,17,43 underlining that the discrimination of new 
nodule lung cancers increases with longer screening time interval. The addition of the 
previously found high-risk volume cutoff of 200mm3 further improved discrimination by 
volume doubling time alone.43 Of new solid nodules <200mm3 at initial detection and 
≥200mm3 at first subsequent screening LDCT, 38% were lung cancer and the addition 
of a volume limit could improve risk stratification also after initial detection.43 
Considering that lung cancer growth was shown to not necessarily be exponential or 
linear,44,45 addition of a volume limit compelling referral to a pulmonologist might 
prevent slow growing lung cancers from evading timely referral. 
The optimized volume doubling time cutoff was 590 days and combined with the 
≥200mm3 high-risk cutoff, thereby classifying nodules positive when at least one 
criterion was fulfilled, provided 100% sensitivity and 84% specificity for discriminating 
lung cancer.43 The observed statistically optimal VDT cutoff of ≤590 days is analogous 
to currently employed cutoffs of ≤600 days, such as in the British Thoracic Society 
guideline for the investigation and management of pulmonary nodules and the 
NELSON management protocol,7,9 and its appropriateness is confirmed for the first 
time in new solid nodules. However, further research is required to determine whether 
immediate referral might be appropriate for all low- and intermediate-risk new solid 
nodules with a VDT ≤600 days (8.3% [1/12] of nodules with VDT 400-600 days and 
34% [22/64] of nodules with VDT <400 days).43 
Importantly, more than half of new nodules resolve until first follow-up after initial 
detection.25 In total, 7% of participants with nonresolving low- and intermediate risk 
new solid nodules (0-3% lung cancer probability based on risk-stratification at initial 
detection) had lung cancer in such a nodule.43 We found that with longer screening 
interval the number of new nodules did not increase proportionally while the 
percentage of lung cancers further increased.17 This phenomenon could be explained 
by the nature of nonresolving new nodules: The longer a screening interval, the higher 
the proportion of nonresolving new nodules and consequently the higher the 




percentage of lung cancers. This is important when assessing new nodules found after 
different screening interval lengths or during short-term follow-up. A previous study of 
the NELSON trial examined the disappearance of intraparenchymal solid baseline 
nodules sized 50-500mm3 and reported that 90% of the nodules persisted, with 3% of 
nonresolving nodules being diagnosed as lung cancer eventually.46 The fact that 
compared to baseline nodules more new nodules resolve can be explained by the 
difference of the two nodule groups. Baseline nodules may have been present for 
years and are therefore more likely to be stable, while new nodules develop within a 
short, known time-frame and are more likely dynamic. Thus, the mere persistence of 
a new nodule might be considered as a risk factor for lung cancer.  
 
Number of Nodules and New Nodule Characteristics 
Multiple nodules are regularly detected in LDCT lung cancer screening participants. 
While risk-stratification should be based on the nodule with the greatest risk of 
malignancy, all nodules need to be assessed carefully to ensure detection of new 
nodules. Most lung cancers are found in a participant’s largest nodule when using 
volumetry.  
Of patients detected with pulmonary nodules, around 50% of participants had more 
than one nodule at baseline and around 20% had more than one new nodule 
detected.47,48 The NLST reported that around 20% of participants had more than one 
new nodule during two incidence screening rounds.23 In 97% of patients at baseline 
and in 100% of patients with new nodules the lung cancer was found in the largest 
nodule.47,48 This contrasts with the results by McWilliams et al.,49 who showed that in 
one-fifth of the participants, the largest nodule was not the one that turned out to be 
malignant at baseline or follow-up. This discrepancy might be explained by the use of 
volumetric measurement in the NELSON study, as compared to manual, two-
dimensional diameter measurements in the PanCan study. It has been shown that 
nodule measurements with volumetric techniques are more accurate as compared to 
diameter techniques.36,37,41 Possibly, diameter measurements cannot identify the 
largest nodule as precise as volumetry. However, while the policy to base screening 
risk-stratification on the nodule with the highest malignancy risk (often the largest) is 
confirmed,1,8 all nodules need to be assessed separately. This ensures the appropriate 
detection of new nodules which have a higher malignancy risk at smaller size.17,23 
While the new nodule lung cancer probability, did not differ significantly between 




participants with one and more than one new nodules, the new nodule count had a 
significant negative association with new nodule lung cancer when assessed together 
with nodule size.48 This may be explained through the observation that an increased 
new nodule count is associated with a greater size of the largest new nodule found in 
a participant, without increase in lung cancer probability.  
 
In new solid nodules, nodule characteristics not influenced by nodule growth, such as 
location in the right upper lung and a central distribution, can potentially improve 
volume-based risk stratification, but in a three category (low, intermediate and high 
risk) stratification approach, this is limited. Nodules visible <15mm3 and at detection 
>30mm3 should be considered fast growing and have a high lung cancer risk. To our 
knowledge there are no comparable studies available for new nodules. 
When added to the previously established new solid nodule volume cutoff values 
(<30mm3, 30-<200mm3, ≥200mm3),1,17 only growth independent nodule 
characteristics remained independent predictors for lung cancer.50 Nodule location in 
the right upper lung and central distribution provided an incremental value, while 
nodule shape and margin did not improve lung cancer discrimination.50 This contrasts 
findings in baseline nodules, where aside of location, nodule morphology remained 
significantly associated with lung cancer when corrected for nodule size.49–52 
Importantly, in univariate analysis nodule features traditionally attributed to lung 
cancer, such as location in the upper lung, central distribution, irregular shape, and a 
lobulated or spiculated margin, were also associated with lung cancer in new solid 
nodules.23,50 This might be explained by the augmented predictive information of 
nodule size in new solid nodules, which developed in a short and known timeframe, 
as compared to baseline nodules, that could have been present for years before 
detection. The volume of a baseline nodule primarily represents its current size, 
whereas the volume of a new nodule more directly translates to its growth rate. This 
is supported by the observation that only morphological characteristics forfeit their 
predictive association through addition of nodule volume, while growth independent 
features remain significant predictors. Visibility as very small nodule (<15mm3) in 
retrospect was significantly associated with lung cancer when combined with the 
volume cutoffs.45 Nodules visible in retrospect are more likely to be persisting nodules 
which could explain their higher cancer risk when further growing.43 Nodules visible in 




retrospect <15mm3 and at detection >30mm3 have a high cancer risk, even higher 
than a new nodule not visible at all in retrospect at similar size.50  
Nevertheless, the identified new solid nodule characteristics did not significantly 
improve risk stratification by volume when considering a three category (low-, 
intermediate-, high-risk) stratification approach, such as advocated in current 
guidelines.1,8,9,17 However, above risk-thresholds of 2%, growth independent new 
nodule characteristics can increase the true positive detection rate without affecting 
the false-positive rate.50 
 
Strengths and Limitations of this Thesis 
This thesis is based on data from the largest randomized European LDCT lung cancer 
screening trial, thus mimizing the risk of selection bias. Furthermore, contrary to 
previous large LDCT lung cancer screening trials, it employed a volume based 
management approach, thereby registering even very small nodules. Nevertheless, 
nodules smaller than <15mm3 were below the trial’s detection limit and were not 
considered when remaining smaller than this margin. While incidentally detected 
nodules visible in retrospect >15mm3 were excluded from analysis (missed nodules), 
nodules visible in retrospect <15mm3 were included for several reasons. First, due CT 
resolution limitations, the possiblity of a minuscule nodule being present on a prior 
screen cannot be excluded for any new nodule. Some nodules might only have 
become apparent in retrospect since they further grew. Second, prior to this thesis, 
there was only very limited knowledge on new nodules overall. Omitting a significant 
proportion of nodules before analysis was not justifiable and would have limited the 
generalizability of the risk-stratification strategy. Third, sensitivity analyses enabled the 
confirmation of the obtained findings and risk-stratification approach in the respective 
new nodule groups. Lastly, these nodules demonstrated potential growth which 
increased their suspiciousness for lung cancer. 
Data used in this thesis based on the NELSON management system as recorded by 
the NELSON radiologist’s during the trial and no additional image reading occured. 
This approach increased the generalizability of the findings as the actual observations 
in a screening setting were represented, but a small proportion of misclassified 
nodules cannot be excluded. Further, the final results of the NELSON trial have not 
yet been released. While all available follow-up data was used for this study, including 
the occurrence of post-screening cancers, the lung cancer frequency of new nodules 




might be even higher. Screen-detected lung cancers that would have never been 
clinically detected is a risk of screening and can lead to unnecessary diagnostic work-
up procedures and even cancer treatment. To limit this, the risk-stratification strategy 
developed in this thesis uses risk-categories (low-, intermediate-, and high-risk) as 
defined in current, well-established lung cancer screening guidelines. Nevertheless, 




I. New nodules are regular findings after baseline lung cancer screening. 
II. New solid nodules are more frequent than new subsolid nodules. 
III. The number of new nodules detected in participants is not directly 
proportional to the screening interval length since more than half are 
resolving nodules. 
IV. With increasing screening interval length, the proportion of resolving new 
nodules decreases and the lung cancer probability increases. 
V. New solid nodules have a higher lung cancer probability than baseline 
nodules, even at a smaller size. 
VI. New solid nodules should be followed up more aggressively than baseline 
nodules by using lower size cutoffs at initial detection. 
VII. At follow-up, growth assessment, potentially in combination with a size limit, 
is appropriate for risk-stratification of new solid nodules. 
VIII. Volumetry is preferred over diameter measurement for new nodule risk-
stratification. 
IX. Risk-stratification of new subsolid nodules can be performed analogous to 
baseline subsolid nodules. 
X. Meticulous lung cancer screening enables detection of new nodule lung 
cancer at an early stage. 




XI. The appropriate risk-stratification of new nodules determines the success of 
a lung cancer screening in terms of detection of lung cancer at an early 
stage. 
XII. Nodule characteristics do not significantly improve new solid nodule risk 
stratification by volume when considering a three-category approach. 
XIII. Location nodule characteristics, but not morphologic nodule characteristics, 
can improve lung cancer discrimination in intermediate and high-risk new 
solid nodules. 
XIV. All lung nodules of a participant need to be assessed separately to ensure 
the detection of new nodules. 
XV. Risk-stratification should be based on the nodule with the highest 























Figure 1: Risk-stratification of new solid nodules detected in low-dose CT lung cancer screening incidence rounds 
VDT - Volume doubling time 




Generalizability and Clinical Implications 
The findings of this thesis are based on data of the randomized NELSON trial 
conducted in the Netherlands and Belgium which included current or former (quit 
maximum 10 years ago) smokers (smoked > 15 cigarettes a day for >25 years or >10 
cigarettes a day for >30 years) aged 50-75 years, without co-morbidity impeding 
curative therapy, thereby corresponding to the target population for lung cancer 
screening.1 While these data represent the high-risk population of the respective 
countries and seem well suited to represent similar European populations, any 
application needs to be carefully evaluated. Differences in epidemiology, inclusion 
criteria or disease prevalence can affect the optimal risk-stratification strategy. 
Therefore, some findings, such as size and VDT cutoffs might require re-estimation 
when the screening population or pretest probability differs substantially. Furthermore, 
the NELSON trial represents a predominantly Caucasian population. Considering the 
volume-based management approach, software for semi-automated volume 
measurements is required. Such packages are provided increasingly with new CT 
machines, but are not available everywhere. Nevertheless, the general conclusions of 
this thesis remain unaffected by this. In the clinical practice, the recommendations 
developed in this thesis could be of use in high-risk patients with similar epidemiology 
as the population of NELSON trial. Nevertheless, considering the different setting, the 
final management decision should always reflect clinical expertise. Furthermore, lung 
cancer screening trials are characterized by pre-defined screening time intervals. In 
clinical practice, the time period prior to new nodule detection may differ substantially. 
In these cases, the use of the VDTmax could correct for such differences. However, 
further research is necessary to confirm this with clinical practice data. 
 
Implementation and Future Perspective 
In response to the evidence generated in this thesis, the findings were confirmed by 
data of the largest randomized controlled lung cancer screening worldwide.23 The 
conclusions of this thesis and the summarized recommendation were implemented in 
a European position statement on lung cancer screening and will be implemented in 
the British Thoracic Society Guidelines for the investigation and management of 
pulmonary 
nodules.1,53 The summarized recommendation was also included in a Polish 
consensus statement for the detection of early lung cancer.54 Furthermore, the new 




solid nodule management protocol of the Chinese National Lung Cancer Screening 
Guideline is partly based on the results of this thesis.55 The European Society for 
Medical Oncology clinical practice guidelines for “Early-Stage and Locally Advanced 
(non-metastatic) Non-Small-Cell Lung Cancer” argue that findings of this thesis might 
be of clinical utility in the management of solitary pulmonary nodules detected in 
clinical practice.56 Citing results of this thesis as sole reference, the 2018 United States 
National Comprehensive Cancer Network guidelines on lung cancer screening 
recommend lower cutoff sizes for new solid nodules.10  
 
The final results of the NELSON trial and other European lung cancer screening trials 
will determine the establishment of lung cancer screening programs in Europe. This 
thesis makes no assertion concerning the necessity or feasibility of lung cancer 
screening. However, considering that lung cancer screening is already ongoing in the 
United States and lung cancer screening studies are being conducted worldwide, 
future research concerning new nodules is imperative. Next to the conformation and 
adaptation of the presented findings in other, independent populations, several 
unanswered questions emerged. First, considering the resolving nature of most new 
nodules, the impact of the screening interval length on risk-stratification needs to be 
established. The time until the subsequent screening moment has important 
implications for the patient but also economic ramifications. Furthermore, findings of 
this thesis indicate that a too short screening interval potentially impairs lung cancer 
discrimination based on size. Second, while volumetry was shown to provide 
significant advantages over manual diameter measurements, the latter remains the 
most commonly used approach in clinical practice. Therefore, existing diameter-based 
lung cancer screening trials should further investigate the appropriate diameter risk-
stratification of new nodules. Third, as shown in this thesis, new nodule characteristics 
carry some incremental discriminative information for lung cancer. While their use is 
limited in the current risk-stratification format, further research is necessary to further 
evaluate their clinical and screening use. Increasingly, patients in clinical practice have 
receive multiple CT examinations. The fact whether an incidental nodule is observable 
in retrospect can be easily obtained in such cases. Fourth, with the rise of advanced 
modeling techniques and use of artificial intelligence or machine learning, the 
detection and risk-stratification of (new) nodules could improve considerably. Fifth, the 
final mortality data of the NELSON trial is not yet available. It will be of great interest 




whether there is a mortality difference in participants with baseline lung cancer and 
new nodule lung cancer. 
LDCT lung cancer screening demonstrated that a lung cancer mortality 
reduction is possible, especially in concert with smoking cessation programs and 
improved lung cancer treatment modalities. Nevertheless, further research remains 
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Part I – Introduction 
Lung cancer screening is recommended in the United States and stakeholders are 
preparing the potential implementation in Europe. Appropriate and accurate risk-
stratification is the basis for any successful screening program. It has been recognized 
that there is limited evidence concerning the risk-stratification of new nodules detected 
after the baseline screening round of low-dose CT (LDCT) lung cancer screening. The 
aim of this thesis is to provide evidence for the risk-stratification of new nodules at 
initial detection and follow-up using data from the largest European randomized 
controlled lung cancer screening study – the Dutch-Belgian NELSON trial.  
In Chapter 2 and Chapter 3, evidence from large lung cancer screening trials is 
reviewed to create a basis for this thesis. It was found that, while data concerning 
baseline nodules are consistently reported, definitions of new nodules varied, and new 
nodule data were often not reported at all. The sparse existing evidence suggests that 
3-10% of LDCT lung cancer screening participants develop new nodules annually and 
that 2-8% of participants develop lung cancer in such a nodule. Compared to baseline 
nodules which might have been present for years, new nodules develop in a short time 
interval. This indicates that new nodules might have a higher lung cancer probability 
than baseline nodules at smaller size.  
Part II - Risk-stratification of New Nodules  
Chapter 4 assessed the occurrence and lung cancer probability of new solid nodules 
in the NELSON trial. In annual screening, 5% of the NELSON participants developed 
a new non-calcified solid nodule, while 11% of the NELSON participants developed a 
new solid nodule within the first two incidence screening rounds (3 years after 
baseline). Overall, 6% of participants with a new solid nodule had lung cancer in such 
a nodule, with 4% of the new nodules being lung cancer. In comparison, in the baseline 
round of the NELSON trial, 1% of participants were detected with lung cancer and 3% 
were detected with lung cancer in the first three rounds (including new nodule cancer). 
The new solid nodule lung cancer probability is high at a small size, especially in 
comparison with nodules detected at baseline. The optimized volume cutoffs for new 
solid nodules were <27mm3 (<1% lung cancer probability, low risk), 27-206mm3 (3% 
lung cancer probability, intermediate risk), and ≥206mm3 (17% lung cancer probability, 
high risk), providing 95% sensitivity. These cutoffs are smaller than the respective 




cutoffs for baseline nodules (<100mm3, 100-300mm3, and ≥300mm3). Summarized, 
new solid nodules have a higher lung cancer probability than baseline nodules at 
smaller size and require lower cutoff sizes at initial detection.  
Chapter 5 investigated the appropriate risk-stratification strategy of new solid nodules 
at first screening after initial detection. More than half of new nodules were resolving. 
Volume provided high and volume doubling time provided very high discrimination for 
lung cancer. Of new solid nodules <200mm3 at initial detection and ≥200mm3 at first 
subsequent screening, 38% were lung cancer and the addition of a 200mm3 volume 
limit improve risk stratification. The optimized volume doubling time cutoff was 590 
days and combined with the ≥200mm3 high-risk cutoff, thereby classifying nodules 
positive when at least one criterion was fulfilled, 100% sensitivity and 84% specificity 
for discriminating lung cancer was reached. 
In Chapter 6, the potential incremental value of nodule characteristics on top of the 
previously found new solid nodule volume cutoff values (adapted to <30mm3, 30-
<200mm3, ≥200mm3) was assessed. Nodule characteristics not influenced by nodule 
growth, such as location in the right upper lung and a central distribution, could 
improve volume-based risk stratification and increased the true positive rate without 
affecting the false-positive rate above risk-thresholds of 2%, but in a three-category 
stratification approach (low, intermediate and high risk) this was limited. 
Chapter 7 focused on new subsolid nodules detected in the NELSON trial. Overall, 
new subsolid nodules were found in <1% of participants with at least one screening 
after the baseline round. While 6% of participants with a new subsolid nodule had a 
lung cancer diagnosed in such a nodule, all new subsolid nodule lung cancers 
detected in the NELSON trial were stage I or adenocarcinoma in situ. This is 
comparable to baseline nodules and a more aggressive risk-stratification strategy 
seems not warranted. 
Part III - Number of New Nodules and Lung Cancer Probability 
Chapter 8 and Chapter 9 assessed whether the number of nodules detected in a lung 
cancer screening participant affect the lung cancer probability. Around 50% of 
participants had more than one nodule at baseline and around 20% had more than 
one new nodule detected. While the new nodule lung cancer probability did not differ 
significantly between participants with one and more than one new nodule, the new 
nodule count had a significant negative association with new nodule lung cancer when 




assessed together with nodule size. In 97% of participants at baseline and in 100% of 
participants with new nodules, the lung cancer was found in the largest (new) nodule. 
However, while risk-stratification should be based on the nodule with the greatest risk 
of malignancy, all nodules need to be assessed carefully to detect new nodules. 
Chapter 10 presents and discusses the main results of this thesis. The implications of 
the findings are evaluated and summarized in general conclusions and summarized 
recommendation (Figure). Finally, the impact of the thesis until now is reviewed and 
future perspectives are presented. So far, results of this thesis were included in a 
European position statement on lung cancer screening, a Polish consensus statement 
for the detection of early lung cancer, the British Thoracic Society Guidelines for the 
investigation and management of pulmonary nodules, the European Society for 
Medical Oncology Clinical Practice Guidelines for Early-Stage and Locally Advanced 
(non-metastatic) Non-Small-Cell Lung Cancer, the new solid nodule management 
protocol of the Chinese National Lung Cancer Screening Guideline, and the American 
National Comprehensive Cancer Network guidelines on lung cancer screening.













































Deel I – Introductie 
In de Verenigde Staten wordt longkankerscreening reeds geadviseerd voor zware 
(ex-)rokers en in Europa bereidt men zich voor op mogelijke implementatie. 
Nauwkeurige risicostratificatie is de basis voor elk succesvol screeningsprogramma. 
Tot voor kort was er weinig kennis omtrent risicostratificatie van longnodules die 
nieuw gedetecteerd worden na de baseline screeningsronde in een lagedosis 
computer tomografie (LDCT) longkankerscreeningsprogramma. Doel van dit 
proefschrift was daarom het in kaart brengen van de risicostratificatie van deze 
nieuw gedetecteerde longnodules, gebruikmakend van de data verzameld in de 
grootste Europese longkankerscreeningstudie – de Nederlands-Belgische NELSON 
studie. 
De basis voor dit proefschrift, een overzicht van de huidige kennis over nieuw 
gedetecteerde longnodules in andere longkankerscreeningsstudies, werd gelegd in 
Hoofdstuk 2 en 3. Er werd geconcludeerd dat de denifitie van een nieuwe nodule, in 
tegenstelling tot de duidelijk gedefinieerde baselinenodule, varieerde binnen 
verschillende screeningsstudies. Tevens bleek dat nieuwe nodules vaak niet als 
zodanig gerapporteerd werden. Het schaarse beschikbare bewijs suggereert dat op 
jaarbasis 3-10% van de deelnemers aan een longkankerscreeningsprogramma een 
nieuwe nodule ontwikkelen, en dat zo’n nieuwe nodule in 2-8% van de deelnemers 
op longkanker blijkt te berusten. Nieuwe nodules ontwikkelen zich in een relatief kort 
tijdsframe, zeker vergeleken met baselinenodules, die al jaren aanwezig kunnen zijn. 
Dit impliceert dat nieuwe nodules al bij een kleinere grootte op moment van detectie 
verdacht zijn voor longkanker. 
Deel II – Risicostratificatie van Nieuwe Nodules 
In Hoofdstuk 4 worden het vóórkomen van nieuwe longnodules en de kans op 
longkanker in zo’n nodule onderzocht in deelnemers van de NELSON studie. Op de 
jaarlijkse follow-up scan na de baselinescreeningsronde bleek 5% van de NELSON 
deelnemers een nieuwe nodule te hebben ontwikkeld. In totaal had 11% van de 
NELSON deelnemers een nieuwe nodule ontwikkeld in de eerste twee follow-up 
screeningsrondes (tot drie jaar na de baselineronde). In totaal werd in 6% van de 
deelnemers met een nieuwe nodule longkanker in een nieuwe nodule 
gediagnosticeerd, 4% van alle nieuwe nodules maligne te zijn. Ter vergelijk: in de 




baselineronde kreeg 1% van de NELSON deelnemers de diagnose longkanker, en in 
de eerste drie rondes 3% van de deelnemers (dit is inclusief deelnemers met 
longkanker in een nieuwe nodule). Nieuwe nodules hebben dus een hogere 
maligniteitskans dan baselinenodules, al bij een kleiner volume op moment van eerste 
detectie. De optimale afkapwaarden voor nodulevolume (95% sensitiviteit) waren 
<27mm3 (<1% kans op longkanker, lag risico), 27-206mm3 (3% kans op longkanker, 
intermediar risico) en ≥206mm3 (17% kans op longkanker, hoog risico). Deze 
afkapwaarden liggen lager dan de corresponderende afkapwaarden voor 
baselinenodules (<100mm3, 100-300mm3, and ≥300mm3). Samengevat hebben 
nieuwe nodules een grotere kans om maligne te zijn dan baselinenodules. Voor 
optimaal longnodulemanagement zijn daarom voor nieuwe nodules lagere 
afkapwaarden voor nodulegrootte noodzakelijk.  
In Hoofdstuk 5 wordt de optimale methode voor risicostratificatie van nieuwe nodules 
op de eerste follow-up scan na initiële detectie onderzocht. Meer dan de helft van alle 
nieuwe nodules bleken spontaan te verdwijnen. De combinatie van nodulevolume en 
groei (volume-verdubbelingstijd, VDT) zijn goede voorspellers voor de kans op 
maligniteit. Van de nieuwe solide nodules met volume <200mm3 op het moment van 
initiële detectie en ≥200mm3 tijdens de eerste follow-up scan bleek 38% maligne te 
zijn. De toevoeging van nodulevolume aan VDT alleen als enige discriminator 
verbeterde de risicostratificatie significant. De optimale nodulestrategie bleek 
verwijzing van een person met een nieuwe nodule met VDT <590 dagen en/of een 
nodulevolume ≥200mm3. Dit leidde tot 100% sensitiviteit en 84% specificiteit voor de 
diagnose longkanker.  
In Hoofdstuk 6 werden geëvalueerd of er andere nodulekarakteristieken zijn die 
bijdragen aan de discriminatie van benigne en maligne nieuwe nodules, bovenop de 
eerder genoemde afkapwaarden voor het nodulevolume (wegens praktische redenen 
afgerond naar <30mm3, 30-<200mm3 en ≥200mm3). Nodulekarakteristieken die niet 
beïnvloed worden door nodulegroei, zoals locatie in de rechter bovenkwab en in het 
centrale deel van de long, bleken een klein positief effect te hebben bovenop 
nodulevolume op de risicostratificatie. In een risicostratificatie in drie categorieën 
(laag-, intermediair en hoogrisico) bleek deze toegevoegde waarde van deze extra 
nodulekarakteristieken echter zeer beperkt te zijn.  
Hoofdstuk 7 focust op nieuwe subsolide nodules die gedetecteerd zijn in de NELSON 
studie. Zo’n nieuwe subsolide nodule werd gedetecteerd in minder dan 1% van alle 




deelnemers met minstens een herhaalscan na baseline. Alhoewel 6% van alle nieuwe 
subsolide nodules maligne bleken te zijn, waren dit allemaal vroegstadium 
longkankers op moment van diagnose (stadium I of in-situ adenocarcinoom). Deze 
bevindingen zijn vergelijkbaar met subsolide baselinenodules, en daarom lijkt een 
meer agressieve vervolgstrategie voor nieuwe subsolide nodules niet nodig.   
Deel III – Aantal Nieuwe Nodules en Kans op Longkanker 
In Hoofdstuk 8 en Hoofdstuk 9 wordt onderzocht of het aantal nodules dat gelijktijdig 
in een deelnemer aan longkankerscreening gedetecteerd wordt van invloed is op de 
kans op longkanker voor deze persoon. Zo’n 50% van alle deelnemers aan 
longkankerscreening had tenminste twee gelijktijdig gedetecteerde longnodules, on 
zo’n 20% van de deelnemers had meer dan een nieuwe nodule. Terwijl het 
longkankerrisico niet significant verschilde tussen deelnemers met een of meerdere 
nieuwe nodules, had het aantal nieuwe nodules wel een negatief verband met 
longkankerrisico wanneer het direct in verband werd gebracht met de grootte van de 
nodule. Longkankerdiagnose werd in 97% van de deelnemers op baseline en in alle 
deelnemers met een nieuwe nodule gesteld op basis van de grootste (nieuwe) nodule. 
Maar hoewel de risicostratificatie daarom gebaseerd moet zijn op de grootste (nieuwe) 
nodule, is het wel belangrijk om alle, dus ook kleinere, nodules nauwkeurig te 
rapporteren om zo makkelijker en beter nieuwe longnodules te kunnen identificeren. 
In Hoofdstuk 10 worden de belangrijkste resultaten van dit proefschrift beschreven 
en in de context van de bestaande literatuur geplaatst. De resultaten van dit 
proefschrift zijn geïmplementeerd in verschillende (inter)nationale richtlijnen, zoals in 
de “European position statement on lung cancer screening”, in een Pools consensus 
document aangaande detective van vroegstadium longkanker, in de richtlijn van “the 
British Thoracic Society”, in de richtlijn van het Europees genootschap voor medische 
oncologie (the European Society for Medical Oncology Clinical Practice Guidelines for 
Early-Stage and Locally Advanced [non-metastatic] Non-Small-Cell Lung Cancer), in 
het management protocol voor nieuwe solide longnodules van de “Chinese National 
Lung Cancer Screening Guideline”, en in de richtlijn van het  “American National 
Comprehensive Cancer Network” ten behoeve van longkankerscreening. 
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